

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

## Over-the-counter provision of emergency contraceptive pills: A systematic review

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054122
Article Type:	Original research
Date Submitted by the Author:	03-Jun-2021
Complete List of Authors:	Atkins, Kaitlyn; Johns Hopkins University Bloomberg School of Public Health, Department of International Health Kennedy, Caitlin; Johns Hopkins University Bloomberg School of Public Health, International Health Yeh, Ping; Johns Hopkins University Bloomberg School of Public Health, Department of International Health Narasimhan, Manjulaa; World Health Organization, Department of Sexual and Reproductive Health and Research
Keywords:	PUBLIC HEALTH, Maternal medicine < OBSTETRICS, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Reproductive medicine < GYNAECOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- Over-the-counter provision of emergency contraceptive pills: A systematic review
- Kaitlyn Atkins<sup>1</sup>, Caitlin E. Kennedy<sup>1</sup>, Ping Teresa Yeh<sup>1</sup>, Manjulaa Narasimhan<sup>2</sup>
- <sup>1</sup> Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Kaitlyn Atkins, PhD Candidate. Caitlin E. Kennedy, Associate Professor. Ping Teresa Yeh, Research Associate.
- <sup>2</sup> Department of Sexual and Reproductive Health and Research, World Health Organization, includes the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction – HRP, Geneva, Switzerland. Manjulaa Narasimhan, Scientist.

#### **Correspondence to:**

- Manjulaa Narasimhan
- Department of Sexual and Reproductive Health and Research
- Ind UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme
- World Health Organization
- 20 Avenue Appia, 1211 Geneva 27, Switzerland
  - Email: narasimhanm@who.int

#### Word count: 4363

#### Abstract

**Introduction:** Improving access to emergency contraception (EC) can reduce unintended pregnancy and improve sexual and reproductive health and rights. We examined the evidence for availability of over-the-counter (OTC) EC in order to expand the evidence base of the World Health Organization's Guideline on Self-care Interventions to include EC.

Methods: We systematically reviewed the literature to evaluate the effectiveness of OTC EC. We searched for
 publications that compared OTC or pharmacy-access EC with prescription-only EC. We included studies
 measuring EC uptake, correct use, unintended pregnancy, abortion, sexual practices or behavior, self-efficacy,
 and side effects or harms. After abstract screening and full-text review, we summarized data in GRADE Evidence
 Profile tables. We also reviewed studies assessing values/preferences and costs of OTC EC.

**Results:** We included 19 studies (reported in 21 articles) evaluating the effectiveness of OTC EC; 56 studies related to values/preferences for OTC EC; and three studies on costs of OTC EC. All studies except one were from high- and middle-income settings. Overall, there were no differences in EC use, pregnancy, or sexual behavior when comparing OTC or pharmacy EC and prescription-only EC groups. Studies showed similar or lower abortion rates in areas with pharmacy availability of EC. There was a wide range of user and provider support for OTC EC, and decisions to use OTC EC were influenced by privacy/confidentiality, convenience, and cost. Three modeling studies found pharmacy-access EC would lower health sector costs.

**Conclusion:** Offering OTC EC is feasible, acceptable, and may increase access to effective contraception. Improving contraceptive choice remains important towards reducing the continued unmet need for underserved populations. Existing evidence suggests OTC EC does not substantively change reproductive health outcomes, but evidence gaps remain due to limited studies in low-resource settings.

Keywords: emergency contraceptives, contraceptives, pregnancy, pharmaceutical services

Systematic review registration number: PROSPERO CRD42021231625

#### Strengths and limitations of this study

- Emergency contraception is recommended by the World Health Organization and can prevent up to 95% of pregnancies when taken within five days of intercourse. Expanding access to over-the-counter emergency contraception without prescription can promote people's autonomy in health decision-making and could increase contraception coverage and uptake.
- Evidence from 19 studies suggests that providing emergency contraception over-the-counter or at pharmacies results in no substantial changes in EC use or sexual practices and behavior, and may reduce abortion rates.
- User and provider support for over-the-counter emergency contraception is motivated by convenience, privacy, comfort, control, cost, and effectiveness amidst concerns about increased risk behavior, repeat use, and less clinician support.
- Evidence from three studies suggests that providing emergency contraception in pharmacies may lower health sector costs.
- Providing emergency contraception over-the-counter or in pharmacies does not negatively impact sexual uni th outconne. and reproductive health outcomes, and may be a preferred option for many users.

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

#### Introduction

The World Health Organization (WHO) recommends the use of several forms of emergency contraception (EC), which can substantially reduce unintended pregnancy when used correctly [1, 2]. Reducing barriers to EC may increase access to effective contraceptive options, reduce unintended pregnancies, and overall improve sexual and reproductive health and rights (SRHR) outcomes.

In many settings, EC is delivered through one or more modalities [3]: (1) prescription-only, wherein physicians or
 other medical providers prescribe EC based on individual need; (2) pharmacy access (also called behind-the counter), wherein the medication is available via screening or prescription from a pharmacist; and (3) OTC,
 wherein medication is available on store shelves without a prescription. While both pharmacy access and OTC
 may reduce barriers to access by no longer requiring a visit to a physician or other health care provider, pharmacy
 access still requires the presence of a pharmacist, while truly OTC availability means an individual can purchase
 medication in the absence of a medical or pharmacy provider.

While countries have varying regulatory criteria involved in making a specific medication available OTC or with eligibility screening by pharmacy staff [4], the WHO is responsible to provide overall guidance to critical guestions of intervention recommendations. The 2019 WHO normative guidance on self-care interventions [5] included a recommendation on OTC oral contraception (contraceptive pills). This was informed by a previous systematic review [6], in which we found that OTC oral contraception may result in higher continuation and limited contraindications among users, and was generally supported by patients and providers. This earlier review and the 2019 WHO guidance did not include OTC delivery of EC. We therefore conducted this systematic review as part of expanding the evidence base of the guideline. 

This review was also conducted in response to the COVID-19 pandemic that has seen overstretched health systems and disruptions of health services globally [7]. WHO has prioritized self-care interventions in response to maintaining essential sexual and reproductive health services during the pandemic as people fail to access care and services, highlighting the need to improve availability of options that people can use outside of formal health facilities [7-10]. Further, WHO has warned that the COVID-19 pandemic has further increased women's exposure to intimate partner violence, as a result of measures such as lockdowns and disruptions to vital support services [11], which may lead more women and girls to need and/or use OTC EC. In addition, supply-side constraints and other barriers related to COVID-19 may reduce access and availability of condoms and other forms of medically prescribed contraceptive options, thus increasing the need for and importance of OTC EC. 

#### Methods

This review addressed the following question: Should emergency contraceptive pills be made available without a clinician's prescription? We reviewed the extant literature in three areas relevant to this question: effectiveness of the intervention, values and preferences of end-users and providers, and cost information. The review followed Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines [12], and the protocol was published on PROSPERO (registration number CRD42021231625). Ethical approval was not required for this systematic review, since all data came from information freely available in the public domain (i.e. published articles).

#### Effectiveness review inclusion criteria

The effectiveness review was designed according to the PICO format as follows:

- Population: Individuals using emergency contraceptive pills
- Intervention: Availability of EC OTC (without a prescription or screening) or from a pharmacist (behind-the-counter or pharmacy access)
- Comparison: Availability of EC by prescription only (by a clinician other than a pharmacist)
- **Outcomes**: (1) Uptake of EC (initial use); (2) Correct use of EC, including comprehension of product label instructions; (3) Unintended pregnancy; (4) Abortion (medical or unsafe); (5) Changes in sexual and reproductive health (SRH) practices or behavior; (6) Self-efficacy, self-determination, autonomy,

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

empowerment; (7) Side effects, adverse events, or social harms and whether harms were corrected/had redress available

To be included in the effectiveness review, an article must have: 1) had a study design comparing OTC or behindthe-counter (pharmacy) access of EC to prescription-only access (including randomized controlled trials (RCTs), non-randomized trials, and comparative observational studies); 2) measured one or more of the outcomes listed above; and 3) been published in a peer-reviewed journal. We did not restrict inclusion on the basis of language or intervention location. Articles in English, French, Spanish, and Chinese were coded directly; articles in other languages were translated before coding.

For the purposes of this review, we considered both behind-the-counter (pharmacy access) and true OTC availability as "over-the-counter" in our intervention definition. Our definition also includes availability through a range of locations other than pharmacies, including drug shops, vending machines, and online or telehealth services. Although IUD insertion can also be a form of EC, it requires insertion by a provider and thus cannot be made available OTC. This review thus focuses on emergency contraceptive pills. Studies that examined the provision of EC for clients to keep at home versus OTC or prescription-only access were not included.

#### Search strategy and screening

We searched four electronic databases (PubMed, CINAL, LILACS, and EMBASE) and four clinical trial registries (clinicaltrials.gov, WHO International Clinical Trials Registry Platform, Pan African Clinical Trials Registry, and Australian New Zealand Clinical Trials Registry). We also searched the website of the Cochrane Fertility Regulation (https://fertility-regulation.cochrane.org/) and its COVID-19 specific page

(<u>https://cgf.cochrane.org/news/covid-19-coronavirus-disease-fertility-and-pregnancy</u>), as well as the International Consortium for Emergency Contraception (<u>https://cecinfo.org</u>) and its regional consortia. Electronic databases were searched through December 2, 2020, using consistent search strings including a list of oral and emergency contraceptives, plus terms associated with medication provision without a prescription (see Appendix).

Secondary reference searching was conducted on all studies included in the review. Further, selected experts in the field were contacted to identify additional articles not identified through other search methods.

Titles, abstracts, citation information, and descriptor terms of citations identified through the search strategy were screened by a member of the study staff. Full text articles were obtained of all selected abstracts and two independent reviewers assessed all full-text articles for eligibility to determine final study selection. Differences were resolved through consensus.

#### Data extraction and management

Two reviewers independently extracted data using standardized forms. Differences in data extraction were resolved through consensus and referral to a senior study team member from WHO when necessary. The following information was gathered from each included study:

- Study identification: Author(s); type of citation; year of publication
- Study description: Study objectives; location; population characteristics; type of EC; description of OTC access; description of any additional intervention components (e.g. any education, training, support provided); study design; sample size; follow-up periods and loss to follow-up
- Outcomes: Analytic approach; outcome measures; comparison groups; effect sizes; confidence intervals; significance levels; conclusions; limitations

For RCTs, we assessed risk of bias using the Cochrane Collaboration's tool for assessing risk of bias [13]. For studies that were non-randomized trials comparative, we assessed study rigor using the Evidence Project eightitem risk of bias tool [14].

#### Data analysis

We analyzed data according to coding categories and outcomes. If multiple studies reported the same outcome, we conducted meta-analysis using random-effects models to combine risk ratios with the Comprehensive Meta-Analysis program.

For each outcome assessed in the review, we summarized data in GRADE Evidence Profile tables using GRADEPro [15]. We used RCT data where they were available; if RCT data were not available for an outcome, we pulled data from observational studies.

Where possible, we stratified analyses by the following subgroups: (1) behind-the-counter vs true OTC; (2) point of access (e.g. stores, pharmacies, telehealth, etc.); (3) type of EC pills (progestin-only vs ulipristal acetate vs combined vs mifepristone); (4) prior use of contraception; (5) age group; (6) vulnerabilities (e.g. poverty, disability, religion, literacy); (7) high-income vs low- or middle-income setting.

#### Additional reviews

We conducted additional reviews examining values and preferences and costs of OTC provision of EC. We used the same search strategy and terms to identify studies for these reviews. Studies were included in these reviews if they presented results from primary data collection; opinion pieces and reviews were excluded. We summarized this literature qualitatively and presented it with consideration of study design, methodology, location, and population.

Values and preferences review. We included studies in this review if they presented primary data examining preferences of women and girls regarding OTC access to emergency contraceptive pill. We focused on studies examining the values and preferences of women and girls who have used or potentially would use emergency contraceptives themselves, but we also included studies examining the values and preferences of healthcare providers, including in particular pharmacists and other providers. We considered issues around OTC access to emergency contraceptive pills as they relate to age of availability and marital status (both in law and in practice), broader social/structural factors that affect values and preferences, informed decision-making, coercion and seeking redress in this section. 

<u>Cost review</u>. We included studies in this review if they presented primary data comparing costing, costeffectiveness, cost-utility, or cost-benefit of the intervention and comparison listed in the PICO above, or if they presented cost-effectiveness of the intervention as it relates to the PICO outcomes listed above. We classified cost literature into four categories (health sector costs, other sector costs, patient/family costs, and productivity impacts) and within each category organized results by study design/methodology, location, and population.

#### Patient and public involvement

Feedback on the review protocol and analysis was received from the WHO patient safety working group. Patients were involved in a global survey of values and preferences conducted to inform the WHO guideline on self-care interventions; they thus play a significant role in the overall recommendation informed by this review.

#### Results

Our search yielded 2581 unique references, of which 129 were retained for full-text review (Figure 1). Ultimately, we identified 19 studies (reported in 21 articles) that met the inclusion criteria for the effectiveness review [16-36], 56 values and preferences studies [37-91], and three cost studies [92-94].

Figure 1. PRISMA flow chart showing disposition of citations through the search and screening process.

#### Effectiveness review

Overall, 19 studies from eight countries (published in 21 articles) met the inclusion criteria for the effectiveness review [16-36] (Table 1). This included one RCT (published in three articles), which was shown to have generally low risk of bias, and 18 observational studies, with risk of bias related to the presence of comparison groups, controls for confounding, and/or pre/post data. All studies were from high-income countries, and most presented data on EC uptake, changes in SRH practices and behavior, or abortion. Only one study [25, 33, 34] assessed

side effects, adverse events, or social harms. There was no comparative data on correct use of emergency contraceptive pills or self-efficacy, self-determination, autonomy, or empowerment. Effect sizes are reported by outcome in Table 2.

#### EC uptake

Nine studies reported on the impacts of OTC and pharmacy-access EC on EC use, prescribing, and uptake. Evidence from one RCT [33] showed no difference in use of EC with pharmacy access (RR 1.15, 95% CI: 0.90-1.48). In the same trial, there were no differences in EC use by age [25]. Three serial cross-sectional studies similarly found no changes in overall EC use over time with implementation of OTC access in Finland [23], the UK [27], and Australia [30]. The studies in Finland and the UK were found to have risk of bias due to lack of comparison groups in either study (both were pre/post only); biases in the study in Australia were related to the absence of a comparison group (pre/post only) and lack of control for confounding in the analysis.

Two cross-sectional studies found that use of EC within 24 hours of sex increased with pharmacy access in the UK (18% increase; p=0.03) [26] and the USA (aOR 2.17, 95% CI: 1.06-4.44) [35]. The study in the UK was found to have risk of bias, having no pre/post data and no control for confounding. The study from the USA was found to have risk of bias due to lack of pre/post data. Finally, a study assessing rates of pharmacy distribution in a safety-net hospital showed that EC distribution increased by 800% over a 1.5-year period, while EC prescribing increased by 50% over the same period [32]. This study was found to have risk of bias related to having no comparison group (pre/post only) or control for confounders.

When assessing impacts among the subgroup of adolescents and young adults, one study among women aged 16-19 in the UK found that EC use increased from 15.3% before EC was available OTC to 21.5% in the year after OTC EC became available ( $X^2$ =1.54, p=0.24), before decreasing 8.5% another year following OTC availability ( $X^2$ =7.11, p=0.01) [27]. Potential bias in this study was from having no comparison group (pre/post only).

#### Unintended pregnancy

Three studies assessed pregnancy as an outcome, which does not explicitly consider whether the pregnancy was intended but is an indirect proxy measure. The one RCT found no significant change in pregnancy among women who did not wish to become pregnant (RR 0.82, 95% CI: 0.53-1.27) [33]; this did not differ by age [25]. A small cross-sectional study among pregnant women receiving prenatal care in the USA found that the proportion of women who reported their pregnancy as unintended increased from 72.7% before pharmacy access to 90.7% after pharmacy access (p=0.02) [31]. This finding was determined to have risk of bias based on having no comparator or control for confounders. Finally, an ecological study assessing changes in conception rate over time in the UK found no differences before or after OTC access among individuals aged 13-19, but was associated with an increase in conception of about 0.9% among women aged 25-44 (p<0.05) [24]. Lack of pre/post data in this study was identified as a potential source of bias.

#### Abortion

Four ecological studies from the USA assessed the impact of pharmacy-access EC on abortion rates per 1,000 women, all with risk of bias related to lack of comparison groups or pre/post data [20-22, 29]. These studies found no difference in overall abortion rates with pharmacy-access EC. Evidence from one study among 18- to 19-year-olds showed a decrease of 1.6 abortions per 1,000 women after pharmacy-access EC became available in the USA (p<0.05) [21]. Another study among 15- to 19-year-olds found a decrease of 1.97 abortions per 1,000 (p<0.01).

Finally, evidence from one serial cross-sectional study showed that reporting ever having an abortion declined from 17.0% before OTC EC access to 15.6% after OTC EC access (p=0.04) [28]. Bias in this study was related to lack of a comparison group (pre/post only).

#### Sexual health-related practices and behavior

Seven studies assessed outcomes related to SRH practices and behavior. Specific outcomes assessed included condom use (three studies), unprotected sex (two studies), reporting multiple partners (three studies), contraceptive method use (four studies), and missing contraceptive pills (two studies).

Evidence from one RCT showed no difference in number of sexual partners (RR 1.24, 95% CI: 0.95-1.61),
condom use at last sex (RR 0.92, 95% CI: 0.81-1.05), consistent condom use (RR 1.07, 95% CI 0.76-1.51),
change in contraceptive method (RR 1.16, 95% CI: 0.92-1.47) or missed contraceptive pills (among pill users; RR
0.92, 95% CI: 0.80-1.06) [33]. The same RCT found decreases in unprotected intercourse with increased access
to OTC EC (RR 0.82, 95% CI: 0.70-0.97). These findings did not vary by age [25].

An observational study found no significant changes in condom use, contraceptive use (including multimethod use), unprotected intercourse, or missed contraceptive pills (among pill users), when comparing outcomes before and after pharmacy-access EC in German-speaking Switzerland [16]. This finding may have been influenced by bias from having no comparator (pre/post only) and no control for confounders. In the USA, evidence from two serial cross-sectional studies showed that increased access to OTC EC had no effect on sexual activity or contraceptive use over time [17, 18], though it reduced condom use among adolescents by 5.2% to 7.2% (p<0.01) [18]. Both serial cross-sectional studies were found to have risk of bias due to lack of comparison groups (pre/post only). Finally, cross-sectional evidence from Lithuania and Poland showed that increased access to OTC EC was associated with reduced reporting of five or more sexual partners (30.6% without OTC access vs 9.6% with OTC access; p<0.001) [19]. Bias in this study were related to lack of pre/post evidence and no control for confounders. 

#### Side effects, adverse events, and social harms

One RCT assessed potential social harms resulting from pharmacy-access EC and found that there was no difference in reporting being pressured into sex (RR 0.82, 95% CI: 0.43-1.56) [33]. For this outcome, there was no difference in age subgroup analyses [25].

			BMJ Open		136/bmjopen-202
able 1. Desc Study	cription of include Study Design	ed studies. Location	Population	Intervention*	Outcomes
Arnet et al. 2009	Pre/Post	Switzerland: Basel, Bern, Zurich	Women aged 15-49 accessing EC at pharmacies; 2003, 2006 N=729	Pharmacy access	5. SRH practices o behavior
Atkins & Bradford 2015	Serial Cross- Sectional	USA: ME, NH, VT, RI	Public school students who responded to sexual activity questions in Youth Risk Behavior Survey; 2003-2009 N=49,454	Pharmacy access	5.ARH practices o
Atkins 2014	Serial Cross- Sectional	USA: national	Non-pregnant women of aged 18-45 who responded to NHANES; 2001-2004, 2007- 2010 N=NR	Pharmacy access	5.SRH practices c
Bumbul et al. 2013	Cross- Sectional	Poland: Warsaw Lithuania: Vilnius	Female students and high school pupils N=1,366	OTC access	1. EC uptake 5. SRH practices c behavior
Cintina & Johansen 2015	Ecological	USA: national (states except AK, DC, DE, HI, IA, MA, ME, NJ, NM, VT, WA)	Women aged 15-19 years; 2000-2010 N=NR	Pharmacy access	4.Abortion
Cintina 2017	Ecological	USA: WA, OR, ID	Women aged 15-44 N=1,747	Pharmacy access	4. Abortion
Durrance 2013 <sup>†</sup>	Ecological	USA: WA	Women aged 15-24 years; 1993-2005 N=507	Pharmacy access	4. Abortion
Falah- Hassani,et al. 2007	Serial Cross- Sectional	Finland: national	Adolescents aged 12-18; 1991, 2001, 2003 N=12,121	OTC access	1. EC uptake
Girma & Paton 2011	Ecological	UK: national	Women aged 13-44; 1998-2004 N=NR	OTC access	3. Unintended
Harper et al. 2005; Raine et al. 2005; Rocca et al. 2007	RCT	USA: California: San Francisco	Women aged 15-24 attending clinics providing family planning; not desiring pregnancy, using long-term hormonal contraception or requesting EC; 2001-2003 N=2,117	Pharmacy access	1. C uptake 3. Inintended pregnancy 5. SRH practices o benavior 7. Side effects, adverse events, sogial harms
Killick & Irving 2004	Cross- Sectional	UK: national	Women accessing EC at pharmacies N=419	Pharmacy access	1. EC uptake

			BMJ Open		136/bmjoper
Marston et al. 2005	Serial Cross- Sectional	UK: national	Women aged 16-49 who responded to Omnibus survey; 2000-2002 N=5,984	OTC access	1.陸C uptake 5.SRH practices o be由avior
Moreau et al. 2006	Serial Cross- Sectional	France: national	Women aged 15-44 years responding to national health surveys; 1999, 2004 N=11,656 (1999: 4,146; 2004: 7,490)	OTC access	4.Nabortion
Mulligan 2016	Cross- Sectional	USA: national (all states except CA, NH (post-1997), MD (post-2006))	Women aged 15-44 in the USA, 1993- 2011; female respondents to the National Longitudinal Survey of Youth; 1997-2009 N=4385 for 1997 NLSY; otherwise NR	Pharmacy access	4. Abortion
Novikova et al. 2009	Serial Cross- Sectional	Australia: Sydney	Women attending abortion clinics N=718	OTC access	1. C uptake
Payaka- chat et al. 2010	Cross- Sectional	USA: AR: Little Rock	Pregnant women receiving prenatal care at a large urban community women's clinic; 2003-2008 N=272	Pharmacy access	3. Unintended pregnancy 5. SRH practices c benavior
Pentel et al. 2004	Ecological	USA: MN: Minneapolis	Female patients at a safety-net hospital N=NR	Pharmacy access	1. EC uptake
Rubin et al. 2011	Cross- Sectional	USA	Females aged 14-19 who had engaged in unprotected sex while aware of EC N=531	Pharmacy access	1.≝C uptake
Soon et al. 2005	Retrospective Cohort	Canada: British Columbia	Women aged 10-59 who received EC prescriptions from 1996-2002 N=1,172	Pharmacy access	9 1.≝C uptake
* For all incluc	ded studies, the co	mparator was prescriptio	n-only access to EC.		nj.com/ on
					mj.com/ on April 20, 2024 by
					guest. Protected by

	BMJ (	Dpen	1 136/bmj	
results.			136/bmjopen-2021-054122	
	N (%) or Mean (SD)		Effect	
Specific Outcome	OTC/pharmacy access	Prescription-only availability	54122	
C Uptake			9	
EC use	197/814 (24.2%)	65/310 (21.0%)	<b>RR 1.15</b> <sup>→</sup> (0.90-1.48)≤	
Physician prescribing of EC	2001: 9,447 2002: 10,669	1996-2000: 8,805/year (95% CI: 7,823-9,787)	NR ch	
cohort [36]         EC         2002: 10,669         (95% CI: 7,823-9,787)           3 serial cross- sectional [23, 27, 30]; 3 cross- sectional [19, 26, 35]         EC         Summary: All studies found no difference in EC use of with increased OTC EC access. Two studies found ind hours (X <sup>2</sup> : 17.08; p=0.03 [26]; aOR 2.17; 95% CI: 1.06				
EC distribution from from				
Jnintended Pregnancy			http	
Unintended pregnancy	58/814 (7.1%)	27/310 (8.7%)	<b>RR 0.82</b> (0.53-1.27)	
Unintended pregnancy	88 (90.7%)	24 (72.7%)	p=0.02	
Conception rate Summary: Among women aged 13-15, 15-17, and 15-19, there was access to OTC EC. Among women aged 25-44 access was associated with increased use (p<0.05)				
bortion			<u> </u>	
Abortion rate per 1000 women	to OTC EC. Two studi a decrease of 1.6 abo	es identified significant decrea tions per 1,000 18-19 year ol	ases among yoၨଳିger age groups d women (p<0.0ୂਙ) [21], and a	
Abortion (ever)	1168/7490 (15.6%)	708/4166 (17.0%)	p=0.04 <sup>02</sup> by	
exual health-related pract	tices and behavior			
Unprotected sex	274/814 (33.7%)	127/310 (41.0%)	RR 0.82	
Consistent condom use	110/814 (13.5%)	39/310 (12.6%)	<b>RR 1.07</b> ភ្ន័ (0.76-1.51)ខ្ល	
Condom use last sex	383/814 (47.1%)	158/310 (51.0%)	<b>RR 0.92</b> ඕ (0.81-1.05)ප	
Multiple partners	192/814 (23.6%)	59/310 (19.0%)	<b>RR 1.24</b> (0.95-1.61)	
	C Uptake         EC use         Physician prescribing of EC         EC use         EC use         EC distribution from pharmacies         Jnintended Pregnancy         Unintended pregnancy         Unintended pregnancy         Conception rate         bortion         Abortion rate per 1000 women         Abortion (ever)         exual health-related pract         Unprotected sex         Consistent condom use         Condom use last sex	Specific Outcome       N (%) or Mean (SD) OTC/pharmacy access         C Uptake       EC use       197/814 (24.2%)         Physician prescribing of EC use       2001: 9,447 2002: 10,669         EC use       Summary: All studies with increased OTC EC hours (X <sup>2</sup> : 17.08; p=0.0         EC distribution from pharmacies       Summary: EC distribu years, while prescription         Unintended Pregnancy       58/814 (7.1%)         Unintended pregnancy       58/814 (7.1%)         Unintended pregnancy       Summary: Among wo EC use with increased access was associated access was associated access of 1.6 abor decrease of 1.6 abor decrease of 1.97 per 1         Abortion rate per 1000 women       Summary: Most studie to OTC EC. Two studie a decrease of 1.97 per 1         Abortion (ever)       1168/7490 (15.6%)         exual health-related practices and behavior       Unprotected sex         Unprotected sex       274/814 (33.7%)         Consistent condom use       110/814 (13.5%)         Condom use last sex       383/814 (47.1%)	Specific OutcomeN (%) or Mean (SD) OTC/pharmacy accessPrescription-only availabilityC UptakeEC use197/814 (24.2%)65/310 (21.0%)Physician prescribing of EC2001: 9,447 2002: 10,6691996-2000: 8,805/year (95% CI: 7,823-9,787)EC useSummary: All studies found no difference in EC use with increased OTC EC access. Two studies found hours (X2: 17.08; p=0.03 [26]; aOR 2.17; 95% CI: 1.EC distribution from pharmaciesSummary: EC distribution from a hospital pharmac years, while prescription use of EC increased by 50Jnintended Pregnancy58/814 (7.1%)27/310 (8.7%)Unintended pregnancy58/814 (7.1%)27/310 (8.7%)Unintended pregnancy58/814 (7.1%)24 (72.7%)Summary: Among women aged 13-15, 15-17, and EC use with increased access to OTC EC. Among v access was associated with increased use (p<0.05)	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		ВМЈ	Open	l 136/bmjopen
	Contraceptive method change	220/814 (27.0%)	72/310 (23.2%)	ළ RR 1.16 හ (0.92-1.47)හු
	Missed pills (among subgroup of reported contraceptive pill users)	245/391 (62.7%)	84/123 (68.3%)	<b>RR 0.92</b> (0.80-1.06)
	Condom use	220/333 (66.0%)	232/350 (66.3%)	NS S
	Oral contraceptive use	69/333 (20.7%)	90/350 (25.7%)	NS <sup>1</sup> / <sub>4</sub>
1 pre/post study	OC + condoms	10/333 (3.0%)	7/350 (2.0%)	NS S
[16]	Unprotected sex	17/340 (5.0%)	25/361 (6.9%)	NS c
	Missed pills	53/79 (67.1%)	47/97 (48.5%)	NS N
	Multiple partners	a 5.2% increase in rep a decrease from 30.6	porting multiple partners (p- % to 9.6% reporting multiple	
3 serial cross- sectional[17, 18, 27]; 2 cross- sectional [19, 31]	Contraceptive use		TC EC. One study [17] fou	n oral contraceptiv∉use with Ind a 7.6% decrea ∰ in injectable
	Condom use	access to OTC EC. A		e in condom use with increased ecreased condom ase among pub 0.01).
PICO Outcome 7:	Side effects, adverse even	ts, and social harms		<u> </u>
1 RCT <b>[33]</b>	Pressured into sex	28/814 (3.4%)	13/310 (4.2%)	RR 0.82 8 (0.43 -1.56)
NS = not significant NR = not reported	at p<0.05			uni.com
				on April 20, 2024 by gu
				guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

#### Values and preferences review

Overall, 56 studies from 33 countries were included in the values and preferences review (Figure 2) [26, 37-91]. There were 39 quantitative studies (all cross-sectional surveys), 11 qualitative studies, and six mixed-methods studies. Twenty-two studies included end-users, 33 studies included pharmacists or other health care providers or professional stakeholders, and one study included both groups. One study [26] was also included in the effectiveness review.

Of the included studies, most were in the USA (n=19) and UK (n=9), followed by Sweden (n=5), Canada (n=4), Australia (n=3), India (n=3), South Africa (n=2), and South Korea (n=2). One study each was conducted in Austria, Barbados, Belgium, Bulgaria, Czech Republic, Democratic Republic of Congo, France, Germany, Hong Kong, Hungary, Indonesia, Jamaica, Kazakhstan, Lithuania, Nicaragua, Norway, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, and Spain.

Figure 2. Map showing distribution of studies included in the values and preferences review.

Of the values and preferences studies among end-users, support for OTC EC varied widely within and across countries, ranging from 12% among college students in India [65] to 100% among women who used OTC EC in Sweden [37]. In one study, where women could choose whether to obtain EC from a pharmacist or a physician [26], satisfaction with information received was 91% among those receiving EC in pharmacies, compared to 58% among those receiving prescription-only EC (p=0.006). Broadly, end-users supported OTC EC because they felt it offered improved access/availability, convenience, more flexible hours (particularly weekend hours), confidentiality/privacy/anonymity, and reduced cost. End-users also anticipated that OTC delivery would offer less opportunity for judgement from providers and greater control for women.

End-users who did not support OTC EC expressed concern about potential lack of privacy or increased cost, in addition to having a preference for more personal contact with providers for support and information. They also expressed some concerns about increased risk behavior. One study noted this concern was for others; the individuals participating in the study, all of whom were EC users, did not believe their own behavior would be shaped by EC use [70].

Of the values and preferences studies among pharmacists and other health care providers and professionals, support for OTC EC ranged widely. In quantitative surveys, pharmacist support ranged from 16% in South Dakota, USA [58] to 97% in San Francisco, USA [48]. Among doctors, support was generally lower, ranging from 6.1% in South Korea [76] to 68.9% in Canada [74]. Broadly, providers supported OTC EC for similar reasons as end-users. Some studies found that providers had concerns about side effects, including the inability to communicate about side effects in OTC delivery modalities [38] and concerns about long-term impacts of repeat EC use [79]. In contrast, one study found that providers supported OTC delivery as they saw EC as having relatively few side effects [76]

Providers were also found to have concerns about increased risk behavior, misuse/repeat use of EC, and communication. Specifically regarding communication, providers felt concerned about discouraging other contraceptives [47, 62, 74, 77, 82], and felt that OTC delivery might preclude delivery of necessary education and counseling. In some studies, providers had religious/moral concerns about OTC delivery [41, 45, 54, 62, 82]. One study found that these concerns were more common among providers who believed EC was an abortifacient [54].

#### Cost review

Three studies met inclusion criteria for the cost review (Table 3) [92-94]. All were modelling studies, two from the USA [92, 93] and one from Canada [94]. All examined the impact of pharmacy-access EC (not true OTC) and found that pharmacy access was expected to lead to lower health sector costs. No studies examined other sector costs, patient/family costs, or productivity impacts.

 Table 3. Description of studies included in the cost review.



Study	Location	Study design	Impact of pharmacy access
Marciante et al., 2001	USA	Decision model	<ul> <li>Among private payers (private insurance): \$158 (95% CI=\$76,</li> <li>\$269) reduction in cost per woman having unprotected intercourse</li> <li>Among public payers: \$48 (95% CI=\$16, \$93) reduction in cost per woman having unprotected intercourse</li> </ul>
Soon et al., 2007	Canada	Three decision model	One-year cost saving to the Ministry of Health (MOH) of \$0.64 million (95% CI: \$0.24 million, \$1.28 million). In sensitivity analyses, there were no set of assumptions that would lead to pharmacy access increasing costs to the MOH.
Foster et al., 2010	USA	Markov model	For Medicare: Compared to no EC use, pharmacy access was more cost-effective than prescription access across all assumptions of amount and frequency of use. Cost savings ratios for pharmacy access: range 1.61 to 2.49 For prescription-only access: range 1.00 to 1.56

#### Discussion

We identified 19 studies from eight countries assessing how OTC EC influences uptake of EC, unintended pregnancy, abortion, and other sexual practices and behavior. Broadly, we found no differences in EC use, pregnancy, or sexual risk behavior when comparing pharmacy access or true OTC availability to prescription-only EC access. We found no comparative data on correct use of ECPs or self-efficacy, self-determination, autonomy, or empowerment.

For most outcomes, our review did not identify any substantial or concerning differences in subgroup analyses by age. Observational evidence included in our review showed that abortion rates decreased significantly among younger age groups with increased access to OTC EC [21, 29], while there was no significant difference in the overall population of women. Given the unique barriers faced by younger women accessing prescription-only EC in many settings, it may be that increased access to OTC EC has unique benefits for younger women. Given that one in four young women who have been in a relationship will have already experienced intimate partner violence by the time they reach their mid-twenties [11, 95], access to contraceptive choice for these younger women is particularly important. This should be explored further.

Due to lack of data, we were not able to compare outcomes by other subgroups (e.g. point of access, type of EC pills, or vulnerabilities). This is an important area for further exploration, given self-care interventions may present unique opportunities and challenges for different populations and in different settings [5]. Equitable implementation of OTC EC as a self-care intervention should consider the intersecting roles of race/ethnicity/culture/language, occupation, gender/sex, religion, education, health literacy, socioeconomic status, and social capital as determinants of SRHR and key factors affecting delivery, uptake, and impact of OTC EC [96].

In terms of values and preferences, we found that OTC EC was supported for its perceived convenience, privacy,
 comfort, control, cost, and effectiveness. Some end-users and providers expressed concerns that OTC EC might
 increase sexual risk behavior. However, our effectiveness review found that there were no differences in sexual
 practices and behavior when comparing OTC or pharmacy EC with prescription-only EC.

While many studies found that women valued the privacy and control offered by OTC EC, two studies found that women were concerned about having limited interaction with providers in true OTC delivery [37, 75]. In both studies, while there was widespread support for OTC availability of EC (between 78 and 100%), a large proportion of women expressed a preference for behind-the-counter modalities which allowed for interaction with a pharmacist. Indeed, in many settings, OTC EC is offered as one of an array of options including receiving EC from a pharmacist (behind-the-counter), from a physician (prescription OTC), or on store shelves (true OTC). We found that, in a study where women could choose whether to obtain EC in a pharmacy or from a physician [26], EC use and knowledge was similar between groups, but pharmacy-access EC resulted in higher use and 

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

**BMJ** Open

satisfaction. Given this and our findings about OTC EC's effectiveness, blended delivery modalities wherein users can choose where and how to access EC may be most responsive to user preferences.

Providers also expressed concern that OTC EC might not allow for sufficient education or counseling, including about how to use OTC EC correctly and counseling about other routine SRH services (including use of other contraceptives and screenings for cervical and breast cancers and sexually transmitted infections [STIs]). In our effectiveness review, we did not identify any studies assessing correct use of OC in OTC vs prescription-only 10 delivery modalities. While knowledge of ECs was not one of our PICO outcomes, one study from the UK found no 11 significant difference in correct knowledge of EC between women receiving EC from a physician vs OTC, with 12 correct knowledge >90% for both groups [26], and another found no significant difference between OTC and 13 prescription delivery in reporting adequate information received about EC [30]. Future research should assess 14 whether correct knowledge of EC translates to correct use in OTC modalities.

15 In terms of routine preventive screenings and other SRH services, we did not assess this as a PICO outcome. 16 17 Findings from our previous review of OTC oral contraceptives suggested that OTC oral contraceptive access might not reduce use of other preventive services [6]. We did not assess STI screenings, though there was mixed 18 19 evidence around STI acquisition. Several included studies found no differences or lower rates of STI acquisition 20 with increased access to OTC EC [19, 25, 29, 33], while others identified increases in STI acquisition among 21 younger age groups [22, 24]. Because this evidence is primarily from observational studies, it is unclear through 22 what mechanisms OTC EC may impact STI acquisition, and if routine preventive SRH care plays a role. This 23 should be investigated further, particularly in light of the finding that these phenomena may differ for younger vs. 24 older women. 25

Results from OTC EC cost studies are promising, though limited. In our three included studies from the US and 26 Canada, pharmacy access was anticipated to yield lower health sector costs. However, we identified no data on 27 cost impacts for patients and families, which will be important to consider as OTC EC access expands. Indeed, 28 several included values and preferences studies noted increased cost as a concern [37, 61, 74, 79]. On the other 29 30 hand, some studies have shown that increased cost was perceived as a benefit, as it may deter repeat or overuse 31 of EC [49, 61]. 32

Finally, though OTC EC is an important contraceptive option for individuals, communities, and health systems 33 worldwide, the evidence base identified through our effectiveness, cost, and values and preferences reviews was 34 concentrated in high-income settings. Specifically, we only found evidence of OTC EC's effectiveness and costs 35 from high-income countries. In our values and preferences review, 80% of identified studies were from high-36 income settings, and a low-income setting (DRC) was represented in a lone study [59]. Meaningful efforts are 37 needed to recognize, invest in, and promote future research on the effects of increased OTC EC in low- and 38 39 middle-income countries, including from user and cost perspectives.

#### Conclusion

40

41 42

43

44

45

60

1

2 3

4

5

6 7

8

9

Increasing OTC contraceptive choice and availability is an urgent need for many women and girls. OTC EC is available in many settings worldwide, suggesting its feasibility as an additional delivery option. This review of existing evidence suggests that providing emergency contraception OTC may be cost-saving and responsive to user preferences, while introducing no negative SRHR outcomes.

26

27

28

29 30

31 32

33

34 35

36 37

38

39 40

41 42

45

46

47 48

49

50

60

#### Acknowledgements

We thank Laura Ferguson and Lianne Gonsalves for reviewing and providing thoughtful feedback on the protocol. We also thank our research assistants from the Johns Hopkins Bloomberg School of Public Health (Hunied Kautsar, Izza Ishak, Sherryn Sherryn, Jingjia (Cynthia) Li, Xuhao Yang, Jaime Marguis, and Vagho Avetisyan) for their assistance screening citations and extracting data.

#### Contributions

MN conceptualized the study. CEK and PTY designed the protocol with feedback from MN. PTY ran the database search and oversaw search, screening, full text review, and data extraction processes. CEK and PTY performed data analysis. KA and PTY assessed guality and risk of bias. CEK and KA drafted the manuscript. PTY and MN reviewed the draft, provided critical review, and read and approved the final manuscript. The corresponding author, as guarantor, accepts full responsibility for the finished article has access to any data and controlled the decision to publish. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

The named authors alone are responsible for the views expressed in this publication and do not necessarily represent the decisions or the policies of the World Health Organization (WHO) nor the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP).

#### **Financial support**

We gratefully acknowledge financial support of The Children's Investment Fund Foundation (CIFF). The funder played no part in the decision to submit the article for publication, nor in the collection, analysis and interpretation of data. All authors had full access to all of the data in the study and can take responsibility for the integrity of the JG data and the accuracy of the data analysis.

#### **Competing interests**

None declared.

#### Patient consent for publication

Not required.

#### Provenance and peer review

Not commissioned; externally peer reviewed.

#### Ethics statement

Ethical approval was not required for this systematic review, since all data came from published articles.

#### 43 Data availability statement 44

Extracted data are available on request to the corresponding author.

#### Transparency declaration

The corresponding author, as guarantor, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

#### References

- 1. World Health Organization. Medical eligibility criteria for contraceptive use, fifth edition. World Health Organization; 2015. Report No.: 9241563885.
- 2. World Health Organization. Selected practice recommendations for contraceptive use, third edition. World Health Organization; 2016. Report No.: 9241562846.
- 3. Rafie S, Stone RH, Wilkinson TA, Borgelt LM, El-Ibiary SY, Ragland D. Role of the community pharmacist in emergency contraception counseling and delivery in the United States: current trends and future prospects. Integrated Pharmacy Research & Practice. 2017;6:99-108.
- 4. Ammerdorffer et al. Regulatory standards and processes for over-the-counter availability of hormonal contraception and drugs for medical abortion in five countries in the Eastern Mediterranean Region. Health Research and Policy Systems. (Expected April 2021).
- 5. World Health Organization. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights. 2019. Report No.: 9241550554.
- 6. Kennedy CE, Yeh PT, Gonsalves L, Jafri H, Gaffield ME, Kiarie J, et al. Should oral contraceptive pills be available without a prescription? A systematic review of over-the-counter and pharmacy access availability. BMJ Global Health. 2019;4(3):e001402.
- 7. World Health Organization. Maintaining essential health services: operational guidance for the COVID-19 context: interim guidance, 1 June 2020. World Health Organization; 2020.
- 8. Brolin Ribacke KJ, Saulnier DD, Eriksson A, von Schreeb J. Effects of the West Africa Ebola Virus Disease on Health-Care Utilization A Systematic Review. Frontiers in public health. 2016;4:222.
- 9. Sharma KA, Zangmo R, Kumari A, Roy KK, Bharti J. Family planning and abortion services in COVID 19 pandemic. Taiwanese journal of obstetrics & gynecology. 2020;59(6):808-11.
- 10. Tolu LB, Feyissa GT, Jeldu WG. Guidelines and best practice recommendations on reproductive health services provision amid COVID-19 pandemic: scoping review. BMC public health. 2021;21(1):276.
- 11. World Health Organization. COVID-19 and violence against women: What the health sector/system can do. World Health Organization; 2020.
- 12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
- 13. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors2019.
- 14. Kennedy CE, Fonner VA, Armstrong KA, Denison JA, Yeh PT, O'Reilly KR, et al. The Evidence Project risk of bias tool: Assessing study rigor for both randomized and non-randomized intervention studies. Systematic Reviews. 2019;8(1):1-10.
- 15. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2020 (developed by Evidence Prime, Inc.); 2020.
- (developed by Evidence Prime, Inc.); 2020.
   Arnet I, Frey Tirri B, Zemp Stutz E, Bitzer J, Hersberger KE. Emergency hormonal contraception in Switzerland: a comparison of the user profile before and three years after deregulation. The European Journal of Contraception & Reproductive Health Care: The Official Journal of the European Society of Contraception. 2009;14(5):349-56.
   Atkins DN. Association between increased availability of emergency contraceptive pills and the
  - 17. Atkins DN. Association between increased availability of emergency contraceptive pills and the sexual and contraceptive behaviors of women. J Public Health Policy. 2014;35(3):292-310.
  - 18. Atkins DN, Bradford WD. The effect of changes in state and federal policy for nonprescription access to emergency contraception on youth contraceptive use: a difference-in-difference analysis across New England states. Contemporary Economic Policy. 2015;33(3):405-17.
- Bumbul E, Starek M, Szymusik I, Pietrzak B, Bumbuliene Z, Kosinska-Kaczynska K, et al.
   Advantages and disadvantages of over-the-counter availability of emergency contraception.
   Neuro Endocrinology Letters. 2013;34(7):655-9.

1		
2 3		
3 4	20.	Cintina I. Behind-the-Counter, but Over-the-Border? The Assessment of the Geographical
5		Spillover Effects of Emergency Contraception on Abortions. Health Economics.
6		2017;26(10):1249-63.
7	21.	Cintina I, Johansen MS. The Effect of Plan B on Teen Abortions: Evidence from the 2006 FDA
8	00	Ruling. Contemporary Economic Policy. 2015;33(3):418-33.
9	22.	Durrance CP. The Effects of Increased Access to Emergency Contraception on Sexually
10	00	Transmitted Disease and Abortion Rates. Economic Inquiry. 2013;51(3):1682-95.
11	23.	Falah-Hassani K, Kosunen E, Shiri R, Rimpelä A. Emergency contraception among Finnish
12		adolescents: awareness, use and the effect of non-prescription status. BMC public health.
13	24.	2007;7:201. Girma S, Paton D. The impact of emergency birth control on teen pregnancy and STIs. Journal
14 15	24.	of Health Economics. 2011;30(2):373-80.
15 16	25.	Harper CC, Cheong M, Rocca CH, Darney PD, Raine TR. The effect of increased access to
17	25.	emergency contraception among young adolescents. Obstetrics and Gynecology.
18		2005;106(3):483-91.
19	26.	Killick SR, Irving G. A national study examining the effect of making emergency hormonal
20	20.	contraception available without prescription. Hum Reprod. 2004;19(3):553-7.
21	27.	Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency
22		hormonal contraception available over the counter in Great Britain: repeated cross sectional
23		surveys. Bmj. 2005;331(7511):271.
24	28.	Moreau C, Bajos N, Trussell J. The impact of pharmacy access to emergency contraceptive pills
25		in France. Contraception. 2006;73(6):602-8.
26	29.	Mulligan K. Access to Emergency Contraception and its Impact on Fertility and Sexual
27		Behavior. Health Economics (United Kingdom). 2016;25(4):455-69.
28 29	30.	Novikova N, Weisberg E, Fraser IS. Does readily available emergency contraception increase
30		women's awareness and use? Eur J Contracept Reprod Health Care. 2009;14(1):39-45.
31	31.	Payakachat N, Ragland D, Houston C. Impact of emergency contraception status on unintended
32		pregnancy; observational data from a pharmacy practice. Pharmacy Practice. 2010;8(3):173-8.
33	32.	Pentel PR, Nelson B, Wikelius N, Cooper C. Hospital-based program for increasing the
34		availability of emergency contraception: simulating nonprescription access. American journal of
35		health-system pharmacy: AJHP: official journal of the American Society of Health-System
36		Pharmacists. 2004;61(8):777-80.
37	33.	Raine T, Harper C, Rocca CH, Fischer R, Padian N, Klausner D, et al. Direct access to
38		emergency contraception through pharmacies and effect on unintended pregnancy and STIs: A
39 40		randomized controlled trial. JAMA - Journal of the American Medical Association.
40 41	0.4	2005;293(1):54-62.
41	34.	Rocca CH, Schwarz EB, Stewart FH, Darney PD, Raine TR, Harper CC. Beyond access:
43		Acceptability, use and nonuse of emergency contraception among young women. American
44	25	Journal of Obstetrics and Gynecology. 2007;196(1):29.e1e6.
45	35.	Rubin AG, Gold MA, Kim Y, Schwarz EB. Use of Emergency Contraception by US Teens: Effect of Access on Promptness of Use and Satisfaction. Journal of Pediatric and Adolescent
46		Gynecology. 2011;24(5):287-90.
47	36.	Soon JA, Levine M, Osmond BL, Ensom MHH, Fielding DW. Effects of making emergency
48	50.	contraception available without a physician's prescription: A population-based study. Canadian
49		Medical Association Journal. 2005;172(7):878-83.
50	37.	Aneblom G, Larsson M, Von Essen L, Tydén T. Women's voices about emergency
51	07.	contraceptive pills "over-the-counter": A Swedish perspective. Contraception. 2002;66(5):339-
52 53		43.
53 54	38.	Aneblom G, Lundborg CS, Carlsten A, Eurenius K, Tyden T. Emergency contraceptive pills
55		over-the-counter: practices and attitudes of pharmacy and nurse-midwife providers. Patient
56		Educ Couns. 2004;55(1):129-35.
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 39. Bissell P. Anderson C. Supplying emergency contraception via community pharmacies in the UK: reflections on the experiences of users and providers. Social Science & Medicine (1982). 2003;57(12):2367-78.
- 40. Bissell P, Savage I, Anderson C. A gualitative study of pharmacists' perspectives on the supply of emergency hormonal contraception via patient group direction in the UK. Contraception. 2006;73(3):265-70.
- 41. Blackwell D, Cooper N, Taylor G, Holden K. Pharmacists' concerns and perceived benefits from deregulation of hormonal emergency contraception (HEC). British Journal of Family Planning. 1999;25(3):100-4.
- 42. Cooper RJ, Bissell P, Wingfield J. Ethical, religious and factual beliefs about the supply of emergency hormonal contraception by UK community pharmacists. The Journal of Family Planning and Reproductive Health Care. 2008;34(1):47-50.
- 43. David M, Berends L, Bartley J. Current Opinion of Obstetricians on the Prescription of Emergency Contraception: A German-American Comparison. Geburtshilfe Und Frauenheilkunde, 2012;72(11):1004-8.
- 44. Dixit A, Khan ME, Bhatnagar I. Mainstreaming of emergency contraception pill in India: challenges and opportunities. Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive & Social Medicine. 2015;40(1):49-55.
- Downing SG, Payze C, Doyle-Adams S, Gorton C. Emergency contraception over-the-counter: 45. practices and attitudes of pharmacists and pharmacy assistants in far North Queensland. Aust N Z J Obstet Gynaecol. 2011:51(6):527-31.
- 46. Dunn S, Brown TER, Cohen MM, Cockerill R, Wichman K, Weir N, et al. Pharmacy provision of emergency contraception: the Ontario emergency contraception pilot project. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique et gynecologie du Canada: JOGC. 2003;25(11):923-30.
- 29 47. Ehrle N, Sarker M. Emergency contraceptive pills: knowledge and attitudes of pharmacy 30 personnel in Managua, Nicaragua. Int Perspect Sex Reprod Health. 2011;37(2):67-74. 31
  - 48. El-Ibiary SY, Raine T, McIntosh J, Darney PD, Harper CC. Pharmacy access to emergency contraception: Perspectives of pharmacists at a chain pharmacy in San Francisco. Journal of the American Pharmacists Association : JAPhA. 2007;47(6):702-10.
- 34 49. Folkes L, Graham A, Weiss M, Folkes L, Graham A, Weiss M. A gualitative study of the views of 35 women aged 18-29 on over-the-counter availability of hormonal emergency contraception. 36 37 Journal of Family Planning & Reproductive Health Care. 2001;27(4):189-92. 38
  - 50. Foster DG, Landau SC, Monastersky N, Chung F, Kim N, Melton M, et al. Pharmacy access to emergency contraception in California. Perspectives on Sexual and Reproductive Health. 2006;38(1):46-52.
  - 51. Fuentes EC, Azize-Vargas Y. Knowledge, attitudes and practices in a group of pharmacists in Puerto Rico regarding emergency contraception, P R Health Sci J. 2007:26(3):191-7.
- 43 52. Gainer E, Blum J, Toverud EL, Portugal N, Tyden T, Nesheim BI, et al. Bringing emergency 44 contraception over the counter: experiences of nonprescription users in France, Norway, 45 Sweden and Portugal. Contraception. 2003;68(2):117-24. 46
- 53. Golden NH, Seigel WM, Fisher M, Schneider M, Quijano E, Suss A, et al. Emergency 47 contraception: Pediatricians' knowledge, attitudes, and opinions. Pediatrics. 2001;107(2):287-48 92. 49
- 54. Griggs SK, Brown CM. Texas community pharmacists' willingness to participate in pharmacist-50 initiated emergency contraception. Journal of the American Pharmacists Association: JAPhA. 2007;47(1):48-57.
- 52 HäggstrÖm-Nordin E, Tydén T. Swedish teenagers' attitudes toward the emergency 55. 53 contraceptive pill. Journal of Adolescent Health. 2001;28(4):313-8. 54
- 55

51

56 57

1

2 3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18 19

20

21

22

23

24

25

26

27

28

32

33

39

40

41

42

1		
2		
3	56.	Hariparsad N. Attitudes and practices of pharmacists towards emergency contraception in
4	00.	Durban, South Africa. European Journal of Contraception and Reproductive Health Care.
5		2001;6(2):87-92.
6	<b>F7</b>	
7	57.	Harvey SM, Beckman LJ, Sherman C, Petitti D. Women's experience and satisfaction with
8		emergency contraception. Fam Plann Perspect. 1999;31(5):237-40, 60.
9	58.	Hellerstedt WL, Van Riper KK. Emergency contraceptive pills: dispensing practices, knowledge
) 10		and attitudes of South Dakota pharmacists. Perspect Sex Reprod Health. 2005;37(1):19-24.
11	59.	Hernandez JH, Muanda M, Garcia M, Matawa G. Awareness and Perceptions of Emergency
		Contraceptive Pills Among Women in Kinshasa, Democratic Republic of the Congo.
12		International Perspectives on Sexual and Reproductive Health. 2017;43(3):121-30.
13	60.	Hickey MT, Shedlin MG. Emergency contraceptive pill users' risk perceptions for sexually
14	00.	
15		transmitted infections and future unintended pregnancy. J Am Assoc Nurse Pract.
16		2017;29(9):527-34.
17	61.	Hobbs M, Taft AJ, Amir LH. The emergency contraceptive pill rescheduled: a focus group study
18		of women's knowledge, attitudes and experiences. J Fam Plann Reprod Health Care.
19		2009;35(2):87-91.
20	62.	Hopkins D, West D. Arkansas pharmacists' perceptions toward emergency contraception and
21	•	nonprescription Plan B. Pharmacy Practice. 2008;6(2):98-102.
22	63.	Hussainy SY, Stewart K, Chapman CB, Taft AJ, Amir LH, Hobbs MK, et al. Provision of the
23	03.	
24		emergency contraceptive pill without prescription: attitudes and practices of pharmacists in
25	<b>.</b> .	Australia. Contraception. 2011;83(2):159-66.
26	64.	Irfan F, Karim SI, Hashmi S, Ali S, Ali SA. Knowledge of emergency contraception among
20 27		women of childbearing age at a teaching hospital of Karachi. Journal of the Pakistan Medical
		Association. 2009;59(4):235-40.
28	65.	Joseph N, Shetty B, Hasreen F, Ishwarya R, Baniya M, Sachdeva S, et al. Awareness and
29		Attitudes Toward Emergency Contraceptives Among College Students in South India. Journal of
30		Obstetrics and Gynaecology of India. 2016;66(Suppl 1):363-9.
31	66	
32	66.	Karim SI, Irfan F, Al Rowais N, Al Zahrani B, Qureshi R, Al Qadrah BH. Emergency
33		contraception: Awareness, attitudes and barriers of Saudi Arabian women. Pakistan Journal of
34		Medical Sciences. 2015;31(6):1500-5.
35	67.	Khan ME, Dixit A, Bhatnagar I, Brady M. Medical barriers to emergency contraception: a cross-
36		sectional survey of doctors in North India. Glob Health Sci Pract. 2014;2(2):210-8.
37	68.	Kim HW. Sex differences in the awareness of emergency contraceptive pills associated with
38		unmarried Korean university students' intention to use contraceptive methods: an online survey.
39		Reprod Health. 2015;12:91.
40	69.	Krassovics M, Viragh G. Usage patterns and attitudes towards emergency contraception: the
41	09.	
42		International Emergency Contraception Research Initiative. Eur J Contracept Reprod Health
43		Care. 2016;21(4):310-7.
	70.	Krishnamurti T, Eggers SL, Fischhoff B. The impact of over-the-counter availability of "Plan B"
44		on teens' contraceptive decision making. Soc Sci Med. 2008;67(4):618-27.
45	71.	Kumar AS, Hall LC, LePage A, Lim PC. Providing emergency contraceptive pills "behind-the-
46		counter": opinions among Minnesota healthcare providers. Contraception. 2003;68(4):253-9.
47	72.	Landau S, Besinque K, Chung F, Dries-Daffner I, Maderas NM, McGhee BT, et al. Pharmacist
48	12.	interest in and attitudes toward direct pharmacy access to hormonal contraception in the United
49		
50	70	States. Journal of the American Pharmacists Association : JAPhA. 2009;49(1):43-50.
51	73.	Landau SC, Tapias MP, McGhee BT. Birth control within reach: a national survey on women's
52		attitudes toward and interest in pharmacy access to hormonal contraception. Contraception.
53		2006;74(6):463-70.
54	74.	Langille DB, Allen M, Whelan AM. Emergency contraception: knowledge and attitudes of Nova
55		Scotian family physicians. Can Fam Physician. 2012;58(5):548-54.
56		
57		
58		
58 59		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
UU		i of peer terrent only integration poper interfacional state about guidelines within

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright


#### **BMJ** Open

1

60

2 3 75. Larsson M. Eurenius K. Westerling R. Tyden T. Emergency contraceptive pills over-the-counter: 4 a population-based survey of young Swedish women. Contraception. 2004;69(4):309-15. 5 Lee ES, Lee CA, Lee JH, Park BR, Lee I. The attitudes of Korean physicians toward emergency 76. 6 contraceptive pills: regarding women's access and rescheduling. Obstetrics & Gynecology 7 Science, 2019:62(3):173-8. 8 77. Lim SW, Iheagwara KN, Legano L, Coupey SM. Emergency contraception: are pediatric 9 residents counseling and prescribing to teens? J Pediatr Adolesc Gynecol. 2008;21(3):129-34. 10 78. Lo SST, Kok WM, Fan SYS. Emergency contraception: Knowledge, attitude and prescription 11 practice among doctors in different specialties in Hong Kong. Journal of Obstetrics and 12 Gynaecology Research. 2009;35(4):767-74. 13 79. Maharaj P, Rogan M. Missing opportunities for preventing unwanted pregnancy: A gualitative 14 study of emergency contraception. Journal of Family Planning and Reproductive Health Care. 15 2011;37(2):89-96. 16 Miller LM. College student knowledge and attitudes toward emergency contraception. 80. 17 Contraception, 2011:83(1):68-73. 18 19 81. Peremans L, Verhoeven V, Philips H, Denekens J, Van Royen P. How does a Belgian health 20 care provider deal with a request for emergency contraception? The European Journal of 21 Contraception & Reproductive Health Care: The Official Journal of the European Society of 22 Contraception. 2007;12(4):317-25. 23 82. Ragland D, West D. Pharmacy students' knowledge, attitudes, and behaviors regarding 24 emergency contraception. American Journal of Pharmaceutical Education. 2009;73(2). 25 83. Syahlul DE, Amir LH. Do Indonesian medical practitioners approve the availability of emergency 26 contraception over-the-counter? A survey of general practitioners and obstetricians in Jakarta. 27 BMC Women's Health. 2005;5. 28 84. Vahratian A, Patel DA, Wolff K, Xu X. College students' perceptions of emergency contraception 29 provision. Journal of Women's Health (2002). 2008;17(1):103-11. 30 85. Wan RSF, Lo SST. Are women ready for more liberal delivery of emergency contraceptive pills? 31 Contraception, 2005;71(6);432-7. 32 86. Whelan AM, Langille D, Hurst E, Aylward S, Wedlake S. Nova Scotia pharmacists and 33 emergency contraception pills: Attitudes and beliefs. Canadian Pharmacists Journal. 34 2011;144(5):e39. 35 Wu J, Gipson T, Chin N, Wynn LL, Cleland K, Morrison C, et al. Women seeking emergency 87. 36 contraceptive pills by using the internet. Obstet Gynecol. 2007;110(1):44-52. 37 88. Xu X, Vahratian A, Patel DA, McRee AL, Ransom SB. Emergency contraception provision: a 38 39 survey of Michigan physicians from five medical specialties. J Womens Health (Larchmt). 40 2007;16(4):489-98. 41 89. Yam EA, Gordon-Strachan G, McIntyre G, Fletcher H, Garcia SG, Becker D, et al. Jamaican 42 and Barbadian health care providers' knowledge, attitudes and practices regarding emergency 43 contraceptive pills. International Family Planning Perspectives. 2007;33(4):160-7. 44 90. Yuksel N, Schindel T, Siyam T, Hocevar S. Pharmacists' beliefs about Plan B as an over-the-45 counter product. Canadian Pharmacists Journal. 2011;144(5):e40. 46 91. Ziebland S, Graham A, McPherson A. Concerns and cautions about prescribing and 47 deregulating emergency contraception: a gualitative study of GPs using telephone interviews. 48 Fam Pract. 1998;15(5):449-56. 49 Foster DG, Raine TR, Brindis C, Rostovtseva DP, Darney PD. Should providers give women 92. 50 advance provision of emergency contraceptive pills? A cost-effectiveness analysis. Women's 51 Health Issues: Official Publication of the Jacobs Institute of Women's Health. 2010;20(4):242-7. 52 93. Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of 53 pharmacist-prescribed emergency contraception. Am J Public Health. 2001;91(9):1443-5. 54 94. Soon JA, Meckley LM, Levine M, Marciante KD, Fielding DW, Ensom MHH. Modelling costs and 55 outcomes of expanded availability of emergency contraceptive use in British Columbia. The 56 57 58 59 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 ว		
2 3		Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique.
4		2007;14(3):e326-38.
5 6	95.	World Health Organization. Devastatingly pervasive: 1 in 3 women globally experience violence
7		2021 [Available from: https://www.who.int/news/item/09-03-2021-devastatingly-pervasive-1-in-3-women-globally-experience-violence.
8 9	96.	O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to
10		interventions: Using PROGRESS ensures consideration of socially stratifying factors to
11 12		illuminate inequities in health. Journal of Clinical Epidemiology. 2014;67(1):56-64.
12		
14		
15 16		
17		
18 19		
20		
21 22		
23		
24 25		
26		
27 28		
28 29		
30 31		
32		
33		
34 35		
36		
37 38		
39 40		
40 41		
42		
43 44		
45		
46 47		
48		
49 50		
51		
52 53		
54		
55 56		
57		
58 59		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml






Figure 1. PRISMA flow chart showing disposition of citations through the search and screening process.

$     \begin{array}{c}       1 \\       2 \\       3 \\       4 \\       5 \\       6 \\       7 \\       8 \\       9 \\       10 \\       11 \\       12 \\       13 \\       14 \\       15 \\       16 \\       17 \\       18 \\       19 \\       20 \\       21 \\       22 \\       23 \\       24 \\       25 \\       26 \\       27 \\       28 \\       29 \\       30 \\       31 \\       32 \\       33 \\       34 \\       35 \\       36 \\       37 \\       38 \\       39 \\       40 \\       41 \\       42 \\       43 \\       44 \\       45 \\       46 \\       47 \\       48 \\       49 \\       50 \\       51 \\       52 \\       53 \\       54 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       55 \\       56 \\       57 \\       57 \\       55 \\       56 \\       57 \\       57 \\       55 \\       56 \\       57 \\       57 \\       57 \\       55 \\       56 \\       57 \\      57 \\      57 \\       57 \\      57 \\      57 \\      57 \\   $	First 2. Map showing distribution of studies included in the values and preferences review.         23x157mm (120 x 120 pr)
57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

57 58 59

60

#### **APPENDIX: Search Strategy**

The following search strategy was adapted for entry into all computer databases. These search terms were used both for the main systematic review (PICO question) and for the values and preferences and cost reviews.

("Contraceptives, Oral" [Mesh] OR "Contraceptives, Postcoital" [Mesh] OR "emergency contraceptive pill" [tiab] OR "emergency contraceptive pills" [tiab] OR "morning-after pill" [tiab] OR "Plan B One-Step" [tiab] OR "Take Action" [tiab] OR "Next Choice One-Dose" [tiab] OR "My Way" [tiab] OR "AfterPill" [tiab] OR "Preventeza" [tiab] OR "My Choice" [tiab] OR "Aftera" [tiab] OR "Athentia Next" [tiab] OR "EContra Ez" [tiab] OR "Fallback Solo" [tiab] OR "Opcicon One-Step" [tiab] OR "Option 2" [tiab] OR "Afirmelle" [tiab] OR "Altavera" [tiab] OR "Amethia" [tiab] OR "Amethia Lo" [tiab] OR "Amethyst" [tiab] OR "Aubra" [tiab] OR "Ayuna" [tiab] OR "Aviane" [tiab] OR "Camrese" [tiab] OR "CamreseLo" [tiab] OR "Chateal" [tiab] OR "Cryselle" [tiab] OR "Elinest" [tiab] OR "Enpresse" [tiab] OR "Falmina" [tiab] OR "Introvale" [tiab] OR "Jolessa" [tiab] OR "Kurvelo" [tiab] OR "Lessina" [tiab] OR "Lenovest" [tiab] OR "Levora" [tiab] OR "LoSeasonique" [tiab] OR "Low-Ogestrel" [tiab] OR "Lutera" [tiab] OR "Marlissa" [tiab] OR "Myzilra" [tiab] OR "Nordette" [tiab] OR "Orsythia" [tiab] OR "Portia" [tiab] OR "Quasense" [tiab] OR "Seasonale" [tiab] OR "Seasonique" [tiab] OR "Setlakin" [tiab] OR "Sronyx" [tiab] OR "Triphasil" [tiab] OR "Trivora" [tiab] OR "Vienva" [tiab] OR "After-1" [tiab] OR "Agesta" [tiab] OR "Ai Wu You" [tiab] OR "Aleze EC" [tiab] OR "Alterna" [tiab] OR "Amor" [tiab] OR "An Ting" [tiab] OR "Anlitin" [tiab] OR "Anthia" [tiab] OR "Auxxil" [tiab] OR "Bao Shi Ting" [tiab] OR "Bi Yun" [tiab] OR "Ciel EC" [tiab] OR "Contragest" [tiab] OR "Contraplan II" [tiab] OR "Control NF" [tiab] OR "Control Uno" [tiab] OR "Copill" [tiab] OR "Curesinor" [tiab] OR "D-Sigyent" [tiab] OR "Dan Mei" [tiab] OR "Dia S MP" [tiab] OR "Diad" [tiab] OR "Dreams" [tiab] OR "Duet" [tiab] OR "Duprisal 30" [tiab] OR "Dvella" [tiab] OR "E Pills" [tiab] OR "E-72" [tiab] OR "e-con" [tiab] OR "ECee2" [tiab] OR "ECP" [tiab] OR "ella" [tiab] OR "ellaOne" [tiab] OR "Emcon" [tiab] OR "Emergyn" [tiab] OR "Emkit" [tiab] OR "Emkit Plus" [tiab] OR "Escapel" [tiab] OR "Escapel-1" [tiab] OR "Escapel-2" [tiab] OR "Escapelle" [tiab] OR "Escinor" [tiab] OR "Estinor" [tiab] OR "Evadir 2" [tiab] OR "Evital" [tiab] OR "Evitarem" [tiab] OR "Fermerleve Sagiram" [tiab] OR "Feminor" [tiab] OR "Fertilan" [tiab] OR "Fu Nai Er" [tiab] OR "G-Nancy" [tiab] OR "Glanique" [tiab] OR "Glanix" [tiab] OR "Glostinor 2" [tiab] OR "Gynepriston" [tiab] OR "Gynotrel 2" [tiab] OR "Hispratel" [tiab] OR "Hou Ding Nuo" [tiab] OR "Hua Dian" [tiab] OR "Hui Ting" [tiab] OR "i-pill" [tiab] OR "Imediat" [tiab] OR "Imediat N" [tiab] OR "Impreviat" [tiab] OR "Jin Xiao" [tiab] OR "Jin Yu Ting" [tiab] OR "Ka Rui Ding" [tiab] OR "L Novafem" [tiab] OR "Laliades" [tiab] OR "Le Ting" [tiab] OR "Lenor 72" [tiab] OR "Levo-72" [tiab] OR "Levodonna" [tiab] OR "Levogest" [tiab] OR "Levogynon 1500" [tiab] OR "Levonelle" [tiab] OR "Levonelle-1" [tiab] OR "Levonia" [tiab] OR "Levonorgestrol Biogaran 1500" [tiab] OR "Levonorgestrel Richter" [tiab] OR "Levonormin" [tiab] OR "Lonel" [tiab] OR "Longil" [tiab] OR "Lydia 1Safe Pill" [tiab] OR "Lydia Post Pill" [tiab] OR "Madonna" [tiab] OR "Max-72" [tiab] OR "Me Tablet" [tiab] OR "Mergynex" [tiab] OR "Mifepristone 72" [tiab] OR "Mifestad 10" [tiab] OR "Minipil 2" [tiab] OR "Morning After" [tiab] OR "MS Pill" [tiab] OR "Negele" [tiab] OR "Nerostinor" [tiab] OR "Next Choice" [tiab] OR "Nicpostinew" [tiab] OR "Nogestrol" [tiab] OR "Nogravide" [tiab] OR "Norgestrel Max Unidosis" [tiab] OR "Norgestrel-Max" [tiab] OR "NorLevo" [tiab] OR "Nortrel 2" [tiab] OR "Novalen" [tiab] OR "Oportuna" [tiab] OR "Optinor" [tiab] OR "Ovocease" [tiab] OR "Ovulol" [tiab] OR "P2" [tiab] OR "PiDaNa" [tiab] OR "Pilem" [tiab] OR "Pill 72" [tiab] OR "Pillanor 2" [tiab] OR "Pillex" [tiab] OR "Pilule S" [tiab] OR "Planfam" [tiab] OR "Poslov" [tiab] OR "PostDav" [tiab] OR "Poster Tablets" [tiab] OR "Postiga 4" [tiab] OR "Postinor" [tiab] OR "Postinor 1" [tiab] OR "Postinor 1.5" [tiab] OR "Postinor 1500" [tiab] OR "Postinor 2 SD" [tiab] OR "Postinor Duo" [tiab] OR "Postinor Life" [tiab] OR "Postinor PI" [tiab] OR "Postinor Uno" [tiab] OR "Postinor-2" [tiab] OR "Postinor-2 Unidosis" [tiab] 45 OR "Postpill" [tiab] OR "Pozato" [tiab] OR "Pozato Uni" [tiab] OR "PPMS" [tiab] OR "Pregnon" [tiab] OR "Pregnon 46 1" [tiab] OR "Pregnon 1.5" [tiab] OR "Prevemb" [tiab] OR "Preventol" [tiab] OR "Previdez 2" [tiab] OR "Previfem" 47 [tiab] OR "Prevyol" [tiab] OR "Prikul" [tiab] OR "Pronta" [tiab] OR "Prudence for Her" [tiab] OR "Rely-X" [tiab] OR 48 "Revoke 1.5" [tiab] OR "Revoke 72" [tiab] OR "Rigesoft" [tiab] OR "Rogotinor" [tiab] OR "Secufem" [tiab] OR 49 "Seguidet" [tiab] OR "Segurit" [tiab] OR "Segurite UD" [tiab] OR "SEKURE" [tiab] OR "Sendinor 2" [tiab] OR 50 "Sexcon One&One" [tiab] OR "Si Mi An" [tiab] OR "Silogin" [tiab] OR "Smart Lady (Pregnon)" [tiab] OR "So-Ezzy" 51 52 [tiab] OR "Tace" [tiab] OR "Tibex" [tiab] OR "Truston-2" [tiab] OR "Ulipristal 30" [tiab] OR "Unlevo 1500" [tiab] OR "Unofem" [tiab] OR "Unwanted 72" [tiab] OR "Upostelle" [tiab] OR "UPRIS" [tiab] OR "Vermagest" [tiab] OR "Vika" 53 54 [tiab] OR "Vikela" [tiab] OR "Vonstrel" [tiab] OR "Xian Ju" [tiab] OR "Yi Ting" [tiab] OR "Yu Ting" [tiab] OR 55 "Zimtemore" [tiab]) 56

4 5 6 7 8 9 10 11 12 13	AND ("Nonprescription Drugs" [Mesh] OR nonprescription [tiab] OR "over the counter" [tiab] OR "over-the-counter" [tiab] OR "without a prescription" [tiab] OR "pharmacist-prescribed" [tiab] OR "pharmacy access" [tiab] OR "clinician-prescribed" [tiab] OR "physician-prescribed" [tiab] OR "GP-prescribed" [tiab] OR "general practitioner prescribed" [tiab] OR "without prescription" [tiab] OR "community pharmacy services" [Mesh] OR "community center" [tiab] OR "community centre" [tiab] OR store [tiab] OR shop [tiab] OR online [tiab] OR mobile [tiab] OR telehealth [tiab])
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



		BMJ Open	Page 28 of 28
PRISMA 20	009 (	Checklist Per-2021-	
Section/topic	#	Checklist item 254	Reported on page #
TITLE	1 1		
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
2 Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	2
s Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4-5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study guthors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	25
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4-5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
2 Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	NA
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for eachemetaranalysis. http://bmjopen.bmj.com/site/about/guidelines.xhtml	NA



### PRISMA 2009 Checklist

#### Page 1 of 2

Page 29 of 28			BMJ Open 6	
1 2	PRISMA 20	009	BMJ Open 36, bmj open 2021	
3 4			Page 1 of 2	
5 6 7	Section/topic	#	Checklist item	Reported on page #
8 9	Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	NA
10 11 12	Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
1	RESULTS			
14 15 16	Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
17	Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOs, follow-up period) and provide the citations.	6-10
19	Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	6-10
2 2 2	Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6-8, 11- 12
23	Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	NA
2	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	NA
20 2	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7-8
28	I DISCUSSION ₽			
29 30 31	Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
32	Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., in complete retrieval of identified research, reporting bias).	15-16
34 35	Canalysiana	26	Provide a general interpretation of the results in the context of other evidence, and implication future research.	15-16
30	36 FUNDING			
38 39	<sup>3</sup> Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data; role of funders for the systematic review.	17
4( 4) 42 43 44	doi:10.1371/journal.pmed1000097	J, Altma	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med For more information, visit: <u>www.prisma-statement.org</u> .	6(7): e1000097.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 45 46
- 47

# **BMJ Open**

## Over-the-counter provision of emergency contraceptive pills: A systematic review

Journal:	BMJ Open				
Manuscript ID	bmjopen-2021-054122.R1				
Article Type:	Original research				
Date Submitted by the Author:	20-Dec-2021				
Complete List of Authors:	Atkins, Kaitlyn; Johns Hopkins University Bloomberg School of Public Health, Department of International Health Kennedy, Caitlin; Johns Hopkins University Bloomberg School of Public Health, International Health Yeh, Ping; Johns Hopkins University Bloomberg School of Public Health, Department of International Health Narasimhan, Manjulaa; World Health Organization, Department of Sexual and Reproductive Health and Research				
<b>Primary Subject Heading</b> :	Obstetrics and gynaecology				
Secondary Subject Heading:	Global health, Health services research, Patient-centred medicine, Sexual health, Reproductive medicine				
Keywords:	PUBLIC HEALTH, Maternal medicine < OBSTETRICS, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Reproductive medicine < GYNAECOLOGY				
	·				

SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

#### Over-the-counter provision of emergency contraceptive pills: A systematic review

Kaitlyn Atkins<sup>1</sup>, Caitlin E. Kennedy<sup>1</sup>, Ping Teresa Yeh<sup>1</sup>, Manjulaa Narasimhan<sup>2</sup>

<sup>1</sup> Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Kaitlyn Atkins, PhD Candidate. Caitlin E. Kennedy, Associate Professor. Ping Teresa Yeh, Research Associate.

<sup>2</sup> Department of Sexual and Reproductive Health and Research, World Health Organization, includes the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction – HRP, Geneva, Switzerland. Manjulaa Narasimhan, Scientist.

#### **Correspondence to:**

Manjulaa Narasimhan

Department of Sexual and Reproductive Health and Research UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme World Health Organization vitzerlan 20 Avenue Appia, 1211 Geneva 27, Switzerland

Email: narasimhanm@who.int

#### Word count: 4867

#### Abstract

**Objective:** To synthesize evidence around over-the-counter (OTC) emergency contraceptive pills (ECPs) to expand the evidence base on self-care interventions..

Design: Systematic review (PROSPERO# CRD42021231625).

**Eligibility criteria:** We included publications comparing OTC or pharmacy-access ECP with prescriptiononly ECPs and measuring ECP uptake, correct use, unintended pregnancy, abortion, sexual practices/behavior, self-efficacy, and side-effects/harms. We also reviewed studies assessing values/preferences and costs of OTC ECPs.

**Data sources:** We searched PubMed, CINAL, LILACS, EMBASE, clinicaltrials.gov, WHO International Clinical Trials Registry Platform, Pan African Clinical Trials Registry, Australian New Zealand Clinical Trials Registry, Cochrane Fertility Regulation, and International Consortium for Emergency Contraception through December 2, 2020.

**Risk of bias:** For trials, we used Cochrane Collaboration's tool for assessing risk of bias; for other studies, we used the Evidence Project risk of bias tool.

**Data extraction and synthesis:** We summarized data in duplicate using GRADE Evidence Profile tables, reporting findings by study design and outcome. We qualitatively synthesized values/preferences and cost data.

**Results:** We included 19 studies evaluating effectiveness of OTC ECP, 56 on values/preferences, and three on costs. All studies except one were from high- and middle-income settings. Broadly, there were no differences in overall ECP use, pregnancy, or sexual behavior, but an increase in timely ECP use, when comparing OTC or pharmacy ECP to prescription-only ECP groups. Studies showed similar/lower abortion rates in areas with pharmacy availability of ECPs. Users and providers generally supported OTC ECPs; decisions for use were influenced by privacy/confidentiality, convenience, and cost. Three modeling studies found pharmacy-access ECPs would lower health sector costs.

**Conclusion:** OTC ECPs are feasible and acceptable. They may increase access to and timely use of effective contraception. Existing evidence suggests OTC ECPs do not substantively change reproductive health outcomes. Future studies should examine OTC ECP's impacts on user costs, among key subgroups, and in low-resource settings.

Keywords: emergency contraceptives, contraceptives, pregnancy, pharmaceutical services, self-care

#### Strengths and limitations of this study

- We comprehensively searched the literature on effectiveness, costs, and values and preferences of over-the-counter emergency contraception.
- We searched four major databases and four clinical trial registries, with no restrictions on •
- Given our focus on over-the-counter delivery modalities, we may have excluded studies that • assessed relevant outcomes of expanded access to emergency contraception through advance
- The findings of this review may not be generalizable, as the majority of studies were conducted in •

## Introduction

The World Health Organization (WHO) recommends the use of several forms of emergency contraception, which can substantially reduce unintended pregnancy when used correctly [1, 2]. Reducing barriers to emergency contraceptive pills (ECPs) may increase access to effective contraceptive options, reduce unintended pregnancies, and overall improve outcomes related to sexual and reproductive health and rights [3].

In many settings, ECPs are delivered through one or more modalities [4]: (1) prescription-only, wherein physicians or other medical providers prescribe ECPs based on individual need; (2) pharmacy access (also called behind-the-counter), wherein the medication is available via screening or prescription from a pharmacist; and (3) OTC, wherein medication is available on store shelves without a prescription. As of December 2021, ECPs are available via pharmacy access in 76 countries, and OTC in 19 countries [5]. While both pharmacy access and OTC may reduce barriers to access by no longer requiring a visit to a physician or other health care provider, pharmacy access still requires the presence of a pharmacist, while truly OTC availability means an individual can purchase medication in the absence of a medical or pharmacy provider.

While countries have varying regulatory criteria involved in making a specific medication available OTC or with eligibility screening by pharmacy staff [6], the WHO is responsible to provide overall guidance to critical questions of intervention recommendations. The 2019 WHO normative guidance on self-care interventions [7] included a recommendation on OTC oral contraception (contraceptive pills). This was informed by a previous systematic review [8], in which we found that OTC oral contraception may result in higher continuation with limited contraindicated use among users, and was generally supported by patients and providers. This earlier review and the 2019 WHO guidance did not include OTC delivery of ECPs. We therefore conducted this systematic review as part of expanding the evidence base of the guideline.

This review was also conducted in response to the COVID-19 pandemic that has seen overstretched health systems and disruptions of health services globally [9, 10]. WHO has prioritized self-care interventions in response to maintaining essential sexual and reproductive health services during the pandemic as people fail to access care and services, highlighting the need to improve availability of options that people can use outside of formal health facilities [9, 11-13]. Further, WHO has warned that the COVID-19 pandemic has further increased women's exposure to intimate partner violence, as a result of measures such as lockdowns and disruptions to vital support services [14], which may lead more women and girls to need and/or use OTC ECPs. In addition, supply-side constraints and other barriers related to COVID-19 may reduce access and availability of condoms and other forms of medically prescribed contraceptive options, thus increasing the need for and importance of OTC ECPs [10, 15-17].

## Methods

This review addressed the following question: Should ECPs be made available without a clinician's prescription? We reviewed the extant literature in three areas relevant to this question: effectiveness of the intervention, values and preferences of end-users and providers, and cost information. These three areas are all required information in the WHO guideline development process [18]. The review followed Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (see Appendix 1) [19], and the protocol was published on PROSPERO (registration number CRD42021231625). Ethical approval was not required for this systematic review, since all data came from information freely available in the public domain (i.e. published articles).

## Effectiveness review inclusion criteria

The effectiveness review was designed according to the PICO format as follows:

• Population: Individuals using ECPs

- **Intervention**: Availability of ECPs OTC (without a prescription or screening) or from a pharmacist (behind-the-counter or pharmacy access)
- **Comparison**: Availability of ECPs by prescription only (by a clinician other than a pharmacist)
- **Outcomes**: (1) Uptake of ECPs (initial use); (2) Correct use of ECPs, including comprehension of product label instructions; (3) Unintended pregnancy; (4) Abortion (medical or unsafe); (5) Changes in sexual and reproductive health (SRH) practices or behavior; (6) Self-efficacy, self-determination, autonomy, empowerment; (7) Side effects, adverse events, or social harms and whether harms were corrected/had redress available

To be included in the effectiveness review, an article must have: 1) had a study design comparing OTC or behind-the-counter (pharmacy) access of ECPs to prescription-only access (including randomized controlled trials (RCTs), non-randomized trials, and comparative observational studies); 2) measured one or more of the outcomes listed above; and 3) been published in a peer-reviewed journal. We did not restrict inclusion on the basis of language or intervention location. Articles in English, French, Spanish, and Chinese were coded directly; articles in other languages were translated before coding.

For the purposes of this review, we considered both behind-the-counter (pharmacy access) and true OTC availability as "over-the-counter" in our intervention definition. Our definition also includes availability through a range of locations other than pharmacies, including drug shops, vending machines, and online or telehealth services. Although IUD insertion can also be a form of emergency contraception, it requires insertion by a provider and thus cannot be made available OTC. This review thus focuses on ECPs. Studies that examined the provision of ECPs for clients to keep at home versus OTC or prescription-only access were not included.

## Search strategy and screening

We searched four electronic databases (PubMed, CINAL, LILACS, and EMBASE) and four clinical trial registries (clinicaltrials.gov, WHO International Clinical Trials Registry Platform, Pan African Clinical Trials Registry, and Australian New Zealand Clinical Trials Registry). We also searched the website of the Cochrane Fertility Regulation (<u>https://fertility-regulation.cochrane.org/</u>) and its COVID-19 specific page (<u>https://cgf.cochrane.org/news/covid-19-coronavirus-disease-fertility-and-pregnancy</u>), as well as the International Consortium for Emergency Contraception (<u>https://cecinfo.org</u>) and its regional consortia. Electronic databases were searched through December 2, 2020, using consistent search strings including a list of oral and emergency contraceptives, plus terms associated with medication provision without a prescription (see Appendix 2).

Secondary reference searching was conducted on all studies included in the review. Further, selected experts in the field were contacted to identify additional articles not identified through other search methods.

Titles, abstracts, citation information, and descriptor terms of citations identified through the search strategy were screened by a member of the study staff. Full text articles were obtained of all selected abstracts and two independent reviewers assessed all full-text articles for eligibility to determine final study selection. Differences were resolved through consensus.

## Data extraction and management

Two reviewers independently extracted data using standardized forms. Differences in data extraction were resolved through consensus and referral to a senior study team member from WHO when necessary. The following information was gathered from each included study:

- Study identification: Author(s); type of citation; year of publication
- Study description: Study objectives; location; population characteristics; type of ECP; description of OTC access; description of any additional intervention components (e.g. any education, training, support provided); study design; sample size; follow-up periods and loss to follow-up

intervals; significance levels; conclusions; limitations

Outcomes: Analytic approach; outcome measures; comparison groups; effect sizes; confidence

- For RCTs, we assessed risk of bias using the Cochrane Collaboration's tool for assessing risk of bias [20]. For studies that were non-randomized comparative trials, we assessed study rigor using the Evidence Project eight-item risk of bias tool (see Appendix 3) [21]. **Data analysis** We analyzed data according to coding categories and outcomes. If multiple studies reported the same outcome, we conducted meta-analysis using random-effects models to combine risk ratios with the Comprehensive Meta-Analysis program.
  - For each outcome assessed in the review, we summarized data in GRADE Evidence Profile tables using GRADEPro [22]. We used RCT data where they were available; if RCT data were not available for an outcome, we pulled data from observational studies.

Where possible, we stratified analyses by the following subgroups: (1) behind-the-counter vs true OTC; (2) point of access (e.g. stores, pharmacies, telehealth, etc.); (3) type of ECPs (progestin-only vs ulipristal acetate vs combined vs mifepristone); (4) prior use of contraception; (5) age group; (6) vulnerabilities (e.g. poverty, disability, religion, literacy); (7) high-income vs low- or middle-income setting.

## Additional reviews

We conducted additional reviews examining values and preferences and costs of OTC provision of ECPs. We used the same search strategy and terms to identify studies for these reviews. Studies were included in these reviews if they presented results from primary data collection; opinion pieces and reviews were excluded. We summarized this literature qualitatively and presented it with consideration of study design, methodology, location, and population.

<u>Values and preferences review</u>. We included studies in this review if they presented primary data examining preferences of women and girls regarding OTC access to ECPs. We focused on studies examining the values and preferences of women and girls who have used or potentially would use emergency contraceptives themselves, but we also included studies examining the values and preferences of healthcare providers, including in particular pharmacists and other providers. We considered issues around OTC access to ECPs as they relate to age of availability and marital status (both in law and in practice), broader social/structural factors that affect values and preferences, informed decision-making, coercion and seeking redress in this section.

<u>Cost review</u>. We included studies in this review if they presented primary data comparing costing, costeffectiveness, cost-utility, or cost-benefit of the intervention and comparison listed in the PICO above, or if they presented cost-effectiveness of the intervention as it relates to the PICO outcomes listed above. We classified cost literature into four categories (health sector costs, other sector costs, patient/family costs, and productivity impacts) and within each category organized results by study design/methodology, location, and population.

## Patient and public involvement

Feedback on the review protocol and analysis was received from the WHO patient safety working group. Patients were involved in a global survey of values and preferences conducted to inform the WHO guideline on self-care interventions; they thus play a significant role in the overall recommendation informed by this review.

## Results

Our search yielded 2581 unique references, of which 129 were retained for full-text review (Figure 1). Ultimately, we identified 19 studies (reported in 21 articles) that met the inclusion criteria for the effectiveness review [23-43], 56 values and preferences studies [44-98], and three cost studies [99-101].

Figure 1. PRISMA flow chart showing disposition of citations through the search and screening process.

## Effectiveness review

Overall, 19 studies from eight countries (published in 21 articles) met the inclusion criteria for the effectiveness review [23-43] (Table 1). This included one RCT (published in three articles), which was shown to have generally low risk of bias, and 18 observational studies, with risk of bias related to the presence of comparison groups, controls for confounding, and/or pre/post data. All studies were from high-income countries, and most presented data on ECP uptake, changes in SRH practices and behavior, or abortion. Only one study [32, 40, 41] assessed side effects, adverse events, or social harms. There was no comparative data on correct use of ECPs or self-efficacy, self-determination, autonomy, or empowerment. Effect sizes are reported by outcome in Table 2.

## ECP uptake

Nine studies reported on the impacts of OTC and pharmacy-access ECP on ECP use, prescribing, and uptake. Evidence from one RCT [40] showed no difference in use of ECPs with pharmacy access (RR 1.15, 95% CI: 0.90-1.48). In the same trial, there were no differences in ECP use by age [32]. Three serial cross-sectional studies similarly found no changes in overall ECP use over time with implementation of OTC access in Finland [30], the UK [34], and Australia [37]. The studies in Finland and the UK were found to have risk of bias due to lack of comparison groups in either study (both were pre/post only); biases in the study in Australia were related to the absence of a comparison group (pre/post only) and lack of control for confounding in the analysis.

Two cross-sectional studies found that use of ECPs within 24 hours of sex increased with pharmacy access in the UK (18% increase; p=0.03) [33] and the USA (aOR 2.17, 95% CI: 1.06-4.44) [42]. The study in the UK was found to have risk of bias, having no pre/post data and no control for confounding. The study from the USA was found to have risk of bias due to lack of pre/post data. Finally, a study assessing rates of pharmacy distribution in a safety-net hospital showed that ECP distribution increased by 800% over a 1.5-year period, while ECP prescribing increased by 50% over the same period [39]. This study was found to have risk of bias related to having no comparison group (pre/post only) or control for confounders.

When assessing impacts among the subgroup of adolescents and young adults, one study among women aged 16-19 in the UK found that ECP use increased from 15.3% before ECPs were available OTC to 21.5% in the year after OTC ECPs became available (X<sup>2</sup>=1.54, p=0.24), before decreasing 8.5% another year following OTC availability (X<sup>2</sup>=7.11, p=0.01) [34]. Potential bias in this study was from having no comparison group (pre/post only).

## Unintended pregnancy

Two studies assessed unintended pregnancy as an outcome. The one RCT found no significant change in pregnancy among women who did not wish to become pregnant (RR 0.82, 95% CI: 0.53-1.27) [40]; this did not differ by age [32]. A small cross-sectional study among pregnant women receiving prenatal care in the USA found that the proportion of women who reported their pregnancy as unintended increased from 72.7% before pharmacy access to 90.7% after pharmacy access (p=0.02) [38]. This finding was determined to have risk of bias based on having no comparator or control for confounders.

Additionally, one ecological study assessed changes in conception rate over time in the UK [31], which does not explicitly consider whether the pregnancy was intended but is an indirect proxy measure. The study found no differences before or after OTC access among individuals aged 13-19, but was associated

with an increase in conception of about 0.9% among women aged 25-44 (p<0.05) [31]. Lack of pre/post data in this study was identified as a potential source of bias.

#### Abortion

Four ecological studies from the USA assessed the impact of pharmacy-access ECPs on abortion rates per 1,000 women, all with risk of bias related to lack of comparison groups or pre/post data [27-29, 36]. These studies found no difference in overall abortion rates with pharmacy-access ECPs. Evidence from one study among 18- to 19-year-olds showed a decrease of 1.6 abortions per 1,000 women after pharmacy-access ECPs became available in the USA (p<0.05) [28]. Another study among 15- to 19-year-olds found a decrease of 1.97 abortions per 1,000 (p<0.01).

Finally, evidence from one serial cross-sectional study from France showed that reporting ever having an abortion declined from 17.0% before OTC ECP access to 15.6% after OTC ECP access (p=0.04) [35]. Bias in this study was related to lack of a comparison group (pre/post only).

#### Sexual health-related practices and behavior

Seven studies assessed outcomes related to SRH practices and behavior. Specific outcomes assessed included condom use (three studies), unprotected sex (two studies), reporting multiple partners (three studies), contraceptive method use (four studies), and missing contraceptive pills (two studies).

Evidence from one RCT showed no difference in number of sexual partners (RR 1.24, 95% CI: 0.95-1.61), condom use at last sex (RR 0.92, 95% CI: 0.81-1.05), consistent condom use (RR 1.07, 95% CI 0.76-1.51), change in contraceptive method (RR 1.16, 95% CI: 0.92-1.47) or missed contraceptive pills (among pill users; RR 0.92, 95% CI: 0.80-1.06) [40]. The same RCT found decreases in unprotected intercourse with increased access to OTC ECPs (RR 0.82, 95% CI: 0.70-0.97). These findings did not vary by age [32].

An observational study found no significant changes in condom use, contraceptive use (including multimethod use), unprotected intercourse, or missed contraceptive pills (among pill users), when comparing outcomes before and after pharmacy-access ECPs in German-speaking Switzerland [23]. This finding may have been influenced by bias from having no comparator (pre/post only) and no control for confounders. In the USA, evidence from two serial cross-sectional studies showed that increased access to OTC ECPs had no effect on sexual activity or contraceptive use over time [24, 25], though it reduced condom use among adolescents by 5.2% to 7.2% (p<0.01) [25]. Both serial cross-sectional studies were found to have risk of bias due to lack of comparison groups (pre/post only). Finally, cross-sectional evidence from Lithuania and Poland showed that increased access to OTC ECPs was associated with reduced reporting of five or more sexual partners (30.6% without OTC access vs 9.6% with OTC access; p<0.001) [26]. Bias in this study were related to lack of pre/post evidence and no control for confounders.

#### Side effects, adverse events, and social harms

One RCT assessed potential social harms resulting from pharmacy-access ECPs and found that there was no difference in reporting being pressured into sex (RR 0.82, 95% CI: 0.43-1.56) [40]. For this outcome, there was no difference in age subgroup analyses [32].

ahle 1 Deer	cription of included	l studies		136/bmjop	
Study	Study Design		Population	Intervention*	Outcomes
Arnet et al. 2009 <b>[23]</b>	Pre/Post	Switzerland: Basel, Bern, Zurich	Women aged 15-49 accessing ECPs at pharmacies; 2003, 2006 N=729	R Pharmacy access	5. SRH practices c behavior
Atkins & Bradford 2015 <b>[25]</b>	Serial Cross- Sectional	USA: ME, NH, VT, RI	Public school students who responded to sexual activity questions in Youth Risk Behavior Survey; 2003-2009 N=49,454	Pharmacy access	5. SRH practices of behavior
Atkins 2014 <b>[24]</b>	Serial Cross- Sectional	USA: national	Non-pregnant women of aged 18-45 who responded to National Health and Nutrition Examination Survey; 2001-2004, 2007-2010 N: Not reported	Pharmacy acaess	5. SRH practices of behavior
Bumbul et al. 2013 <b>[26]</b>	Cross- Sectional	Poland: Warsaw Lithuania: Vilnius	Female students and high school pupils N=1,366		1. ECP uptake 5. SRH practices of behavior
Cintina & Johansen 2015 <b>[28]</b>	Ecological	USA: national (states except AK, DC, DE, HI, IA, MA, ME, NJ, NM, VT, WA)	Women aged 15-19 years; 2000-2010 N: Not reported	Pharmacy access	4. Abortion
Cintina 2017 <b>[27]</b>	Ecological	USA: WA, OR, ID	Women aged 15-44 N=1,747	Pharmacy access	4. Abortion
Durrance 2013 [29]	Ecological	USA: WA	Women aged 15-24 years; 1993-2005 N=507	Pharmacy access	4. Abortion
Falah- Hassani,et al. 2007 [30]	Serial Cross- Sectional	Finland: national	Adolescents aged 12-18; 1991, 2001, 2003 N=12,121	OTS access	1. ECP uptake
Girma & Paton 2011 <b>[31]</b>	Ecological	UK: national	Women aged 13-44; 1998-2004 N: Not reported	ਤ OT€ access ਨੂ	3. Unintended pregnancy <sup>†</sup>
Harper et al. 2005 <b>[32]</b> ; Raine et al. 2005 <b>[40]</b> ; Rocca et al. 2007 <b>[41]</b>	RCT	USA: California: San Francisco	Women aged 15-24 attending clinics providing family planning; not desiring pregnancy, using long-term hormonal contraception or requesting ECPs; 2001-2003 N=2,117	April 20, 2022 Pharmacy aceess guest. P Prot Pharmacy	<ol> <li>ECP uptake</li> <li>Unintended</li> <li>pregnancy</li> <li>SRH practices of behavior</li> <li>Side effects, adverse events, social harms</li> </ol>
Killick & Irving 2004 [33]	Cross- Sectional	UK: national	Women accessing ECPs at pharmacies N=419	acœess	1. ECP uptake
Marston et al. 2005 [34]	Serial Cross- Sectional	UK: national	Women aged 16-49 who responded to Omnibus survey; 2000- 2002 N=5,984	OT& access	1. ECP uptake 5. SRH practices of behavior

## BMJ Open

l of 42			BMJ Open	136/bm	
Moreau et al. 2006 <b>[35]</b>	Serial Cross- Sectional	France: national	Women aged 15-44 years responding to national health surveys; 1999, 2004 N=11,656 (1999: 4,146; 2004: 7,490)	0T€2021	4. Abortion
Mulligan 2016 <b>[36]</b>	Cross- Sectional	USA: national (all states except CA, NH (post-1997), MD (post-2006))	Women aged 15-44 in the USA, 1993-2011; female respondents to the National Longitudinal Survey of Youth; 1997-2009 N=4385 for 1997 NLSY; otherwise not reported	Pharmacy access	4. Abortion
Novikova et al. 2009 <b>[37]</b>	Serial Cross- Sectional	Australia: Sydney	Women attending abortion clinics N=718	OT to access	1. ECP uptake
Payaka- chat et al. 2010 <b>[38]</b>	Cross- Sectional	USA: AR: Little Rock	Pregnant women receiving prenatal care at a large urban community women's clinic; 2003-2008 N=272	Pharmacy access	<ol> <li>Unintended</li> <li>pregnancy</li> <li>SRH practices of</li> <li>behavior</li> </ol>
Pentel et al. 2004 <b>[39]</b>	Ecological	USA: MN: Minneapolis	Female patients at a safety-net hospital N: Not reported	Pharmacy access	1. ECP uptake
Rubin et al. 2011 <b>[42]</b>	Cross- Sectional	USA	Females aged 14-19 who had engaged in unprotected sex while aware of ECPs N=531	Pharmacy access	1. ECP uptake
Soon et al. 2005 <b>[43]</b>	Retrospective Cohort	Canada: British Columbia	Women aged 10-59 who received ECP prescriptions from 1996- 2002 N=1,172	Pharmacy access	1. ECP uptake
† This study a	ssessed changes in	n conception rate, which	does not explicitly consider whether the pregnancy was intended but is con-	ıj.com	proxy measure.
		For pee	r review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

			BMJ Open		Bage
able 2. Summary of results.					ය Page වි Page න ව ද
		N (%) or Mean (SD)	)	Effect	20 Risk of Bias
No. and type of studies	Specific Outcome	OTC/pharmacy access	Prescription-only availability		21-054
PICO Outcome 1: ECP Upta	ake	1			1122
1 RCT <b>[40]</b>	ECP use	197/814 (24.2%)	65/310 (21.0%)	<b>RR 1.15</b> (0.90-1.48)	on Low
1 Retrospective cohort [43]	Physician prescribing of ECPs	2001: 9,447 2002: 10,669	1996-2000: 8,805/year (95% CI: 7,823-9,787)	Not reported	Lack of comparison; no
3 serial cross-sectional <b>[30,</b> <b>34, 37]</b> ; 3 cross-sectional <b>[26, 33, 42]</b>	ECP use	subgroups with incre	es found no difference in E eased OTC ECP access. T CPs within 24 hours (X <sup>2</sup> : 17, 4.44 [42]).	wo studies found	No control for
1 ecological [39]	ECP distribution from pharmacies		tribution from a hospital ph s, while prescription use of	5	Description: Desc
PICO Outcome 3: Unintene	ded Pregnancy				
1 RCT <b>[40]</b>	Unintended pregnancy	58/814 (7.1%)	27/310 (8.7%)	<b>RR 0.82</b> (0.53-1.27)	from Low
1 cross-sectional [38]	Unintended pregnancy	88 (90.7%)	24 (72.7%)	p=0.02	Lack of comparison; no
1 ecological <b>[31]</b>	Conception rate*	change in conceptio	women aged 13-15, 15-17, on rate with increased acces increased access was ass	ss to OTC ECPs. Am	ong
PICO Outcome 4: Abortion		, , , , , , , , , , , , , , , , , , ,			 
4 ecological <b>[27-29, 36]</b>	Abortion rate per 1000 women	increased access to decreases among y 1,000 18-19 year old	idies found no difference in OTC ECPs. Two studies in ounger age groups: a decro d women (p<0.05) [28], and n aged 15-19 (p<0.01) [36]	dentified significant ease of 1.6 abortions I a decrease of 1.97 p	S No pre/post [28]; Lack of comparison [27, 29, 36] per 2 per 2 No pre/post [28]; Lack of
1 serial cross-sectional [35]	Abortion (ever)	1168/7490 (15.6%)	708/4166 (17.0%)	p=0.04	$\frac{2}{5}$ Lack of comparison
PICO Outcome 5: Sexual h	ealth-related practices	and behavior			ע פר ג
	Unprotected sex	274/814 (33.7%)	127/310 (41.0%)	<b>RR 0.82</b> (0.70-0.97)	о e st. т
1 RCT <b>[40]</b>	Consistent condom use	110/814 (13.5%)	39/310 (12.6%)	<b>RR 1.07</b> (0.76-1.51)	Protect
	Condom use last sex	383/814 (47.1%)	158/310 (51.0%)	<b>RR 0.92</b> (0.81-1.05)	by
	Multiple partners	192/814 (23.6%)	59/310 (19.0%)	<b>RR 1.24</b> (0.95-1.61)	copyright.

Page	13	of	42
------	----	----	----

3 of 42			BMJ Open		1 136/bm
	Contraceptive method change	220/814 (27.0%)	72/310 (23.2%)	<b>RR 1.16</b> (0.92-1.47)	jopen-2
	Missed pills (among subgroup of reported contraceptive pill users)	245/391 (62.7%)	84/123 (68.3%)	<b>RR 0.92</b> (0.80-1.06)	136/bmjopen-2021-054122
	Condom use	220/333 (66.0%)	232/350 (66.3%)	Not significant at p<0.0	
	Oral contraceptive use	69/333 (20.7%)	90/350 (25.7%)	Not significant at p<0.0	control for confounding
1 pre/post study <b>[23]</b>	Oral contraceptives + condoms	10/333 (3.0%)	7/350 (2.0%)	Not significant at p<0.0	arc <del>B</del> 20
	Unprotected sex	17/340 (5.0%)	25/361 (6.9%)	Not significant at p<0.0	.03
	Missed pills	53/79 (67.1%)	47/97 (48.5%)	Not significant at p<0.0	
	Multiple partners			ad mixed effects. One ing multiple partners ease from 30.6% to 9.6%	Lack of comparison [24, 25, 34, 38]; No pre/post [26]; No control for confounding [26, 38]
3 serial cross-sectional <b>[24</b> , <b>25</b> , <b>34]</b> ; 2 cross-sectional <b>[26</b> , <b>38]</b>	Contraceptive use	with increased acces	studies found no differences to OTC ECPs. One stu le contraceptive use (p<0	bg http://	
	Condom use	increased access to	ly [34] identified no differe OTC ECPs. Another stud public school students by	dg	
PICO Outcome 7: Side effe	cts, adverse events, ar				8
1 RCT <b>[40]</b>	Pressured into sex	28/814 (3.4%)	13/310 (4.2%)	<b>RR 0.82</b> (0.43 -1.56)	R Low
* This study assessed changes i	n conception rate, which d	oes not explicitly conside	er whether the pregnancy wa	as intended but is considered	edan indirect proxy measure.
					il 20, 2024 by guest. Protected by copyright.
	For peer	review only - http://bm	jopen.bmj.com/site/about,	/guidelines.xhtml	

## Values and preferences review

Overall, 56 studies from 33 countries were included in the values and preferences review (Figure 2) [33, 44-98]. There were 39 quantitative studies (all cross-sectional surveys), 11 qualitative studies, and six mixed-methods studies. Twenty-two studies included end-users, 33 studies included pharmacists or other health care providers or professional stakeholders, and one study included both groups. One study [33] was also included in the effectiveness review.

Of the included studies, most were in the USA (n=19) and UK (n=9), followed by Sweden (n=5), Canada (n=4), Australia (n=3), India (n=3), South Africa (n=2), and South Korea (n=2). One study each was conducted in Austria, Barbados, Belgium, Bulgaria, Czech Republic, Democratic Republic of Congo, France, Germany, Hong Kong, Hungary, Indonesia, Jamaica, Kazakhstan, Lithuania, Nicaragua, Norway, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, and Spain.

Figure 2. Map showing distribution of studies included in the values and preferences review.

Of the values and preferences studies among end-users, support for OTC ECPs varied widely within and across countries, ranging from 12% among college students in India [72] to 100% among women who used OTC ECPs in Sweden [44]. In one study, where women could choose whether to obtain ECPs from a pharmacist or a physician [33], satisfaction with information received was 91% among those receiving ECPs in pharmacies, compared to 58% among those receiving prescription-only ECPs (p=0.006). Broadly, end-users supported OTC ECPs because they felt it offered improved access/availability, convenience, more flexible hours (particularly weekend hours), confidentiality/privacy/anonymity, and reduced cost. End-users also anticipated that OTC delivery would offer less opportunity for judgement from providers and greater control for women.

End-users who did not support OTC ECPs expressed concern about potential lack of privacy or increased cost, in addition to having a preference for more personal contact with providers for support and information. They also expressed some concerns about increased risk behavior. One study noted this concern was for others; the individuals participating in the study, all of whom were ECP users, did not believe their own behavior would be shaped by ECP use [77].

Of the values and preferences studies among pharmacists and other health care providers and professionals. support for OTC ECPs ranged widely. In quantitative surveys, pharmacist support ranged from 16% in South Dakota, USA [65] to 97% in San Francisco, USA [55]. Among doctors, support was generally lower, ranging from 6.1% in South Korea [83] to 68.9% in Canada [81]. Broadly, providers supported OTC ECPs for similar reasons as end-users. Some studies found that providers had concerns about side effects, including the inability to communicate about side effects in OTC delivery modalities [45] and concerns about long-term impacts of repeat ECP use [86]. In contrast, one study found that providers supported OTC delivery as they saw ECPs as having relatively few side effects [83]. 

Providers were also found to have concerns about increased risk behavior, misuse/repeat use of ECPs, and communication. Specifically regarding communication, providers felt concerned about discouraging other contraceptives [54, 69, 81, 84, 89], and felt that OTC delivery might preclude delivery of necessary education and counseling. In some studies, providers had religious/moral concerns about OTC delivery [48, 52, 61, 69, 89]. One study found that these concerns were more common among providers who believed ECPs were an abortifacient [61].

## Cost review

Three studies met inclusion criteria for the cost review (Table 3) [99-101]. All were modelling studies, two from the USA [99, 100] and one from Canada [101]. All examined the impact of pharmacy-access ECPs (not true OTC) and found that pharmacy access was expected to lead to lower health sector costs. No studies examined other sector costs, patient/family costs, or productivity impacts.

1	
2	
3	
4	
4 5 6	
2	
6	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
18	
10	
19	
20	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 22 33 34 35 36 37 28	
22	
23	
24	
25	
25	
20	
27	
28	
29	
30	
31	
27	
22	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
48	
49	
50	
51	
52	
52	
54	
55	
56	
57	
58	
59	
22	

60

 Table 3. Description of studies included in the cost review.

Study	Location	Study design	Impact of pharmacy access
Marciante et al., 2001 <b>[100]</b>	USA	Decision model	Among private payers (private insurance): \$158 (95% CI=\$76, \$269) reduction in cost per woman having unprotected intercourse Among public payers: \$48 (95% CI=\$16, \$93) reduction in cost per woman having unprotected intercourse
Soon et al., 2007 <b>[101]</b>	Canada	Three decision model	One-year cost saving to the Ministry of Health (MOH) of \$0.64 million (95% CI: \$0.24 million, \$1.28 million). In sensitivity analyses, there were no set of assumptions that would lead to pharmacy access increasing costs to the MOH.
Foster et al., 2010 <b>[99]</b>	USA	Markov model	For Medicare: Compared to no ECP use, pharmacy access was more cost-effective than prescription access across all assumptions of amount and frequency of use. Cost savings ratios for pharmacy access: range 1.61 to 2.49 For prescription-only access: range 1.00 to 1.56

## Discussion

## OTC ECP effectiveness

We identified 19 studies from eight countries assessing how OTC ECPs influence uptake of ECPs, unintended pregnancy, abortion, and other sexual practices and behavior. Broadly, we found no differences in overall ECP use, pregnancy, or sexual risk behavior when comparing pharmacy access or true OTC availability to prescription-only ECP access. We found no comparative data on correct use of ECPs or self-efficacy, self-determination, autonomy, or empowerment.

Though we found minimal changes in overall ECP use in OTC models, two studies included in the review found that after OTC provision, use of ECPs within 24 hours of sex increased [33, 42]. This is promising, given ECPs are more effective when used promptly.

For most outcomes, our review did not identify any substantial or concerning differences by age. However, there is promising evidence regarding OTC ECPs among younger women. Observational evidence included in our review showed that abortion rates decreased significantly among younger age groups with increased access to OTC ECPs [28, 36], while there was no significant difference in the overall population of women. Given the unique barriers faced by younger women accessing prescription-only ECPs in many settings, it may be that increased access to OTC ECPs has unique benefits for younger women. Since one in four young women who have been in a relationship will have already experienced intimate partner violence by the time they reach their mid-twenties [14, 102], access to contraceptive choice for these younger women is particularly important.

Our finding that OTC ECPs had minimal impacts on unintended pregnancy and abortion may be explained in part by overall low use of ECPs, regardless of conception intention [103, 104]. However, there is some evidence that even with increased access and uptake, ECPs may have minimal impacts on unintended pregnancy or abortion

[105]. Most studies in our review did not report on both pregnancy or abortion and ECP use. In the sole study reporting both unintended pregnancy and ECP uptake [106], the authors found no change in either ECP uptake or unintended pregnancy with expanded access. This suggests that additional efforts may be required to ensure that increased ECP access reaches those most at risk of unintended pregnancy [103].

In terms of routine preventive screenings and other SRH services, we did not assess this as a PICO outcome. Findings from our previous review of OTC oral contraceptives suggested that OTC oral contraceptive access might not reduce use of other preventive services [8]. We did not assess STI screenings, though there was mixed evidence around STI acquisition. Several included studies found no differences or lower rates of STI acquisition with increased access to OTC ECPs [26, 32, 36, 40], while others identified increases in STI acquisition among younger age groups [29, 31]. Because this evidence is primarily from observational studies, the mechanisms of OTC ECPs' impacts in this area remain unclear.

## Values and preferences

1

2 3

4

5

6

7 8

9

10

11

12

13

14

15

16 17

18

19

20

21

22

In terms of values and preferences, we found that OTC ECPs were supported for their perceived convenience, privacy, comfort, control, cost, and effectiveness. Some end-users and providers expressed concerns that OTC ECPs might increase sexual risk behavior. However, our effectiveness review found that there were no differences in sexual practices and behavior when comparing OTC or pharmacy ECPs with prescription-only ECPs.

23 While many studies found that women valued the privacy and control offered by OTC ECPs, two studies found 24 that women were concerned about having limited interaction with providers in true OTC delivery [44, 82]. In both 25 studies, while there was widespread support for OTC availability of ECPs (between 78 and 100%), a large 26 proportion of women expressed a preference for behind-the-counter modalities which allowed for interaction with 27 a pharmacist. Indeed, in many settings, OTC ECPs are offered as one of an array of options including receiving 28 ECPs from a pharmacist (behind-the-counter), from a physician (prescription OTC), or on store shelves (true 29 OTC). We found that, in a study where women could choose whether to obtain ECPs in a pharmacy or from a 30 physician [33], ECP use and knowledge was similar between groups, but pharmacy-access ECPs resulted in 31 higher use and satisfaction. Given this and our findings about OTC ECPs' effectiveness, blended delivery 32 modalities wherein users can choose where and how to access ECPs may be most responsive to user 33 preferences. 34

35 Providers also expressed concern that OTC ECPs might not allow for sufficient education or counseling, including 36 about how to use OTC ECPs correctly and counseling about other routine SRH services (including use of other 37 contraceptives and screenings for cervical and breast cancers and sexually transmitted infections [107]). In our 38 effectiveness review, we did not identify any studies assessing correct use of OC in OTC vs prescription-only 39 delivery modalities. While knowledge of ECPs was not one of our PICO outcomes, one study from the UK found 40 no significant difference in correct knowledge of ECPs between women receiving ECPs from a physician vs OTC, 41 with correct knowledge >90% for both groups [33], and another found no significant difference between OTC and 42 prescription delivery in reporting adequate information received about ECPs [37]. 43

## Cost

44

45

53

60

Results from OTC ECP cost studies are promising, though limited. In our three included studies from the US and
 Canada, pharmacy access was anticipated to yield lower health sector costs. However, we identified no data on
 cost impacts for patients and families, which will be important to consider as OTC ECP access expands. Indeed,
 several included values and preferences studies noted increased cost as a concern [44, 68, 81, 86]. On the other
 hand, some studies have shown that increased cost was perceived as a benefit, as it may deter repeat or overuse
 of ECPs [56, 68].

## Areas for future research

2 3

4

5

6 7

8

9

25

38

39 40

41

42

43

#### **BMJ** Open

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

Our review highlights some critical areas for future research on OTC ECPs. First, given provider concerns identified in our review, future research should also assess whether correct knowledge of ECPs translates to correct use in OTC modalities.

Second, future research should more closely examine the impact of OTC ECPs among key subgroups, including younger women. This is important as self-care interventions may present unique opportunities and challenges for different populations and in different settings [7]. For example, it is unclear through what mechanisms OTC ECPs 10 may differentially impact outcomes such as abortion or STI acquisition among younger age groups, and if routine 11 preventive SRH care plays a role. Equitable implementation of OTC ECPs as a self-care intervention should 12 consider the intersecting roles of race/ethnicity/culture/language, occupation, gender/sex, religion, education, 13 health literacy, socioeconomic status, and social capital as determinants of sexual and reproductive health and 14 rights and key factors affecting delivery, uptake, and impact of OTC ECPs [108]. 15

Finally, though OTC ECPs are an important contraceptive option for individuals, communities, and health systems 16 worldwide, the evidence base identified through our effectiveness, cost, and values and preferences reviews was 17 concentrated in high-income settings. Specifically, we only found evidence of OTC ECPs' effectiveness and costs 18 19 from high-income countries. In our values and preferences review, 80% of identified studies were from high-20 income settings, and a low-income setting (Democratic Republic of Congo) was represented in a single study 21 [66]. Meaningful efforts are needed to recognize, invest in, and promote future research on the effects of 22 increased OTC ECPs in low- and middle-income countries. Future research should particularly consider impacts 23 on user cost in these settings, given concerns identified in this review. 24

#### Strengths and limitations

26 Our review has several strengths and limitations. Our search was comprehensive and included not only literature 27 on the effectiveness of OTC ECPs, but on their costs and the values and preferences of providers and end users. 28 However, we did not include grey literature and conference abstracts, which may have provided valuable 29 information given the evolving nature of this field. We also did not include studies of expanded access to ECPs 30 that did not specifically assess OTC availability, such as trials of advance provision of ECPs direct to potential 31 users. Conclusions of this review are also limited by the quality and diversity of included studies. Many 32 observational studies lacked comparison groups or pre/post data, and several did not control for confounding. 33 Further, given the wide range of included study designs and outcomes, we were unable to perform meta-analysis 34 but instead summarized findings qualitatively. Our conclusions are also limited by the concentration of articles in 35 high- and middle-income settings; future research should examine the impacts of OTC ECPs in resource-limited 36 37 settings.

## Conclusion

Increasing OTC contraceptive choice and availability is an urgent need for many women and girls. OTC ECPs are available in many settings worldwide, suggesting its feasibility as an additional delivery option. This review of existing evidence suggests that providing emergency contraception OTC may be cost-saving and responsive to user preferences, while introducing no negative sexual and reproductive health and rights outcomes.

48

49 50

51

52

60

## Acknowledgements

We thank Laura Ferguson, University of Southern California and Lianne Gonsalves; World Health Organization for reviewing and providing thoughtful feedback on the protocol. We also thank our research assistants from the Johns Hopkins Bloomberg School of Public Health (Hunied Kautsar, Izza Ishak, Sherryn Sherryn, Jingjia (Cynthia) Li, Xuhao Yang, Jaime Marguis, and Vagho Avetisyan) for their assistance screening citations and extracting data.

## Contributions

MN conceptualized the study. CEK and PTY designed the protocol with feedback from MN. PTY ran the database search and oversaw search, screening, full text review, and data extraction processes. CEK and PTY performed data analysis. KA and PTY assessed quality and risk of bias. CEK and KA drafted the manuscript. PTY and MN reviewed the draft, provided critical review, and read and approved the final manuscript. The corresponding author, as guarantor, accepts full responsibility for the finished article has access to any data and controlled the decision to publish. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

The named authors alone are responsible for the views expressed in this publication and do not necessarily represent the decisions or the policies of the World Health Organization (WHO) nor the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP).

## **Financial support**

We gratefully acknowledge financial support of The Children's Investment Fund Foundation (CIFF). The funder played no part in the decision to submit the article for publication, nor in the collection, analysis and interpretation of data. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. iez on

## **Competing interests**

None declared.

## Patient consent for publication

Not required.

## Provenance and peer review

Not commissioned; externally peer reviewed.

## Ethics statement

Ethical approval was not required for this systematic review, since all data came from published articles.

## Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. Extracted data are available on request to the corresponding author.

## **Transparency declaration**

The corresponding author, as guarantor, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

#### 1 2 3 References 4 1. World Health Organization. Medical eligibility criteria for contraceptive use, fifth edition. World 5 Health Organization; 2015. Report No.: 9241563885. 6 2. World Health Organization. Selected practice recommendations for contraceptive use, third 7 edition. World Health Organization; 2016. Report No.: 9241562846. 8 World Health Organization. Emergency contraception. World Health Organization: 2021. 9 3. 10 Rafie S, Stone RH, Wilkinson TA, Borgelt LM, El-Ibiary SY, Ragland D. Role of the community 4. 11 pharmacist in emergency contraception counseling and delivery in the United States: current 12 trends and future prospects. Integrated Pharmacy Research & Practice. 2017;6:99-108. 13 5. International Consortium for Emergency Contraception. EC Status and Availability: Countries 14 with non-prescription access to EC 2021 [Available from: https://www.cecinfo.org/country-by-15 country-information/status-availability-database/countries-with-non-prescription-access-to-ec/. 16 6. Ammerdorffer et al. Regulatory standards and processes for over-the-counter availability of 17 hormonal contraception and drugs for medical abortion in five countries in the Eastern 18 Mediterranean Region. Health Research and Policy Systems. (Expected April 2021). 19 7. World Health Organization. WHO consolidated guideline on self-care interventions for health: 20 sexual and reproductive health and rights. 2019. Report No.: 9241550554. 21 Kennedy CE, Yeh PT, Gonsalves L, Jafri H, Gaffield ME, Kiarie J, et al. Should oral 8. 22 contraceptive pills be available without a prescription? A systematic review of over-the-counter 23 and pharmacy access availability. BMJ Global Health. 2019;4(3):e001402. 24 9. World Health Organization. Maintaining essential health services: operational guidance for the 25 COVID-19 context: interim guidance, 1 June 2020. World Health Organization; 2020. 26 10. Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the Potential Impact of the COVID-19 27 Pandemic on Sexual and Reproductive Health In Low- and Middle-Income Countries. Int 28 29 Perspect Sex Reprod Health. 2020;46:73-6. 30 11. Brolin Ribacke KJ, Saulnier DD, Eriksson A, von Schreeb J. Effects of the West Africa Ebola 31 Virus Disease on Health-Care Utilization - A Systematic Review. Frontiers in public health. 32 2016;4:222. 33 12. Sharma KA, Zangmo R, Kumari A, Roy KK, Bharti J. Family planning and abortion services in 34 COVID 19 pandemic. Taiwanese journal of obstetrics & gynecology. 2020;59(6):808-11. 35 13. Tolu LB, Feyissa GT, Jeldu WG. Guidelines and best practice recommendations on 36 reproductive health services provision amid COVID-19 pandemic: scoping review. BMC public 37 health. 2021;21(1):276. 38 World Health Organization. COVID-19 and violence against women: What the health 14. 39 sector/system can do. World Health Organization; 2020. 40 15. Haddad LB, RamaRao S, Hazra A, Birungi H, Sailer J. Addressing contraceptive needs 41 exacerbated by COVID-19: A call for increasing choice and access to self-managed methods. 42 Contraception. 2021:103(6):377-9. 43 16. Aly J, Haeger KO, Christy AY, Johnson AM. Contraception access during the COVID-19 44 pandemic. Contracept Reprod Med. 2020;5:17. 45

- 17. Wood SN, Karp C, OlaOlorun F, Pierre AZ, Guiella G, Gichangi P, et al. Need for and use of
   contraception by women before and during COVID-19 in four sub-Saharan African geographies:
   results from population-based national or regional cohort surveys. Lancet Glob Health.
   2021;9(6):e793-e801.
   World Health Organization. WHO Handbook for Guideline Development. World Health
  - 18. World Health Organization. WHO Handbook for Guideline Development. World Health Organization; 2014.
  - 19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
  - 20. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors2019.
    - For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

59 60

51

52

53

54

55

- 21. Kennedy CE, Fonner VA, Armstrong KA, Denison JA, Yeh PT, O'Reilly KR, et al. The Evidence Project risk of bias tool: Assessing study rigor for both randomized and non-randomized intervention studies. Systematic Reviews. 2019;8(1):1-10. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2020 22. (developed by Evidence Prime, Inc.): 2020. 23. Arnet I, Frey Tirri B, Zemp Stutz E, Bitzer J, Hersberger KE. Emergency hormonal contraception in Switzerland: a comparison of the user profile before and three years after deregulation. The European Journal of Contraception & Reproductive Health Care: The Official Journal of the European Society of Contraception. 2009;14(5):349-56. Atkins DN. Association between increased availability of emergency contraceptive pills and the 24. sexual and contraceptive behaviors of women. J Public Health Policy. 2014;35(3):292-310. 25. Atkins DN. Bradford WD. The effect of changes in state and federal policy for nonprescription access to emergency contraception on youth contraceptive use: a difference-in-difference analysis across New England states. Contemporary Economic Policy. 2015;33(3):405-17. 26. Bumbul E. Starek M. Szymusik I. Pietrzak B. Bumbuliene Z. Kosinska-Kaczynska K. et al. Advantages and disadvantages of over-the-counter availability of emergency contraception. Neuro Endocrinology Letters. 2013;34(7):655-9. Cintina I. Behind-the-Counter, but Over-the-Border? The Assessment of the Geographical 27. Spillover Effects of Emergency Contraception on Abortions. Health Economics. 2017;26(10):1249-63. Cintina I. Johansen MS. The Effect of Plan B on Teen Abortions: Evidence from the 2006 FDA 28. Ruling. Contemporary Economic Policy. 2015;33(3):418-33. 29. Durrance CP. The Effects of Increased Access to Emergency Contraception on Sexually Transmitted Disease and Abortion Rates. Economic Inquiry. 2013;51(3):1682-95. 30. Falah-Hassani K, Kosunen E, Shiri R, Rimpelä A. Emergency contraception among Finnish adolescents: awareness, use and the effect of non-prescription status. BMC public health. 2007;7:201. 31. Girma S, Paton D. The impact of emergency birth control on teen pregnancy and STIs. Journal of Health Economics. 2011;30(2):373-80. 32. Harper CC, Cheong M, Rocca CH, Darney PD, Raine TR. The effect of increased access to emergency contraception among young adolescents. Obstetrics and Gynecology. 2005;106(3):483-91. Killick SR, Irving G. A national study examining the effect of making emergency hormonal 33. contraception available without prescription. Hum Reprod. 2004;19(3):553-7. 34. Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys. Bmj. 2005;331(7511):271. Moreau C, Bajos N, Trussell J. The impact of pharmacy access to emergency contraceptive pills 35. in France. Contraception. 2006;73(6):602-8. 36. Mulligan K. Access to Emergency Contraception and its Impact on Fertility and Sexual Behavior. Health Economics (United Kingdom). 2016;25(4):455-69. 37. Novikova N, Weisberg E, Fraser IS. Does readily available emergency contraception increase women's awareness and use? Eur J Contracept Reprod Health Care. 2009;14(1):39-45. 38. Payakachat N, Ragland D, Houston C. Impact of emergency contraception status on unintended pregnancy; observational data from a pharmacy practice. Pharmacy Practice. 2010;8(3):173-8. 39. Pentel PR, Nelson B, Wikelius N, Cooper C. Hospital-based program for increasing the availability of emergency contraception: simulating nonprescription access. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists. 2004;61(8):777-80. 40. Raine T, Harper C, Rocca CH, Fischer R, Padian N, Klausner D, et al. Direct access to
  - emergency contraception through pharmacies and effect on unintended pregnancy and STIs: A
    - For peer review only http://bmjopen.bmj.com/site/about/guidelines.xhtml

59 60

1

2 3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18 19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38 39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

1		
2		
3		randomized controlled trial. JAMA - Journal of the American Medical Association.
4		2005;293(1):54-62.
5	41.	Rocca CH, Schwarz EB, Stewart FH, Darney PD, Raine TR, Harper CC. Beyond access:
6		Acceptability, use and nonuse of emergency contraception among young women. American
7		Journal of Obstetrics and Gynecology. 2007;196(1):29.e1e6.
8	42.	Rubin AG, Gold MA, Kim Y, Schwarz EB. Use of Emergency Contraception by US Teens: Effect
9		of Access on Promptness of Use and Satisfaction. Journal of Pediatric and Adolescent
10		Gynecology. 2011;24(5):287-90.
11	43.	Soon JA, Levine M, Osmond BL, Ensom MHH, Fielding DW. Effects of making emergency
12		contraception available without a physician's prescription: A population-based study. Canadian
13 14		Medical Association Journal. 2005;172(7):878-83.
14	44.	Aneblom G, Larsson M, Von Essen L, Tydén T. Women's voices about emergency
15		contraceptive pills "over-the-counter": A Swedish perspective. Contraception. 2002;66(5):339-
17		43.
18	45.	Aneblom G, Lundborg CS, Carlsten A, Eurenius K, Tyden T. Emergency contraceptive pills
19	45.	over-the-counter: practices and attitudes of pharmacy and nurse-midwife providers. Patient
20		
20	46	Educ Couns. 2004;55(1):129-35.
22	46.	Bissell P, Anderson C. Supplying emergency contraception via community pharmacies in the
23		UK: reflections on the experiences of users and providers. Social Science & Medicine (1982).
24	47	
25	47.	Bissell P, Savage I, Anderson C. A qualitative study of pharmacists' perspectives on the supply
26		of emergency hormonal contraception via patient group direction in the UK. Contraception.
27		2006;73(3):265-70.
28	48.	Blackwell D, Cooper N, Taylor G, Holden K. Pharmacists' concerns and perceived benefits from
29		deregulation of hormonal emergency contraception (HEC). British Journal of Family Planning.
30		1999;25(3):100-4.
31	49.	Cooper RJ, Bissell P, Wingfield J. Ethical, religious and factual beliefs about the supply of
32		emergency hormonal contraception by UK community pharmacists. The Journal of Family
33		Planning and Reproductive Health Care. 2008;34(1):47-50.
34	50.	David M, Berends L, Bartley J. Current Opinion of Obstetricians on the Prescription of
35		Emergency Contraception: A German-American Comparison. Geburtshilfe Und
36		Frauenheilkunde. 2012;72(11):1004-8.
37	51.	Dixit A, Khan ME, Bhatnagar I. Mainstreaming of emergency contraception pill in India:
38		challenges and opportunities. Indian Journal of Community Medicine: Official Publication of
39		Indian Association of Preventive & Social Medicine. 2015;40(1):49-55.
40	52.	Downing SG, Payze C, Doyle-Adams S, Gorton C. Emergency contraception over-the-count fer:
41		practices and attitudes of pharmacists and pharmacy assistants in far North Queensland. Aust
42		N Z J Obstet Gynaecol. 2011;51(6):527-31.
43	53.	Dunn S, Brown TER, Cohen MM, Cockerill R, Wichman K, Weir N, et al. Pharmacy provision of
44		emergency contraception: the Ontario emergency contraception pilot project. Journal of
45		obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique et gynecologie du Canada:
46		JOGC. 2003;25(11):923-30.
47	54.	Ehrle N, Sarker M. Emergency contraceptive pills: knowledge and attitudes of pharmacy
48	01.	personnel in Managua, Nicaragua. Int Perspect Sex Reprod Health. 2011;37(2):67-74.
49	55.	El-Ibiary SY, Raine T, McIntosh J, Darney PD, Harper CC. Pharmacy access to emergency
50	00.	contraception: Perspectives of pharmacists at a chain pharmacy in San Francisco. Journal of
51		the American Pharmacists Association : JAPhA. 2007;47(6):702-10.
52	56.	Folkes L, Graham A, Weiss M, Folkes L, Graham A, Weiss M. A qualitative study of the views of
53	50.	women aged 18-29 on over-the-counter availability of hormonal emergency contraception.
54		
55 56		Journal of Family Planning & Reproductive Health Care. 2001;27(4):189-92.
56 57		
57 58		
58 59		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00		

1

2 3

4

5

6

7

8

9

60

57. Foster DG, Landau SC, Monastersky N, Chung F, Kim N, Melton M, et al. Pharmacy access to emergency contraception in California. Perspectives on Sexual and Reproductive Health. 2006;38(1):46-52. 58. Fuentes EC, Azize-Vargas Y. Knowledge, attitudes and practices in a group of pharmacists in Puerto Rico regarding emergency contraception. P R Health Sci J. 2007;26(3):191-7. 59. Gainer E, Blum J, Toverud EL, Portugal N, Tyden T, Nesheim BI, et al. Bringing emergency contraception over the counter: experiences of nonprescription users in France, Norway, 10 Sweden and Portugal. Contraception. 2003;68(2):117-24. 11 Golden NH, Seigel WM, Fisher M, Schneider M, Quijano E, Suss A, et al. Emergency 60. 12 contraception: Pediatricians' knowledge, attitudes, and opinions. Pediatrics. 2001;107(2):287-13 92. 14 61. Griggs SK, Brown CM. Texas community pharmacists' willingness to participate in pharmacist-15 initiated emergency contraception. Journal of the American Pharmacists Association: JAPhA. 16 2007;47(1):48-57. 17 62. HäggstrÖm-Nordin E. Tydén T. Swedish teenagers' attitudes toward the emergency 18 contraceptive pill. Journal of Adolescent Health. 2001;28(4):313-8. 19 20 63. Hariparsad N. Attitudes and practices of pharmacists towards emergency contraception in 21 Durban, South Africa. European Journal of Contraception and Reproductive Health Care. 22 2001;6(2):87-92. 23 64. Harvey SM, Beckman LJ, Sherman C, Petitti D. Women's experience and satisfaction with 24 emergency contraception. Fam Plann Perspect. 1999;31(5):237-40, 60. 25 65. Hellerstedt WL, Van Riper KK. Emergency contraceptive pills: dispensing practices, knowledge 26 and attitudes of South Dakota pharmacists. Perspect Sex Reprod Health. 2005;37(1):19-24. 27 Hernandez JH, Muanda M, Garcia M, Matawa G. Awareness and Perceptions of Emergency 66. 28 Contraceptive Pills Among Women in Kinshasa, Democratic Republic of the Congo. 29 International Perspectives on Sexual and Reproductive Health. 2017;43(3):121-30. 30 67. Hickey MT, Shedlin MG. Emergency contraceptive pill users' risk perceptions for sexually 31 transmitted infections and future unintended pregnancy. J Am Assoc Nurse Pract. 32 2017:29(9):527-34. 33 Hobbs M, Taft AJ, Amir LH. The emergency contraceptive pill rescheduled: a focus group study 68. 34 of women's knowledge, attitudes and experiences. J Fam Plann Reprod Health Care. 35 2009;35(2):87-91. 36 Hopkins D, West D. Arkansas pharmacists' perceptions toward emergency contraception and 37 69. nonprescription Plan B. Pharmacy Practice. 2008;6(2):98-102. 38 39 70. Hussainy SY, Stewart K, Chapman CB, Taft AJ, Amir LH, Hobbs MK, et al. Provision of the 40 emergency contraceptive pill without prescription: attitudes and practices of pharmacists in 41 Australia. Contraception. 2011;83(2):159-66. 42 71. Irfan F, Karim SI, Hashmi S, Ali S, Ali SA. Knowledge of emergency contraception among 43 women of childbearing age at a teaching hospital of Karachi. Journal of the Pakistan Medical 44 Association. 2009;59(4):235-40. 45 72. Joseph N, Shetty B, Hasreen F, Ishwarya R, Baniya M, Sachdeva S, et al. Awareness and 46 Attitudes Toward Emergency Contraceptives Among College Students in South India. Journal of 47 Obstetrics and Gynaecology of India. 2016;66(Suppl 1):363-9. 48 73. Karim SI, Irfan F, Al Rowais N, Al Zahrani B, Qureshi R, Al Qadrah BH. Emergency 49 contraception: Awareness, attitudes and barriers of Saudi Arabian women. Pakistan Journal of 50 Medical Sciences. 2015;31(6):1500-5. 51 74. Khan ME, Dixit A, Bhatnagar I, Brady M. Medical barriers to emergency contraception: a cross-52 sectional survey of doctors in North India. Glob Health Sci Pract. 2014;2(2):210-8. 53 75. Kim HW. Sex differences in the awareness of emergency contraceptive pills associated with 54 unmarried Korean university students' intention to use contraceptive methods: an online survey. 55 Reprod Health. 2015;12:91. 56 57 58 59

1		
2		
3 4	76.	Krassovics M, Viragh G. Usage patterns and attitudes towards emergency contraception: the International Emergency Contraception Research Initiative. Eur J Contracept Reprod Health
5		Care. 2016;21(4):310-7.
6 7	77.	Krishnamurti T, Eggers SL, Fischhoff B. The impact of over-the-counter availability of "Plan B"
8	70	on teens' contraceptive decision making. Soc Sci Med. 2008;67(4):618-27.
9	78.	Kumar AS, Hall LC, LePage A, Lim PC. Providing emergency contraceptive pills "behind-the-
10	70	counter": opinions among Minnesota healthcare providers. Contraception. 2003;68(4):253-9.
11	79.	Landau S, Besinque K, Chung F, Dries-Daffner I, Maderas NM, McGhee BT, et al. Pharmacist
12		interest in and attitudes toward direct pharmacy access to hormonal contraception in the United States. Journal of the American Pharmacists Association : JAPhA. 2009;49(1):43-50.
13	80.	Landau SC, Tapias MP, McGhee BT. Birth control within reach: a national survey on women's
14 15	00.	attitudes toward and interest in pharmacy access to hormonal contraception. Contraception.
16		2006;74(6):463-70.
17	81.	Langille DB, Allen M, Whelan AM. Emergency contraception: knowledge and attitudes of Nova
18	-	Scotian family physicians. Can Fam Physician. 2012;58(5):548-54.
19	82.	Larsson M, Eurenius K, Westerling R, Tyden T. Emergency contraceptive pills over-the-counter:
20		a population-based survey of young Swedish women. Contraception. 2004;69(4):309-15.
21	83.	Lee ES, Lee CA, Lee JH, Park BR, Lee I. The attitudes of Korean physicians toward emergency
22		contraceptive pills: regarding women's access and rescheduling. Obstetrics & Gynecology
23 24		Science. 2019;62(3):173-8.
24 25	84.	Lim SW, Iheagwara KN, Legano L, Coupey SM. Emergency contraception: are pediatric
26		residents counseling and prescribing to teens? J Pediatr Adolesc Gynecol. 2008;21(3):129-34.
27	85.	Lo SST, Kok WM, Fan SYS. Emergency contraception: Knowledge, attitude and prescription
28		practice among doctors in different specialties in Hong Kong. Journal of Obstetrics and
29	00	Gynaecology Research. 2009;35(4):767-74.
30	86.	Maharaj P, Rogan M. Missing opportunities for preventing unwanted pregnancy: A qualitative study of emergency contraception. Journal of Family Planning and Reproductive Health Care.
31		2011;37(2):89-96.
32 33	87.	Miller LM. College student knowledge and attitudes toward emergency contraception.
33 34	01.	Contraception. 2011;83(1):68-73.
35	88.	Peremans L, Verhoeven V, Philips H, Denekens J, Van Royen P. How does a Belgian health
36		care provider deal with a request for emergency contraception? The European Journal of
37		Contraception & Reproductive Health Care: The Official Journal of the European Society of
38		Contraception. 2007;12(4):317-25.
39	89.	Ragland D, West D. Pharmacy students' knowledge, attitudes, and behaviors regarding
40		emergency contraception. American Journal of Pharmaceutical Education. 2009;73(2).
41 42	90.	Syahlul DE, Amir LH. Do Indonesian medical practitioners approve the availability of emergency
42 43		contraception over-the-counter? A survey of general practitioners and obstetricians in Jakarta.
44	01	BMC Women's Health. 2005;5.
45	91.	Vahratian A, Patel DA, Wolff K, Xu X. College students' perceptions of emergency contraception provision. Journal of Women's Health (2002). 2008;17(1):103-11.
46	92.	Wan RSF, Lo SST. Are women ready for more liberal delivery of emergency contraceptive pills?
47	92.	Contraception. 2005;71(6):432-7.
48	93.	Whelan AM, Langille D, Hurst E, Aylward S, Wedlake S. Nova Scotia pharmacists and
49 50	00.	emergency contraception pills: Attitudes and beliefs. Canadian Pharmacists Journal.
50 51		2011;144(5):e39.
52	94.	Wu J, Gipson T, Chin N, Wynn LL, Cleland K, Morrison C, et al. Women seeking emergency
53		contraceptive pills by using the internet. Obstet Gynecol. 2007;110(1):44-52.
54	95.	Xu X, Vahratian A, Patel DA, McRee AL, Ransom SB. Emergency contraception provision: a
55		survey of Michigan physicians from five medical specialties. J Womens Health (Larchmt).
56		2007;16(4):489-98.
57		
58 59		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 96. Yam EA, Gordon-Strachan G, McIntyre G, Fletcher H, Garcia SG, Becker D, et al. Jamaican and Barbadian health care providers' knowledge, attitudes and practices regarding emergency contraceptive pills. International Family Planning Perspectives. 2007;33(4):160-7.
  - 97. Yuksel N, Schindel T, Siyam T, Hocevar S. Pharmacists' beliefs about Plan B as an over-thecounter product. Canadian Pharmacists Journal. 2011;144(5):e40.
- 98. Ziebland S, Graham A, McPherson A. Concerns and cautions about prescribing and deregulating emergency contraception: a qualitative study of GPs using telephone interviews. Fam Pract. 1998;15(5):449-56.
- 99. Foster DG, Raine TR, Brindis C, Rostovtseva DP, Darney PD. Should providers give women advance provision of emergency contraceptive pills? A cost-effectiveness analysis. Women's Health Issues: Official Publication of the Jacobs Institute of Women's Health. 2010;20(4):242-7.
- 100. Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. Am J Public Health. 2001;91(9):1443-5.
- 101. Soon JA, Meckley LM, Levine M, Marciante KD, Fielding DW, Ensom MHH. Modelling costs and outcomes of expanded availability of emergency contraceptive use in British Columbia. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 2007;14(3):e326-38.
- 102. World Health Organization. Devastatingly pervasive: 1 in 3 women globally experience violence 2021 [Available from: https://www.who.int/news/item/09-03-2021-devastatingly-pervasive-1-in-3-women-globally-experience-violence.
  - 103. Glasier A, Fairhurst K, Wyke S, Ziebland S, Seaman P, Walker J, et al. Advanced provision of emergency contraception does not reduce abortion rates. Contraception. 2004;69(5):361-6.
- 104. Lakha F, Glasier A. Unintended pregnancy and use of emergency contraception among a large cohort of women attending for antenatal care or abortion in Scotland. Lancet. 2006;368(9549):1782-7.
- Hu X, Cheng L, Hua X, Glasier A. Advanced provision of emergency contraception to postnatal women in China makes no difference in abortion rates: a randomized controlled trial.
   Contraception. 2005;72(2):111-6.
  - 106. Raine TR, Harper CC, Rocca CH, Fischer R, Padian N, Klausner JD, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. Jama. 2005;293(1):54-62.
  - 107. Newmeyer MN, Concheiro M, da Costa JL, Flegel R, Gorelick DA, Huestis MA. Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal I-methamphetamine administration. Drug Test Anal. 2015;7(10):877-83.
  - 108. O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: Using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. Journal of Clinical Epidemiology. 2014;67(1):56-64.

ΒM	
ے O	
per	
BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen	
irst p	
lqnc	
lish	
ed a	
as 1	
ned as 10.1136/	
13	
6/bi	
/bmjopen-:	
per	
en-2021-054122 on 14 March ;	
21.	
ဗို	
412	
N O	
n 1	
4 <	
larc	
э N	
022	
0.	
Ň	
nlo	
ade	
d fr	
ôm	
htt	
p://	
<u> </u>	
ope	
aded from http://bmjopen.bmj.cor	
<u>, ă</u> ,	
ŝ	
<b>N</b> 0	
n A	
pril	
ril 20,	
20	
24	
٥ کم	
gue	
st. I	
Prot	
tect	
ed	
by c	
doc	
yrig	
ht.	

ω




Figure 1. PRISMA flow chart showing disposition of citations through the search and screening process.

338x190mm (54 x 54 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




Figure 2. Map showing distribution of studies included in the values and preferences review.

273x157mm (120 x 120 DPI)



# **PRISMA 2009 Checklist**

Pa	ige 27 of 42		BMJ Open 50	
1 2	PRISMA 20	009	Checklist Phere 202	
3 4 5	Section/topic	#	Checklist item	Reported on page #
6 7	TITLE		e e e e e e e e e e e e e e e e e e e	
8	Title	1	Identify the report as a systematic review, meta-analysis, or both. $$	1
9 10				
11 12 13	Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
15	INTRODUCTION			
16	Rationale	3	Describe the rationale for the review in the context of what is already known.	4
18 18 19	B Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, in error comparisons, outcomes, and study design (PICOS).	4
20	METHODS			
21 22 23	Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	2
24 25	Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4-5
26 27 29	, Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
29 30	) Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	25
31	Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
34 35	Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
36	Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4-5
39 39 40	Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
41	Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	NA
42 43 44	Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including network of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	NA
45 46 47	5		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	



# PRISMA 2009 Checklist

		BMJ Open 66	Page 28 of
PRISMA 2	009	Checklist	
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	NA
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS	•		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOs, follow-up period) and provide the citations.	6-10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	6-10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summare data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6-8, 11- 12
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of gonsistency.	NA
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	NA
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7-8
DISCUSSION			
<sup>3</sup> Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; congider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING	<u> </u>		
, Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data), role of funders for the systematic review.	17
	J, Altm	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The ᢓRISMA Statement. PLoS Mec	d 6(7): e1000097
doi:10.1371/journal.pmed1000097		For more information, visit: <u>www.prisma-statement.org</u> .	
2		For more information, visit: <u>www.prisma-statement.org</u> .	
4 5		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

59

60

2 3 WHO self-care v2 (2020) 4 Over the counter emergency contraception 5 Search strategy documentation 6 7 Search date: 27 April 2020 / updated 02 Dec 2020 8 9 Total hits: 3902 10 After removing duplicates: 2581 11 Assigned for primary screening: 2581 12 13 Pubmed: 1492 hits 14 ("Contraceptives, Oral" [Mesh] OR "Contraceptives, Postcoital" [Mesh] OR "emergency contraceptive 15 pill" [tiab] OR "emergency contraceptive pills" [tiab] OR "morning-after pill" [tiab] OR "Plan B One-Step" 16 [tiab] OR "Take Action" [tiab] OR "Next Choice One-Dose" [tiab] OR "My Way" [tiab] OR "AfterPill" [tiab] 17 OR "Preventeza" [tiab] OR "My Choice" [tiab] OR "Aftera" [tiab] OR "Athentia Next" [tiab] OR "EContra 18 Ez" [tiab] OR "Fallback Solo" [tiab] OR "Opcicon One-Step" [tiab] OR "Option 2" [tiab] OR "Afirmelle" 19 20 [tiab] OR "Altavera" [tiab] OR "Amethia" [tiab] OR "Amethia Lo" [tiab] OR "Amethyst" [tiab] OR "Aubra" 21 [tiab] OR "Ayuna" [tiab] OR "Aviane" [tiab] OR "Camrese" [tiab] OR "CamreseLo" [tiab] OR "Chateal" 22 [tiab] OR "Cryselle" [tiab] OR "Elinest" [tiab] OR "Enpresse" [tiab] OR "Falmina" [tiab] OR "Introvale" 23 [tiab] OR "Jolessa" [tiab] OR "Kurvelo" [tiab] OR "Lessina" [tiab] OR "Lenovest" [tiab] OR "Levora" [tiab] 24 OR "LoSeasonique" [tiab] OR "Low-Ogestrel" [tiab] OR "Lutera" [tiab] OR "Marlissa" [tiab] OR "Myzilra" 25 [tiab] OR "Nordette" [tiab] OR "Orsythia" [tiab] OR "Portia" [tiab] OR "Quasense" [tiab] OR "Seasonale" 26 [tiab] OR "Seasonique" [tiab] OR "Setlakin" [tiab] OR "Sronyx" [tiab] OR "Triphasil" [tiab] OR "Trivora" 27 [tiab] OR "Vienva" [tiab] OR "After-1" [tiab] OR "Agesta" [tiab] OR "Ai Wu You" [tiab] OR "Aleze EC" 28 29 [tiab] OR "Alterna" [tiab] OR "Amor" [tiab] OR "An Ting" [tiab] OR "Anlitin" [tiab] OR "Anthia" [tiab] OR 30 "Auxxil" [tiab] OR "Bao Shi Ting" [tiab] OR "Bi Yun" [tiab] OR "Ciel EC" [tiab] OR "Contragest" [tiab] OR 31 "Contraplan II" [tiab] OR "Control NF" [tiab] OR "Control Uno" [tiab] OR "Copill" [tiab] OR "Curesinor" 32 [tiab] OR "D-Sigyent" [tiab] OR "Dan Mei" [tiab] OR "Dia S MP" [tiab] OR "Diad" [tiab] OR "Dreams" [tiab] 33 OR "Duet" [tiab] OR "Duprisal 30" [tiab] OR "Dvella" [tiab] OR "E Pills" [tiab] OR "E-72" [tiab] OR "e-con" 34 [tiab] OR "ECee2" [tiab] OR "ECP" [tiab] OR "ella" [tiab] OR "ellaOne" [tiab] OR "Emcon" [tiab] OR 35 "Emergyn" [tiab] OR "Emkit" [tiab] OR "Emkit Plus" [tiab] OR "Escapel" [tiab] OR "Escapel-1" [tiab] OR 36 "Escapel-2" [tiab] OR "Escapelle" [tiab] OR "Escinor" [tiab] OR "Estinor" [tiab] OR "Evadir 2" [tiab] OR 37 "Evital" [tiab] OR "Evitarem" [tiab] OR "Fermerleve Sagiram" [tiab] OR "Feminor" [tiab] OR "Fertilan" 38 39 [tiab] OR "Fu Nai Er" [tiab] OR "G-Nancy" [tiab] OR "Glanique" [tiab] OR "Glanix" [tiab] OR "Glostinor 2" 40 [tiab] OR "Gynepriston" [tiab] OR "Gynotrel 2" [tiab] OR "Hispratel" [tiab] OR "Hou Ding Nuo" [tiab] OR 41 "Hua Dian" [tiab] OR "Hui Ting" [tiab] OR "i-pill" [tiab] OR "Imediat" [tiab] OR "Imediat N" [tiab] OR 42 "Impreviat" [tiab] OR "Jin Xiao" [tiab] OR "Jin Yu Ting" [tiab] OR "Ka Rui Ding" [tiab] OR "L Novafem" 43 [tiab] OR "Laliades" [tiab] OR "Le Ting" [tiab] OR "Lenor 72" [tiab] OR "Levo-72" [tiab] OR "Levodonna" 44 [tiab] OR "Levogest" [tiab] OR "Levogynon 1500" [tiab] OR "Levonelle" [tiab] OR "Levonelle-1" [tiab] OR 45 "Levonia" [tiab] OR "Levonorgestrol Biogaran 1500" [tiab] OR "Levonorgestrel Richter" [tiab] OR 46 "Levonormin" [tiab] OR "Lonel" [tiab] OR "Longil" [tiab] OR "Lydia 1Safe Pill" [tiab] OR "Lydia Post Pill" 47 [tiab] OR "Madonna" [tiab] OR "Max-72" [tiab] OR "Me Tablet" [tiab] OR "Mergynex" [tiab] OR 48 49 "Mifepristone 72" [tiab] OR "Mifestad 10" [tiab] OR "Minipil 2" [tiab] OR "Morning After" [tiab] OR "MS 50 Pill" [tiab] OR "Negele" [tiab] OR "Nerostinor" [tiab] OR "Next Choice" [tiab] OR "Nicpostinew" [tiab] OR 51 "Nogestrol" [tiab] OR "Nogravide" [tiab] OR "Norgestrel Max Unidosis" [tiab] OR "Norgestrel-Max" [tiab] 52 OR "NorLevo" [tiab] OR "Nortrel 2" [tiab] OR "Novalen" [tiab] OR "Oportuna" [tiab] OR "Optinor" [tiab] 53 OR "Ovocease" [tiab] OR "Ovulol" [tiab] OR "P2" [tiab] OR "PiDaNa" [tiab] OR "Pilem" [tiab] OR "Pill 72" 54 [tiab] OR "Pillanor 2" [tiab] OR "Pillex" [tiab] OR "Pilule S" [tiab] OR "Planfam" [tiab] OR "Poslov" [tiab] 55 OR "PostDay" [tiab] OR "Poster Tablets" [tiab] OR "Postiga 4" [tiab] OR "Postinor" [tiab] OR "Postinor 1" 56 57 58

[tiab] OR "Postinor 1.5" [tiab] OR "Postinor 1500" [tiab] OR "Postinor 2 SD" [tiab] OR "Postinor Duo" [tiab] OR "Postinor Life" [tiab] OR "Postinor PI" [tiab] OR "Postinor Uno" [tiab] OR "Postinor-2" [tiab] OR "Postinor-2 Unidosis" [tiab] OR "Postpill" [tiab] OR "Pozato" [tiab] OR "Pozato Uni" [tiab] OR "PPMS" [tiab] OR "Pregnon" [tiab] OR "Pregnon 1" [tiab] OR "Pregnon 1.5" [tiab] OR "Prevemb" [tiab] OR "Preventol" [tiab] OR "Previdez 2" [tiab] OR "Previfem" [tiab] OR "Prevyol" [tiab] OR "Prikul" [tiab] OR "Pronta" [tiab] OR "Prudence for Her" [tiab] OR "Rely-X" [tiab] OR "Revoke 1.5" [tiab] OR "Revoke 72" [tiab] OR "Rigesoft" [tiab] OR "Rogotinor" [tiab] OR "Secufem" [tiab] OR "Seguidet" [tiab] OR "Segurit" [tiab] OR "Segurite UD" [tiab] OR "SEKURE" [tiab] OR "Sendinor 2" [tiab] OR "Sexcon One&One" [tiab] OR "Si Mi An" [tiab] OR "Silogin" [tiab] OR "Smart Lady (Pregnon)" [tiab] OR "So-Ezzy" [tiab] OR "Tace" [tiab] OR "Tibex" [tiab] OR "Truston-2" [tiab] OR "Ulipristal 30" [tiab] OR "Unlevo 1500" [tiab] OR "Unofem" [tiab] OR "Unwanted 72" [tiab] OR "Upostelle" [tiab] OR "UPRIS" [tiab] OR "Vermagest" [tiab] OR "Vika" [tiab] OR "Vikela" [tiab] OR "Vonstrel" [tiab] OR "Xian Ju" [tiab] OR "Yi Ting" [tiab] OR "Yu Ting" [tiab] OR "Zimtemore" [tiab])

#### AND

("Nonprescription Drugs" [Mesh] OR nonprescription [tiab] OR "over the counter" [tiab] OR "over-thecounter" [tiab] OR "without a prescription" [tiab] OR "pharmacist-prescribed" [tiab] OR "pharmacy access" [tiab] OR "clinician-prescribed" [tiab] OR "physician-prescribed" [tiab] OR "GP-prescribed" [tiab] OR "general practitioner prescribed" [tiab] OR "without prescription" [tiab] OR "community pharmacy services" [Mesh] OR "community center" [tiab] OR "community centre" [tiab] OR store [tiab] OR shop [tiab] OR online [tiab] OR mobile [tiab] OR telehealth [tiab])

## CINAHL: 184 hits

AB ("Contraceptives postcoital" OR "emergency contraception" OR "emergency contraceptive" OR "emergency contraceptives" OR "morning after pill" OR "plan b") AND AB ("Nonprescription Drugs" OR nonprescription OR "over the counter" OR "over-the-counter" OR "without a prescription" OR "pharmacist-prescribed" OR "pharmacy access" OR "clinician-prescribed" OR "physician-prescribed" OR "GP-prescribed" OR "general practitioner prescribed" OR "without prescription" OR "community center" OR "community centre" OR store OR shop OR online OR mobile OR telehealth)

## LILACS: 204 hits

Title/abstract/subject: ("Contraceptives postcoital" OR "emergency contraception" OR "emergency contraceptive" OR "emergency contraceptives" OR "morning after pill" OR "plan b")

## EMBASE: 494 hits

AB,TI ('Contraceptives postcoital' OR 'emergency contraception' OR 'emergency contraceptive' OR 'emergency contraceptives' OR 'morning after pill' OR 'plan b') AND AB,TI ('Nonprescription Drugs' OR nonprescription OR 'over the counter' OR 'over-the-counter' OR 'without a prescription' OR 'pharmacist-prescribed' OR 'pharmacy access' OR 'clinician-prescribed' OR 'physician-prescribed' OR 'GP-prescribed' OR 'general practitioner prescribed' OR 'without prescription' OR 'community center' OR 'community center' OR store OR shop OR online OR mobile OR telehealth)

Page 31 of 42

#### Appendix 3: Risk of Bias Assessments

#### Non-Randomized Trials (n=18): Evidence Project Risk of Bias Tool

f 42					נואום	Open			open-202	
Appendix 3: Ris <u>Non-Randomize</u>			e Project Risk c	of Bias Tool					Vbmiopen-2021-054122 on 14 M	
Citation ID	Pre/Post	Comp. group	Cohort	Baseline Eq Demos	uivalence Outcome	Random selection	Random allocation	Control for	Follow-up	Specific Concerns
Arnet et al. 2009 [23]	Yes	No	No	NA	NA	No	No		Winhogded f	Lack of comparison group, no control for confounding
Atkins & Bradford 2015 [25]	Yes	No	No	NA	NA	No	No	Yes -	om NA	Lack of comparison
Atkins 2014 [24]	Yes	No	No	NA	NA	No	No	Yes	₽. 9 NA	Lack of comparison
Bumbul et al. 2013 [26]	No	Yes	No	No	NA	NR	No	No	NA	No pre/post, no contro for confounding
Cintina & Johansen 2015 [28]	No	Yes	No	NR	NA	No	No	Yes	<del>on Abril 20.</del>	No pre/post
Cintina 2017 [27]	Yes	No	No	NA	NA	No	No	Yes	<u>202</u> 102 102 102 102 102 102 102 102 102 102	Lack of comparison
Durrance 2013 [29]	Yes	No	No	NA	NA	No	No	res	A A A A	Lack of comparison
Falah- Hassani,et al. 2007 [30]	Yes	No	No	NA	NA	Yes	NA	No	- <del>Protected by c</del> opyright.	Lack of comparison, no control for confounding

Page 3	32 of 42
--------	----------

					BMJ	Open			/bmjopen-2021-0 <del>54122</del>	
									021-0 <del>54122 0</del>	(though random selection)
Girma & Paton 2011[31]	No	Yes	No	No	NA	No	No	Yes		No pre/post
Killick & Irving 2004 [33]	No	Yes	No	NR	NR	No	No	No	<del>8</del> 2022 22	No pre/post, no control for confounding
Marston et al. 2005 [34]	Yes	No	No	NA	NA	Yes	No	Yes	U Downlor	Lack of comparison
Moreau et al. 2006 [35]	Yes	No	No	NA	NA	Yes	No		A A NA	Lack of comparison
Mulligan 2016 [36]	Yes	No	Yes	NA	NA	NR	No	Yes		Lack of comparison
Novikova et al. 2009 [37]	Yes	No	No	NA	NA	No	No	No	1000 NA	Lack of comparison group, no control for confounding
Payakachat et al. 2010 [38]	Yes	No	No	NA	NA	No	No	No	<u>₽</u> 800 NA 91	Lack of comparison group, no control for confounding
Pentel et al. 2004 [39]	Yes	No	No	NA	NA	No	No	No	<del>() 120, 202</del>	Lack of comparison group, no control for confounding
Rubin et al. 2011 [42]	No	Yes	No	NA	NA	No	No	Yes	<del>≜ygu</del> NA	No pre/post
Soon et al. 2005 [43]	Yes	No	No	NA	NA	No	No	No	95 Protectee	Lack of comparison group, no control for confounding

## Randomized Controlled Trials (n=3 papers reporting 1 RCT): Cochrane Collaboration Tool

				BMJ Op				2002 2002	
andomized Controlled Trials (n=	-3 papers re	porting 1 RCT	): Cochrane (	Collaboratior	<u>n Tool</u>		-004	- 0 7 4	
udy ID : Harper et al. 2005 [32];	Raine et al.	2005 [40]; Rc	occa et al. 200	07 [41]				3	
omain 1: Risk of bias aris	ing from	the randon	nization pr	ocess			- + 2	4 2 2	
Signalling questions	EC use	Pregnanc Y	Unprotect ed sex	Consisten t condom use	Condom use last sex	Multiple partners	Contrace ptive method		Comments
1.1 Was the allocation sequence random?	Y	Y	Y	Y	Y	Y			
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	Y	Y	Y CO	Y C	Y	Y		Y Y	
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	N	N	N	N	N		2022	There was also a slightly higher proportion of blacks in the clinic access group (P=.045), but no other notable differences
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low y guess.	Low	
Optional: What is the predicted direction of bias	NA	NA	NA	NA	NA	NA		NA V	

		BMJ Ope	'n	mjopen-:	
arising from the				/bmjopen-2021-054122	
randomization process?				22 on	
				14 March	
				2022. Dov	
				wnloaded	
				from http://www.interview.com/in	
				p://bmjop	
				pen.bmj.c	
				com/ on /	
				April	
				20,	
				20, 2024 by	
				20, 2024 by guest. F	
	κο,			20, 2024 by guest. Protecter	
				20, 2024 by guest. Protected by cop	
				20, 2024 by guest. Protected by copyright.	

Page 34 of 42

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracept ive 14 method March	Missed pills	Comments
2.1. Were participants aware of their assigned intervention during the trial?	Y	Y	Y	Y	Y	Y	Y 2022.	Y	Blinding not possibl given the intervention
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y		× 500	Y	Y	Ŷ	vnloaded from ht	Y	
2.3. <u>If Y/PY/NI to 2.1 or 2.2</u> : Were there deviations from the intended intervention that arose because of the trial context?	N	N	N	N	N N	N	Downloaded from http://bmjopen.bmj.com	N	California legalize pharmacy access si months into th trial, but this is no related to tria context
2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	NA	NA	NA	NA	NA	N on April 2 NA	NA	
2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	NA	NA	NA	NA	NA	NA ,	NA	
2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Ϋ́	Y	Y	Y	Ϋ́	Y	2024 by guest. Protected by	Y	Modified ITT used

f 42 BMJ Open gMJ Ope

 i/bmjopen-202

2.7 If M/PM/NI to 2.6; Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?       NA       <	2 7 IF NI /DNI /NII ++ 2 C. \A/	NIA						NIA	054	NIA	
Risk-of-bias judgement     Low     Low     Low     Low     Low     Low     Low     Low       Optional: What is the predicted direction of bias due to deviations from intended interventions?     NA     NA     NA     NA     NA     NA     NA     NA	substantial impact (on the result) of the failure to analyse participants in the group to which they were	NA	1122 on 14 March 2022	NA							
Optional: What is the predicted direction of bias due to deviations from intended interventions?       NA	Risk-of-bias judgement	Low	Dow	Low							
to://bmj:com/ on April 20, 2024 by guest. P	predicted direction of bias due to deviations from	NA	NA						nloaded from h	NA	
5									n.bmj.com/ on April :		

2 3 4	D	)(
5		
6		
7		
8		
9		
10		
11		
12		
13		-
14		
15		
16		
17		
18		
19 20		-
20		
21 22		
22		
23		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37 38		
30 39		
40		
40 41		
42		
43		
44		

45 46

omain 2: Risk of bias due <mark>Signalling questions</mark>	EC use	Pregnancy	Unprotect ed sex	Consistent	Condom use last	Multiple partners	Contracep	<u>.</u>	Comments
				use	sex		method change	A	
2.1. Were participants aware of their assigned intervention during the trial?	Y	Y	Y	Y	Y	Y	Y	20022 Y	Blinding not possib given the intervention
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	Y	Y D C C	Y	Y	Y	Y	Downloaded from http://bosicoop.html	
2.3. [If applicable:] <u>If</u> <u>Y/PY/NI to 2.1 or 2.2</u> : Were important non-protocol interventions balanced across intervention groups?	NA	NA	NA	NA	NA	NA	NA	NA	
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?	Y	Y	Y	Y	Y	YO	Y		Yes, deviations because of change in CA law but rerandomized
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants' outcomes?	РҮ	РҮ	РҮ	ΡΥ	РҮ	РҮ	PY y	₹ PY	Contamination between groups du to change in law

				ВМЈ Ор	en		i/bmjopen-2		
2.6. <u>If N/PN/NI to 2.3, or</u> <u>Y/PY/NI to 2.4 or 2.5</u> : Was an appropriate analysis used	Y	Ϋ́	Ϋ́	Y	Y	Y	i/bmjopen-2021-054122 on γ_		
to estimate the effect of adhering to the intervention?							14 March 20		
Risk-of-bias judgement	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some N concerns	Some	
Optional: What is the predicted direction of bias due to deviations from intended interventions?	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors ad experime ntal	experime ntal	
						ν <sub>0</sub> ,	ttp://bmjopen.bmj.com/ on April 20, 2024 by gue		
							y guest. Protected by copyright		

i/bmjopen-2021-054122

2	
3	
4	
5	
6	
7	
8	
9	
9 10 11	
11	
12	
13 14	
14	
15	
16	
15 16 17 18	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
22	
36 37	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
45	

46

## Domain 3: Missing outcome data

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	method change	14 March	Missed pills	Comments
3.1 Were data for this outcome available for all, or nearly all, participants randomized?	<u>PY</u>	PY	<u>PY</u>	<u>PY</u>	<u>PY</u>	<u>PY</u>	<u>PY</u>	2022.	<u>PY</u>	814/889 pharmacy access; 826/884 advance provision; 310/344 clinic access
3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	NA	NA	NA	NA	NA	NA	NA	Downloaded from http://bmiopen.bmi.com/ on April 20,	NA	
3.3 <u>If N/PN to 3.2</u> : Could missingness in the outcome depend on its true value?	NA	NA	NA	NA	NA	NA	NA	bmjopen.br	NA	
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	NA	NA	NA	NA	NA	NA	ii.com/ on Apr	NA	
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low			Low	
Optional: What is the predicted direction of bias due to missing outcome data?	NA	NA	NA	NA	NA	NA	NA d	v quest. Prote	NA	
							-	2024 by guest. Protected by copyright.		

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contrace ive change	Missed pills	Comments
4.1 Was the method of measuring the outcome inappropriate?	N	N	<u>N</u>	N	N	N	2022. <b>Z</b>	<u>N</u>	
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	N	<sup>≥</sup> 200	N	N	N	Downloaded from http://bmjopen.bmj.com ∠I	<u>N</u>	
4.3 <u>If N/PN/NI to 4.1 and</u> <u>4.2</u> : Were outcome assessors aware of the intervention received by study participants?	Y	Y	Y	Y CO	Y Ve	Y	Y Y	Y	
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	PN	PN	v on April 20, 2024 ₽	<u>PN</u>	
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	P by guest. Protected by copyright.	<u>PN</u>	

				BMJ	Open			3mjopen-2		
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low	/bmjopen-2021-054122 (	Low	
Optional: What is the predicted direction of bias in measurement of the outcome?	NA	NA	NA	NA	NA	NA	NA	on 14 March 2022. [	NA	
								wnloaded fror		
								m http://bmjop		
								en.bmj.cor		
								n∕ or		
								n/ on April 20, 2024		
					Prie			oy gue		
								n/ on April 20, 2024 by guest. Protected by copyright.		

Page 41 of 42

24

44 45

main 5: Risk of bias in s	election o	f the repor	ted result	Consistent	Condom	Multiple	/bmjopen-2021-054122 Contraceg	Missed	Comments
			ed sex	condom use	use last sex	partners	ive 14 method March	pills	
5.1 Were the data that produ unblinded outcome data were			accordance	with a pre-sp	ecified analy	sis plan that	was finalize		
	<u>Y</u>	<u>Y</u>	Y	<u>Y</u>	<u>Y</u>	<u>Y</u>	Y wnlo	<u>Y</u>	
s the numerical result being a	assessed like	ly to have bee	en selected, c	on the basis o	of the results	, from	oadeo	1	
5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	N	N C C	N	<u>N</u>	N	d from http://bmjopen.bmj.com/ on	N	
5.3 multiple eligible analyses of the data?	N	N	N	N	Z	N	en.bmj.com/ on ∠l	N	
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	n April 20, 2024 Low	Low	
Optional: What is the predicted direction of bias due to selection of the reported result?	NA	NA	NA	NA	NA	NA	N N N N N	NA	

 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## Overall risk of bias

2				ВМЈ Ор	en		i/bmjopen-2021-054122		
overall risk of bias							21-054122		
Overall assessment	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracept	Missed	Comments
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low	Low	
Optional: What is the overall predicted direction of bias for this outcome?	NA	NA	NA	NA	NA	NA	NA http://b	NA	
						ν <sub>ο,</sub>	14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.         ive method         Low         NA		
		For peer revie	ew only - http:	://bmjopen.br	nj.com/site/al	oout/guideline			

# **BMJ Open**

## Over-the-counter provision of emergency contraceptive pills: A systematic review

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-054122.R2
Article Type:	Original research
Date Submitted by the Author:	28-Jan-2022
Complete List of Authors:	Atkins, Kaitlyn; Johns Hopkins University Bloomberg School of Public Health, Department of International Health Kennedy, Caitlin; Johns Hopkins University Bloomberg School of Public Health, International Health Yeh, Ping; Johns Hopkins University Bloomberg School of Public Health, Department of International Health Narasimhan, Manjulaa; World Health Organization, Department of Sexual and Reproductive Health and Research
<b>Primary Subject Heading</b> :	Obstetrics and gynaecology
Secondary Subject Heading:	Global health, Health services research, Patient-centred medicine, Sexual health, Reproductive medicine
Keywords:	PUBLIC HEALTH, Maternal medicine < OBSTETRICS, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Reproductive medicine < GYNAECOLOGY
	·

SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

#### Over-the-counter provision of emergency contraceptive pills: A systematic review

Kaitlyn Atkins<sup>1</sup>, Caitlin E. Kennedy<sup>1</sup>, Ping Teresa Yeh<sup>1</sup>, Manjulaa Narasimhan<sup>2</sup>

<sup>1</sup> Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Kaitlyn Atkins, PhD Candidate. Caitlin E. Kennedy, Associate Professor. Ping Teresa Yeh, Research Associate.

<sup>2</sup> Department of Sexual and Reproductive Health and Research, World Health Organization, includes the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction – HRP, Geneva, Switzerland. Manjulaa Narasimhan, Scientist.

#### **Correspondence to:**

Manjulaa Narasimhan

Department of Sexual and Reproductive Health and Research UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme World Health Organization vitzerlan 20 Avenue Appia, 1211 Geneva 27, Switzerland

Email: narasimhanm@who.int

#### Word count: 4916

### Abstract

**Objective:** To synthesize evidence around over-the-counter (OTC) emergency contraceptive pills (ECPs) to expand the evidence base on self-care interventions..

Design: Systematic review (PROSPERO# CRD42021231625).

**Eligibility criteria:** We included publications comparing OTC or pharmacy-access ECP with prescriptiononly ECPs and measuring ECP uptake, correct use, unintended pregnancy, abortion, sexual practices/behavior, self-efficacy, and side-effects/harms. We also reviewed studies assessing values/preferences and costs of OTC ECPs.

**Data sources:** We searched PubMed, CINAL, LILACS, EMBASE, clinicaltrials.gov, WHO International Clinical Trials Registry Platform, Pan African Clinical Trials Registry, Australian New Zealand Clinical Trials Registry, Cochrane Fertility Regulation, and International Consortium for Emergency Contraception through December 2, 2020.

**Risk of bias:** For trials, we used Cochrane Collaboration's tool for assessing risk of bias; for other studies, we used the Evidence Project risk of bias tool.

**Data extraction and synthesis:** We summarized data in duplicate using GRADE Evidence Profile tables, reporting findings by study design and outcome. We qualitatively synthesized values/preferences and cost data.

**Results:** We included 19 studies evaluating effectiveness of OTC ECP, 56 on values/preferences, and three on costs. All studies except one were from high- and middle-income settings. Broadly, there were no differences in overall ECP use, pregnancy, or sexual behavior, but an increase in timely ECP use, when comparing OTC or pharmacy ECP to prescription-only ECP groups. Studies showed similar/lower abortion rates in areas with pharmacy availability of ECPs. Users and providers generally supported OTC ECPs; decisions for use were influenced by privacy/confidentiality, convenience, and cost. Three modeling studies found pharmacy-access ECPs would lower health sector costs.

**Conclusion:** OTC ECPs are feasible and acceptable. They may increase access to and timely use of effective contraception. Existing evidence suggests OTC ECPs do not substantively change reproductive health outcomes. Future studies should examine OTC ECP's impacts on user costs, among key subgroups, and in low-resource settings.

Keywords: emergency contraceptives, contraceptives, pregnancy, pharmaceutical services, self-care

## Strengths and limitations of this study

- We comprehensively searched the literature on effectiveness, costs, and values and preferences of over-the-counter emergency contraception.
- We searched four major databases and four clinical trial registries, with no restrictions on •
- inditions inter-counter of income countries income countries Given our focus on over-the-counter delivery modalities, we may have excluded studies that • assessed relevant outcomes of expanded access to emergency contraception through advance
- The findings of this review may not be generalizable, as the majority of studies were conducted in •

### Introduction

The World Health Organization (WHO) recommends the use of several forms of emergency contraception, which can substantially reduce unintended pregnancy when used correctly [1, 2]. Reducing barriers to emergency contraceptive pills (ECPs) may increase access to effective contraceptive options, reduce unintended pregnancies, and overall improve outcomes related to sexual and reproductive health and rights [3].

In many settings, ECPs are delivered through one or more modalities [4]: (1) prescription-only, wherein physicians or other medical providers prescribe ECPs based on individual need; (2) pharmacy access (also called behind-the-counter), wherein the medication is available via screening or prescription from a pharmacist; and (3) OTC, wherein medication is available on store shelves without a prescription. As of December 2021, ECPs are available via pharmacy access in 76 countries, and OTC in 19 countries [5]. While both pharmacy access and OTC may reduce barriers to access by no longer requiring a visit to a physician or other health care provider, pharmacy access still requires the presence of a pharmacist, while truly OTC availability means an individual can purchase medication in the absence of a medical or pharmacy provider.

While countries have varying regulatory criteria involved in making a specific medication available OTC or with eligibility screening by pharmacy staff [6], the WHO is responsible to provide overall guidance to critical questions of intervention recommendations. The 2019 WHO normative guidance on self-care interventions [7] included a recommendation on OTC oral contraception (contraceptive pills). This was informed by a previous systematic review [8], in which we found that OTC oral contraception may result in higher continuation with limited contraindicated use among users, and was generally supported by patients and providers. This earlier review and the 2019 WHO guidance did not include OTC delivery of ECPs. We therefore conducted this systematic review as part of expanding the evidence base of the guideline.

This review was also conducted in response to the COVID-19 pandemic that has seen overstretched health systems and disruptions of health services globally [9, 10]. WHO has prioritized self-care interventions in response to maintaining essential sexual and reproductive health services during the pandemic as people fail to access care and services, highlighting the need to improve availability of options that people can use outside of formal health facilities [9, 11-13]. Further, WHO has warned that the COVID-19 pandemic has further increased women's exposure to intimate partner violence, as a result of measures such as lockdowns and disruptions to vital support services [14], which may lead more women and girls to need and/or use OTC ECPs. In addition, supply-side constraints and other barriers related to COVID-19 may reduce access and availability of condoms and other forms of medically prescribed contraceptive options, thus increasing the need for and importance of OTC ECPs [10, 15-17].

### Methods

This review addressed the following question: Should ECPs be made available without a clinician's prescription? We reviewed the extant literature in three areas relevant to this question: effectiveness of the intervention, values and preferences of end-users and providers, and cost information. These three areas are all required information in the WHO guideline development process [18]. The review followed Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (see Appendix 1) [19], and the protocol was published on PROSPERO (registration number CRD42021231625). Ethical approval was not required for this systematic review, since all data came from information freely available in the public domain (i.e. published articles).

#### Effectiveness review inclusion criteria

The effectiveness review was designed according to the PICO format as follows:

• Population: Individuals using ECPs

- **Intervention**: Availability of ECPs OTC (without a prescription or screening) or from a pharmacist (behind-the-counter or pharmacy access)
- **Comparison**: Availability of ECPs by prescription only (by a clinician other than a pharmacist)
- **Outcomes**: (1) Uptake of ECPs (initial use); (2) Correct use of ECPs, including comprehension of product label instructions; (3) Unintended pregnancy; (4) Abortion (medical or unsafe); (5) Changes in sexual and reproductive health (SRH) practices or behavior; (6) Self-efficacy, self-determination, autonomy, empowerment; (7) Side effects, adverse events, or social harms and whether harms were corrected/had redress available

To be included in the effectiveness review, an article must have: 1) had a study design comparing OTC or behind-the-counter (pharmacy) access of ECPs to prescription-only access (including randomized controlled trials (RCTs), non-randomized trials, and comparative observational studies); 2) measured one or more of the outcomes listed above; and 3) been published in a peer-reviewed journal. We did not restrict inclusion on the basis of language or intervention location. Articles in English, French, Spanish, and Chinese were coded directly; articles in other languages were translated before coding.

For the purposes of this review, we considered both behind-the-counter (pharmacy access) and true OTC availability as "over-the-counter" in our intervention definition. Our definition also includes availability through a range of locations other than pharmacies, including drug shops, vending machines, and online or telehealth services. Although IUD insertion can also be a form of emergency contraception, it requires insertion by a provider and thus cannot be made available OTC. This review thus focuses on ECPs. Studies that examined the provision of ECPs for clients to keep at home versus OTC or prescription-only access were not included.

## Search strategy and screening

We searched four electronic databases (PubMed, CINAL, LILACS, and EMBASE) and four clinical trial registries (clinicaltrials.gov, WHO International Clinical Trials Registry Platform, Pan African Clinical Trials Registry, and Australian New Zealand Clinical Trials Registry). We also searched the website of the Cochrane Fertility Regulation (<u>https://fertility-regulation.cochrane.org/</u>) and its COVID-19 specific page (<u>https://cgf.cochrane.org/news/covid-19-coronavirus-disease-fertility-and-pregnancy</u>), as well as the International Consortium for Emergency Contraception (<u>https://cecinfo.org</u>) and its regional consortia. Electronic databases were searched through December 2, 2020, using consistent search strings including a list of oral and emergency contraceptives, plus terms associated with medication provision without a prescription (see Appendix 2).

Secondary reference searching was conducted on all studies included in the review. Further, selected experts in the field were contacted to identify additional articles not identified through other search methods.

Titles, abstracts, citation information, and descriptor terms of citations identified through the search strategy were screened by a member of the study staff. Full text articles were obtained of all selected abstracts and two independent reviewers assessed all full-text articles for eligibility to determine final study selection. Differences were resolved through consensus.

## Data extraction and management

Two reviewers independently extracted data using standardized forms. Differences in data extraction were resolved through consensus and referral to a senior study team member from WHO when necessary. The following information was gathered from each included study:

- Study identification: Author(s); type of citation; year of publication
- Study description: Study objectives; location; population characteristics; type of ECP; description of OTC access; description of any additional intervention components (e.g. any education, training, support provided); study design; sample size; follow-up periods and loss to follow-up

• Outcomes: Analytic approach; outcome measures; comparison groups; effect sizes; confidence intervals; significance levels; conclusions; limitations

For RCTs, we assessed risk of bias using the Cochrane Collaboration's tool for assessing risk of bias [20]. For studies that were non-randomized comparative trials, we assessed study rigor using the Evidence Project eight-item risk of bias tool, which has been shown to have moderate to substantial reliability [21]. We selected the Evidence Project tool given its applicability to a wide range of study designs, ease of use and interpretation, and consistency in assessing bias for individual studies rather than outcomes, which may vary across studies and topics.

#### Data analysis

We analyzed data according to coding categories and outcomes. If multiple studies reported the same outcome, we conducted meta-analysis using random-effects models to combine risk ratios with the Comprehensive Meta-Analysis program.

For each outcome assessed in the review, we summarized data in GRADE Evidence Profile tables using GRADEPro [22]. We used RCT data where they were available; if RCT data were not available for an outcome, we pulled data from observational studies.

Where possible, we stratified analyses by the following subgroups: (1) behind-the-counter vs true OTC; (2) point of access (e.g. stores, pharmacies, telehealth, etc.); (3) type of ECPs (progestin-only vs ulipristal acetate vs combined vs mifepristone); (4) prior use of contraception; (5) age group; (6) vulnerabilities (e.g. poverty, disability, religion, literacy); (7) high-income vs low- or middle-income setting.

#### Additional reviews

We conducted additional reviews examining values and preferences and costs of OTC provision of ECPs. We used the same search strategy and terms to identify studies for these reviews. Studies were included in these reviews if they presented results from primary data collection; opinion pieces and reviews were excluded. We summarized this literature qualitatively and presented it with consideration of study design, methodology, location, and population.

<u>Values and preferences review</u>. We included studies in this review if they presented primary data examining preferences of women and girls regarding OTC access to ECPs. We focused on studies examining the values and preferences of women and girls who have used or potentially would use emergency contraceptives themselves, but we also included studies examining the values and preferences of healthcare providers, including in particular pharmacists and other providers. We considered issues around OTC access to ECPs as they relate to age of availability and marital status (both in law and in practice), broader social/structural factors that affect values and preferences, informed decision-making, coercion and seeking redress in this section.

<u>Cost review</u>. We included studies in this review if they presented primary data comparing costing, costeffectiveness, cost-utility, or cost-benefit of the intervention and comparison listed in the PICO above, or if they presented cost-effectiveness of the intervention as it relates to the PICO outcomes listed above. We classified cost literature into four categories (health sector costs, other sector costs, patient/family costs, and productivity impacts) and within each category organized results by study design/methodology, location, and population.

### Patient and public involvement

Feedback on the review protocol and analysis was received from the WHO patient safety working group. Patients were involved in a global survey of values and preferences conducted to inform the WHO guideline on self-care interventions; they thus play a significant role in the overall recommendation informed by this review.

#### Results

Our search yielded 2581 unique references, of which 129 were retained for full-text review (Figure 1). Ultimately, we identified 19 studies (reported in 21 articles) that met the inclusion criteria for the effectiveness review [23-43], 56 values and preferences studies [44-98], and three cost studies [99-101].

Figure 1. PRISMA flow chart showing disposition of citations through the search and screening process.

#### Effectiveness review

Overall, 19 studies from eight countries (published in 21 articles) met the inclusion criteria for the effectiveness review [23-43] (Table 1). This included one RCT (published in three articles), which was shown to have generally low risk of bias, and 18 observational studies, with risk of bias related to the presence of comparison groups, controls for confounding, and/or pre/post data. All studies were from high-income countries, and most presented data on ECP uptake, changes in SRH practices and behavior, or abortion. Only one study [32, 40, 41] assessed side effects, adverse events, or social harms. There was no comparative data on correct use of ECPs or self-efficacy, self-determination, autonomy, or empowerment. Effect sizes are reported by outcome in Table 2, and risk of bias assessments are presented in Appendix 3.

#### ECP uptake

Nine studies reported on the impacts of OTC and pharmacy-access ECP on ECP use, prescribing, and uptake. Evidence from one RCT [40] showed no difference in use of ECPs with pharmacy access (RR 1.15, 95% CI: 0.90-1.48). In the same trial, there were no differences in ECP use by age [32]. Three serial cross-sectional studies similarly found no changes in overall ECP use over time with implementation of OTC access in Finland [30], the UK [34], and Australia [37]. The studies in Finland and the UK were found to have risk of bias due to lack of comparison groups in either study (both were pre/post only); biases in the study in Australia were related to the absence of a comparison group (pre/post only) and lack of control for confounding in the analysis.

Two cross-sectional studies found that use of ECPs within 24 hours of sex increased with pharmacy access in the UK (18% increase; p=0.03) [33] and the USA (aOR 2.17, 95% CI: 1.06-4.44) [42]. The study in the UK was found to have risk of bias, having no pre/post data and no control for confounding. The study from the USA was found to have risk of bias due to lack of pre/post data. Finally, a study assessing rates of pharmacy distribution in a safety-net hospital showed that ECP distribution increased by 800% over a 1.5-year period, while ECP prescribing increased by 50% over the same period [39]. This study was found to have risk of bias related to having no comparison group (pre/post only) or control for confounders.

When assessing impacts among the subgroup of adolescents and young adults, one study among women aged 16-19 in the UK found that ECP use increased from 15.3% before ECPs were available OTC to 21.5% in the year after OTC ECPs became available ( $X^2$ =1.54, p=0.24), before decreasing 8.5% another year following OTC availability ( $X^2$ =7.11, p=0.01) [34]. Potential bias in this study was from having no comparison group (pre/post only).

#### Unintended pregnancy

Two studies assessed unintended pregnancy as an outcome. The one RCT found no significant change in pregnancy among women who did not wish to become pregnant (RR 0.82, 95% CI: 0.53-1.27) [40]; this did not differ by age [32]. A small cross-sectional study among pregnant women receiving prenatal care in the USA found that the proportion of women who reported their pregnancy as unintended increased from 72.7% before pharmacy access to 90.7% after pharmacy access (p=0.02) [38]. This finding was determined to have risk of bias based on having no comparator or control for confounders.

Additionally, one ecological study assessed changes in conception rate over time in the UK [31], which does not explicitly consider whether the pregnancy was intended but is an indirect proxy measure. The study found no differences before or after OTC access among individuals aged 13-19, but was associated with an increase in conception of about 0.9% among women aged 25-44 (p<0.05) [31]. Lack of pre/post data in this study was identified as a potential source of bias.

#### Abortion

Four ecological studies from the USA assessed the impact of pharmacy-access ECPs on abortion rates per 1,000 women, all with risk of bias related to lack of comparison groups or pre/post data [27-29, 36]. These studies found no difference in overall abortion rates with pharmacy-access ECPs. Evidence from one study among 18- to 19-year-olds showed a decrease of 1.6 abortions per 1,000 women after pharmacy-access ECPs became available in the USA (p<0.05) [28]. Another study among 15- to 19-year-olds found a decrease of 1.97 abortions per 1,000 (p<0.01).

Finally, evidence from one serial cross-sectional study from France showed that reporting ever having an abortion declined from 17.0% before OTC ECP access to 15.6% after OTC ECP access (p=0.04) [35]. Bias in this study was related to lack of a comparison group (pre/post only).

#### Sexual health-related practices and behavior

Seven studies assessed outcomes related to SRH practices and behavior. Specific outcomes assessed included condom use (three studies), unprotected sex (two studies), reporting multiple partners (three studies), contraceptive method use (four studies), and missing contraceptive pills (two studies).

Evidence from one RCT showed no difference in number of sexual partners (RR 1.24, 95% CI: 0.95-1.61), condom use at last sex (RR 0.92, 95% CI: 0.81-1.05), consistent condom use (RR 1.07, 95% CI 0.76-1.51), change in contraceptive method (RR 1.16, 95% CI: 0.92-1.47) or missed contraceptive pills (among pill users; RR 0.92, 95% CI: 0.80-1.06) [40]. The same RCT found decreases in unprotected intercourse with increased access to OTC ECPs (RR 0.82, 95% CI: 0.70-0.97). These findings did not vary by age [32].

An observational study found no significant changes in condom use, contraceptive use (including multimethod use), unprotected intercourse, or missed contraceptive pills (among pill users), when comparing outcomes before and after pharmacy-access ECPs in German-speaking Switzerland [23]. This finding may have been influenced by bias from having no comparator (pre/post only) and no control for confounders. In the USA, evidence from two serial cross-sectional studies showed that increased access to OTC ECPs had no effect on sexual activity or contraceptive use over time [24, 25], though it reduced condom use among adolescents by 5.2% to 7.2% (p<0.01) [25]. Both serial cross-sectional studies were found to have risk of bias due to lack of comparison groups (pre/post only). Finally, cross-sectional evidence from Lithuania and Poland showed that increased access to OTC ECPs was associated with reduced reporting of five or more sexual partners (30.6% without OTC access vs 9.6% with OTC access; p<0.001) [26]. Bias in this study were related to lack of pre/post evidence and no control for confounders.

#### Side effects, adverse events, and social harms

One RCT assessed potential social harms resulting from pharmacy-access ECPs and found that there was no difference in reporting being pressured into sex (RR 0.82, 95% CI: 0.43-1.56) [40]. For this outcome, there was no difference in age subgroup analyses [32].

1 2 4 5 6 7 8 9	
11 12 13 14 15	<u>)</u> } 
16 17 18 19 20	5 7 8
21 22 23 24	<u>2</u> 5
25 26 27 28 29	5 7 8
30 31 32 33	) <u>-</u> }
34 35 36 37 38	5
39 40 41 42	) ) <u>)</u>
43 44 45 46 47	 ;

Study	cription of include	Location	Population	Intervention*	136/bmjopen-202 Outcomes
<b>j</b>	Design				054122
					22 01
Arnet et al. 2009 <b>[23]</b>	Pre/Post	Switzerland: Basel, Bern, Zurich	Women aged 15-49 accessing ECPs at pharmacies; 2003, 2006 N=729	Pharmacy access	5.4SRH practices o
Atkins & Bradford 2015 <b>[25]</b>	Serial Cross- Sectional	USA: ME, NH, VT, RI	Public school students who responded to sexual activity questions in Youth Risk Behavior Survey; 2003-2009 N=49,454	Pharmacy access	22 22 5.SRH practices o benavior
Atkins 2014 <b>[24]</b>	Serial Cross- Sectional	USA: national	Non-pregnant women of aged 18-45 who responded to National Health and Nutrition Examination Survey; 2001-2004, 2007- 2010 N: Not reported	Pharmacy access	5. SRH practices of behavior
Bumbul et al. 2013 <b>[26]</b>	Cross- Sectional	Poland: Warsaw Lithuania: Vilnius	Female students and high school pupils N=1,366	OTC access	1. ECP uptake 5. SRH practices c benavior
Cintina & Johansen 2015 <b>[28]</b>	Ecological	USA: national (states except AK, DC, DE, HI, IA, MA, ME, NJ, NM, VT, WA)	Women aged 15-19 years; 2000-2010 N: Not reported	Pharmacy access	April 2024 by
Cintina 2017 <b>[27]</b>	Ecological	USA: WA, OR, ID	Women aged 15-44 N=1,747	Pharmacy access	4.%Abortion
Durrance 2013 <b>[29]</b>	Ecological	USA: WA	Women aged 15-24 years; 1993-2005 N=507	Pharmacy access	t. Protectebortion 4.ed by copyright

Page	11	of	44
------	----	----	----

Falah-					136/bmjopen-202
Hassani,et al. 2007 <b>[30]</b>	Serial Cross- Sectional	Finland: national	Adolescents aged 12-18; 1991, 2001, 2003 N=12,121	OTC access	1. CP uptake
Girma & Paton 2011 <b>[31]</b>	Ecological	UK: national	Women aged 13-44; 1998-2004 N: Not reported	OTC access	3. Unintended prégnancy <sup>†</sup>
Harper et al. 2005 <b>[32]</b> ; Raine et al. 2005 <b>[40]</b> ; Rocca et al. 2007 <b>[41]</b>	RCT	USA: California: San Francisco	Women aged 15-24 attending clinics providing family planning; not desiring pregnancy, using long-term hormonal contraception or requesting ECPs; 2001- 2003 N=2,117	Pharmacy access	1. ECP uptake 3. Pinintended prognancy 5. BRH practices behavior 7. Side effects, adverse events, social harms
Killick & Irving 2004 <b>[33]</b>	Cross- Sectional	UK: national	Women accessing ECPs at pharmacies N=419	Pharmacy access	1.≩CP uptake
Marston et al. 2005 <b>[34]</b>	Serial Cross- Sectional	UK: national	Women aged 16-49 who responded to Omnibus survey; 2000-2002 N=5,984	OTC access	1. ECP uptake 5. SRH practices bepavior
Moreau et al. 2006 <b>[35]</b>	Serial Cross- Sectional	France: national	Women aged 15-44 years responding to national health surveys; 1999, 2004 N=11,656 (1999: 4,146; 2004: 7,490)	OTC access	1. 20 4. Abortion 24 by
Mulligan 2016 <b>[36]</b>	Cross- Sectional	USA: national (all states except CA, NH (post-1997), MD (post-2006))	Women aged 15-44 in the USA, 1993- 2011; female respondents to the National Longitudinal Survey of Youth; 1997-2009 N=4385 for 1997 NLSY; otherwise not reported	Pharmacy access	4. Abortion

			BMJ Open		136/bmjope
Novikova et al. 2009 <b>[37]</b>	Serial Cross- Sectional	Australia: Sydney	Women attending abortion clinics N=718	OTC access	1.25CP uptake
Payaka- chat et al. 2010 <b>[38]</b>	Cross- Sectional	USA: AR: Little Rock	Pregnant women receiving prenatal care at a large urban community women's clinic; 2003-2008 N=272	Pharmacy access	3. Winintended pregnancy 5. ARH practices or begavior
Pentel et al. 2004 <b>[39]</b>	Ecological	USA: MN: Minneapolis	Female patients at a safety-net hospital N: Not reported	Pharmacy access	1.№ D O
Rubin et al. 2011 <b>[42]</b>	Cross- Sectional	USA	Females aged 14-19 who had engaged in unprotected sex while aware of ECPs N=531	Pharmacy access	1. ECP uptake
Soon et al. 2005 <b>[43]</b>	Retrospective Cohort	Canada: British Columbia	Women aged 10-59 who received ECP prescriptions from 1996-2002 N=1,172	Pharmacy access	1.4 CP uptake
	ssessed changes		on-only access to ECPs. h does not explicitly consider whether the pregnancy	v was intended bu	t is considered an
					guest. Protected by copyright

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		N (%) or Mean (SI	))	Effect	136/bmjopen-2021C
No. and type of studies	Specific Outcome	OTC/pharmacy access	Prescription-only availability		154122 on
PICO Outcome 1	: ECP Uptake				
1 RCT <b>[40]</b>	ECP use	197/814 (24.2%)	65/310 (21.0%)	<b>RR 1.15</b> (0.90-1.48)	14 March 202
1 Retrospective cohort <b>[43]</b>	Physician prescribing of ECPs	2001: 9,447 2002: 10,669	1996-2000: 8,805/year (95% Cl: 7,823-9,787)	Not reported	Lack of comparis
3 serial cross- sectional <b>[30</b> , <b>34</b> , <b>37]</b> ; 3 cross- sectional <b>[26, 33, 42]</b>	ECP use	Summary: All stud subgroups with inc increased use of E 2.17; 95% CI: 1.06	Lack of comparis for [30, 34, 37]; No control for confounding [26, 33, 37]; No pre/p [26, 33, 42]		
1 ecological [39]	ECP distribution from pharmacies		stribution from a hospital p rs, while prescription use o		Lack of comparis no control for confounding
PICO Outcome 3	: Unintended Pregna	ncy		0,	Apri
1 RCT <b>[40]</b>	Unintended pregnancy	58/814 (7.1%)	27/310 (8.7%)	<b>RR 0.82</b> (0.53-1.27)	20, 202
1 cross-sectional [38]	Unintended pregnancy	88 (90.7%)	24 (72.7%)	p=0.02	Lack of comparis
1 ecological [31]	Conception rate*	Summary: Among change in concepti women aged 25-44 use (p<0.05).	Protected by copyright		

			BMJ Open		136/bmjope
4 ecological <b>[27-</b> 29, 36]	Abortion rate per 1000 women	increased access to decreases among yo 1,000 18-19 year old		s identified significant crease of 1.6 abortions per and a decrease of 1.97 per	9 2021-2021 Lack of comparison 6 [27, 29, 36]
1 serial cross- sectional <b>[35]</b>	Abortion (ever)	1168/7490 (15.6%)	708/4166 (17.0%)	p=0.04	Lack of comparison
PICO Outcome 5	: Sexual health-related	I practices and behav	vior		ch 20
	Unprotected sex	274/814 (33.7%)	127/310 (41.0%)	<b>RR 0.82</b> (0.70-0.97)	2022 2. Low Dov
	Consistent condom use	110/814 (13.5%)	39/310 (12.6%)	<b>RR 1.07</b> (0.76-1.51)	nloaded
	Condom use last sex	383/814 (47.1%)	158/310 (51.0%)	<b>RR 0.92</b> (0.81-1.05)	from http
1 RCT <b>[40]</b>	Multiple partners	192/814 (23.6%)	59/310 (19.0%)	<b>RR 1.24</b> (0.95-1.61)	p;//bmjop
	Contraceptive method change	220/814 (27.0%)	72/310 (23.2%)	<b>RR 1.16</b> (0.92-1.47)	yen.bmj.
	Missed pills (among subgroup of reported contraceptive pill users)	245/391 (62.7%)	84/123 (68.3%)	<b>RR 0.92</b> (0.80-1.06)	Downloaded from http://bmjopen.bmj.com/ on April 2
	Condom use	220/333 (66.0%)	232/350 (66.3%)	Not significant at p<0.05	$\mathcal{L}_{N}^{\mathfrak{S}}$ Lack of comparison $\mathcal{R}_{N}^{\mathfrak{S}}$ no control for
	Oral contraceptive use	69/333 (20.7%)	90/350 (25.7%)	Not significant at p<0.05	4
1 pre/post study [23]	Oral contraceptives + condoms	10/333 (3.0%)	7/350 (2.0%)	Not significant at p<0.05	est. Prot
	Unprotected sex	17/340 (5.0%)	25/361 (6.9%)	Not significant at p<0.05	ectec
	Missed pills	53/79 (67.1%)	47/97 (48.5%)	Not significant at p<0.05	d by copyright

			BMJ Open		136/bmjope			
3 serial cross-	Multiple partners	<b>Summary:</b> Increased study [24] identified a (p<0.01); another stud reporting multiple par	Lack of comparison [24, 25, 34, 38]; No pre/post [26]; No					
sectional [24, 25, 34]; 2 cross- sectional [26, 38]	Contraceptive use		s to OTC ECPs. One	rence in oral contraceptive use study [24] found a 7.6% o<0.05).	<sup>10</sup> confounding [26, 38 14 4 4 4 4 4 4 4 4 4 4 4 4 4			
20]	Condom use	increased access to C						
PICO Outcome 7	: Side effects, adverse	e events, and social ha	irms		iloade			
1 RCT <b>[40]</b>	Pressured into sex	28/814 (3.4%)	13/310 (4.2%)	<b>RR 0.82</b> (0.43 -1.56)	trom			
				r V	open.bmj.com/ on April 20, 2024 by guest. Prote			
					guest. Protected by copyright			

## Values and preferences review

Overall, 56 studies from 33 countries were included in the values and preferences review (Figure 2) [33, 44-98]. There were 39 quantitative studies (all cross-sectional surveys), 11 qualitative studies, and six mixed-methods studies. Twenty-two studies included end-users, 33 studies included pharmacists or other health care providers or professional stakeholders, and one study included both groups. One study [33] was also included in the effectiveness review.

Of the included studies, most were in the USA (n=19) and UK (n=9), followed by Sweden (n=5), Canada (n=4), Australia (n=3), India (n=3), South Africa (n=2), and South Korea (n=2). One study each was conducted in Austria, Barbados, Belgium, Bulgaria, Czech Republic, Democratic Republic of Congo, France, Germany, Hong Kong, Hungary, Indonesia, Jamaica, Kazakhstan, Lithuania, Nicaragua, Norway, Pakistan, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Slovakia, and Spain.

Figure 2. Map showing distribution of studies included in the values and preferences review.

Of the values and preferences studies among end-users, support for OTC ECPs varied widely within and across countries, ranging from 12% among college students in India [72] to 100% among women who used OTC ECPs in Sweden [44]. In one study, where women could choose whether to obtain ECPs from a pharmacist or a physician [33], satisfaction with information received was 91% among those receiving ECPs in pharmacies, compared to 58% among those receiving prescription-only ECPs (p=0.006). Broadly, end-users supported OTC ECPs because they felt it offered improved access/availability, convenience, more flexible hours (particularly weekend hours), confidentiality/privacy/anonymity, and reduced cost. End-users also anticipated that OTC delivery would offer less opportunity for judgement from providers and greater control for women.

End-users who did not support OTC ECPs expressed concern about potential lack of privacy or increased cost, in addition to having a preference for more personal contact with providers for support and information. They also expressed some concerns about increased risk behavior. One study noted this concern was for others; the individuals participating in the study, all of whom were ECP users, did not believe their own behavior would be shaped by ECP use [77].

Of the values and preferences studies among pharmacists and other health care providers and professionals. support for OTC ECPs ranged widely. In quantitative surveys, pharmacist support ranged from 16% in South Dakota, USA [65] to 97% in San Francisco, USA [55]. Among doctors, support was generally lower, ranging from 6.1% in South Korea [83] to 68.9% in Canada [81]. Broadly, providers supported OTC ECPs for similar reasons as end-users. Some studies found that providers had concerns about side effects, including the inability to communicate about side effects in OTC delivery modalities [45] and concerns about long-term impacts of repeat ECP use [86]. In contrast, one study found that providers supported OTC delivery as they saw ECPs as having relatively few side effects [83]. 

Providers were also found to have concerns about increased risk behavior, misuse/repeat use of ECPs, and communication. Specifically regarding communication, providers felt concerned about discouraging other contraceptives [54, 69, 81, 84, 89], and felt that OTC delivery might preclude delivery of necessary education and counseling. In some studies, providers had religious/moral concerns about OTC delivery [48, 52, 61, 69, 89]. One study found that these concerns were more common among providers who believed ECPs were an abortifacient [61].

## Cost review

Three studies met inclusion criteria for the cost review (Table 3) [99-101]. All were modelling studies, two from the USA [99, 100] and one from Canada [101]. All examined the impact of pharmacy-access ECPs (not true OTC) and found that pharmacy access was expected to lead to lower health sector costs. No studies examined other sector costs, patient/family costs, or productivity impacts.

Table 3. Description of studies included in the	cost review.

Study	Location	Study design	Impact of pharmacy access
Marciante et al., 2001 <b>[100]</b>	USA	Decision model	Among private payers (private insurance): \$158 (95% CI=\$76, \$269) reduction in cost per woman having unprotected intercourse Among public payers: \$48 (95% CI=\$16, \$93) reduction in cost per woman having unprotected intercourse
Soon et al., 2007 <b>[101]</b>	Canada	Three decision model	One-year cost saving to the Ministry of Health (MOH) of \$0.64 million (95% CI: \$0.24 million, \$1.28 million). In sensitivity analyses, there were no set of assumptions that would lead to pharmacy access increasing costs to the MOH.
Foster et al., 2010 <b>[99]</b>	USA	Markov model	For Medicare: Compared to no ECP use, pharmacy access was more cost-effective than prescription access across all assumptions of amount and frequency of use. Cost savings ratios for pharmacy access: range 1.61 to 2.49 For prescription-only access: range 1.00 to 1.56

## Discussion

We identified 19 studies from eight countries assessing how OTC ECPs influence uptake of ECPs, unintended pregnancy, abortion, and other sexual practices and behavior. Broadly, we found no differences in overall ECP use, pregnancy, or sexual risk behavior when comparing pharmacy access or true OTC availability to prescription-only ECP access. We found no comparative data on correct use of ECPs or self-efficacy, self-determination, autonomy, or empowerment.

## OTC ECP effectiveness

Though we found minimal changes in overall ECP use in OTC models, two studies included in the review found that after OTC provision, use of ECPs within 24 hours of sex increased [33, 42]. This is promising, given ECPs are more effective when used promptly.

For most outcomes, our review did not identify any substantial or concerning differences by age. However, there is promising evidence regarding OTC ECPs among younger women. Observational evidence included in our review showed that abortion rates decreased significantly among younger age groups with increased access to OTC ECPs [28, 36], while there was no significant difference in the overall population of women. Given the unique barriers faced by younger women accessing prescription-only ECPs in many settings, it may be that increased access to OTC ECPs has unique benefits for younger women. Since one in four young women who have been in a relationship will have already experienced intimate partner violence by the time they reach their mid-twenties [14, 102], access to contraceptive choice for these younger women is particularly important.

Our finding that OTC ECPs had minimal impacts on unintended pregnancy and abortion may be explained in part by overall low use of ECPs, regardless of conception intention [103, 104]. However, there is some evidence that even with increased access and uptake, ECPs may have minimal impacts on unintended pregnancy or abortion

[105]. Most studies in our review did not report on both pregnancy or abortion and ECP use. In the sole study reporting both unintended pregnancy and ECP uptake [106], the authors found no change in either ECP uptake or unintended pregnancy with expanded access. This suggests that additional efforts may be required to ensure that increased ECP access reaches those most at risk of unintended pregnancy [103].

In terms of routine preventive screenings and other SRH services, we did not assess this as a PICO outcome. Findings from our previous review of OTC oral contraceptives suggested that OTC oral contraceptive access might not reduce use of other preventive services [8]. We did not assess STI screenings, though there was mixed evidence around STI acquisition. Several included studies found no differences or lower rates of STI acquisition with increased access to OTC ECPs [26, 32, 36, 40], while others identified increases in STI acquisition among younger age groups [29, 31]. Because this evidence is primarily from observational studies, the mechanisms of OTC ECPs' impacts in this area remain unclear.

## Values and preferences

1

2 3

4

5

6

7 8

9

10

11

12

13

14

15

16 17

18

19

20

21

22

In terms of values and preferences, we found that OTC ECPs were supported for their perceived convenience, privacy, comfort, control, cost, and effectiveness. Some end-users and providers expressed concerns that OTC ECPs might increase sexual risk behavior. However, our effectiveness review found that there were no differences in sexual practices and behavior when comparing OTC or pharmacy ECPs with prescription-only ECPs.

23 While many studies found that women valued the privacy and control offered by OTC ECPs, two studies found 24 that women were concerned about having limited interaction with providers in true OTC delivery [44, 82]. In both 25 studies, while there was widespread support for OTC availability of ECPs (between 78 and 100%), a large 26 proportion of women expressed a preference for behind-the-counter modalities which allowed for interaction with 27 a pharmacist. Indeed, in many settings, OTC ECPs are offered as one of an array of options including receiving 28 ECPs from a pharmacist (behind-the-counter), from a physician (prescription OTC), or on store shelves (true 29 OTC). We found that, in a study where women could choose whether to obtain ECPs in a pharmacy or from a 30 physician [33], ECP use and knowledge was similar between groups, but pharmacy-access ECPs resulted in 31 higher use and satisfaction. Given this and our findings about OTC ECPs' effectiveness, blended delivery 32 modalities wherein users can choose where and how to access ECPs may be most responsive to user 33 preferences. 34

35 Providers also expressed concern that OTC ECPs might not allow for sufficient education or counseling, including 36 about how to use OTC ECPs correctly and counseling about other routine SRH services (including use of other 37 contraceptives and screenings for cervical and breast cancers and sexually transmitted infections [107]). In our 38 effectiveness review, we did not identify any studies assessing correct use of OC in OTC vs prescription-only 39 delivery modalities. While knowledge of ECPs was not one of our PICO outcomes, one study from the UK found 40 no significant difference in correct knowledge of ECPs between women receiving ECPs from a physician vs OTC, 41 with correct knowledge >90% for both groups [33], and another found no significant difference between OTC and 42 prescription delivery in reporting adequate information received about ECPs [37]. 43

## Cost

44

45

53

60

Results from OTC ECP cost studies are promising, though limited. In our three included studies from the US and
 Canada, pharmacy access was anticipated to yield lower health sector costs. However, we identified no data on
 cost impacts for patients and families, which will be important to consider as OTC ECP access expands. Indeed,
 several included values and preferences studies noted increased cost as a concern [44, 68, 81, 86]. On the other
 hand, some studies have shown that increased cost was perceived as a benefit, as it may deter repeat or overuse
 of ECPs [56, 68].

## Areas for future research

Our review highlights some critical areas for future research on OTC ECPs and its impacts. First, given provider concerns identified in our review, future research should also assess whether correct knowledge of ECPs translates to correct use in OTC modalities.

Second, future research should more closely examine OTC ECPs' impacts among key subgroups, including
 younger women. This is important given self-care interventions may present unique opportunities and challenges
 for different populations and in different settings [7]. For example, it is unclear through what mechanisms OTC
 ECPs may differentially impact outcomes such as abortion or STI acquisition among younger age groups, and if
 routine preventive SRH care plays a role. Equitable implementation of OTC ECPs as a self-care intervention
 should consider the intersecting roles of race/ethnicity/culture/language, occupation, gender/sex, religion,
 education, health literacy, socioeconomic status, and social capital as determinants of sexual and reproductive
 health and rights and key factors affecting delivery, uptake, and impact of OTC ECPs [108].

Finally, though OTC ECPs are an important contraceptive option for individuals, communities, and health systems worldwide, the evidence base identified through our effectiveness, cost, and values and preferences reviews was concentrated in high-income settings. Specifically, we only found evidence of OTC ECPs' effectiveness and costs from high-income countries. In our values and preferences review, 80% of identified studies were from high-income settings, and a low-income setting (Democratic Republic of Congo) was represented in a single study [66]. Meaningful efforts are needed to recognize, invest in, and promote future research on the effects of increased OTC ECPs in low- and middle-income countries. Future research should particularly consider impacts on user cost in these settings, given concerns identified in this review. 

### Strengths and limitations

Our review has several strengths and limitations. Our search was comprehensive and included not only literature on the effectiveness of OTC ECPs, but on their costs and the values and preferences of providers and end users. However, we may have been limited by our exclusion of grey literature and conference abstracts, which may have provided valuable information given the evolving nature of this field. As OTC ECPs have expanded, communities and health systems may observe its impacts without rigorous or published evaluations. It is also possible that we excluded relevant findings from studies of expanded access to ECPs that did not specifically assess OTC modalities, such as trials of advance provision of ECPs.

We were also limited by the quality and diversity of included studies. Many observational studies in the review were limited by lack of comparison groups or pre/post data, and several did not control for confounding. Further, given the wide range of included study designs and outcomes, we were unable to perform meta-analysis but instead summarized findings qualitatively. Our conclusions are also limited by the concentration of articles in high-and middle-income settings; future research should examine the impacts of OTC ECPs in resource-limited settings.

### Conclusion

Increasing OTC contraceptive choice and availability is an urgent need for many women and girls. OTC ECPs are available in many settings worldwide, suggesting its feasibility as an additional delivery option. This review of existing evidence suggests that providing emergency contraception OTC may be cost-saving and responsive to user preferences, while introducing no negative sexual and reproductive health and rights outcomes.

BMJ Open: first published as 10.1136/bmjopen-2021-054122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

#### 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50

51

60

## Acknowledgements

We thank Laura Ferguson, University of Southern California and Lianne Gonsalves; World Health Organization for reviewing and providing thoughtful feedback on the protocol. We also thank our research assistants from the Johns Hopkins Bloomberg School of Public Health (Hunied Kautsar, Izza Ishak, Sherryn Sherryn, Jingjia (Cynthia) Li, Xuhao Yang, Jaime Marguis, and Vagho Avetisyan) for their assistance screening citations and extracting data.

## Contributions

MN conceptualized the study. CEK and PTY designed the protocol with feedback from MN. PTY ran the database search and oversaw search, screening, full text review, and data extraction processes. CEK and PTY performed data analysis. KA and PTY assessed quality and risk of bias. CEK and KA drafted the manuscript. PTY and MN reviewed the draft, provided critical review, and read and approved the final manuscript. The corresponding author, as guarantor, accepts full responsibility for the finished article has access to any data and controlled the decision to publish. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

The named authors alone are responsible for the views expressed in this publication and do not necessarily represent the decisions or the policies of the World Health Organization (WHO) nor the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP).

## **Financial support**

We gratefully acknowledge financial support of The Children's Investment Fund Foundation (CIFF). The funder played no part in the decision to submit the article for publication, nor in the collection, analysis and interpretation of data. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. iez on

### **Competing interests**

None declared.

### Patient consent for publication

Not required.

#### Provenance and peer review

Not commissioned; externally peer reviewed.

#### Ethics statement

Ethical approval was not required for this systematic review, since all data came from published articles.

#### Data availability statement

Extracted data are available on request to the corresponding author.

### Transparency declaration

The corresponding author, as guarantor, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

#### 2 3 References 4 1. World Health Organization. Medical eligibility criteria for contraceptive use, fifth edition. World 5 Health Organization; 2015. Report No.: 9241563885. 6 2. World Health Organization. Selected practice recommendations for contraceptive use, third 7 edition. World Health Organization; 2016. Report No.: 9241562846. 8 World Health Organization. Emergency contraception. World Health Organization: 2021. 9 3. 10 Rafie S, Stone RH, Wilkinson TA, Borgelt LM, El-Ibiary SY, Ragland D. Role of the community 4. 11 pharmacist in emergency contraception counseling and delivery in the United States: current 12 trends and future prospects. Integrated Pharmacy Research & Practice. 2017;6:99-108. 13 5. International Consortium for Emergency Contraception. EC Status and Availability: Countries 14 with non-prescription access to EC 2021 [Available from: https://www.cecinfo.org/country-by-15 country-information/status-availability-database/countries-with-non-prescription-access-to-ec/. 16 6. Ammerdorffer et al. Regulatory standards and processes for over-the-counter availability of 17 hormonal contraception and drugs for medical abortion in five countries in the Eastern 18 Mediterranean Region. Health Research and Policy Systems. (Expected April 2021). 19 7. World Health Organization. WHO consolidated guideline on self-care interventions for health: 20 sexual and reproductive health and rights. 2019. Report No.: 9241550554. 21 Kennedy CE, Yeh PT, Gonsalves L, Jafri H, Gaffield ME, Kiarie J, et al. Should oral 8. 22 contraceptive pills be available without a prescription? A systematic review of over-the-counter 23 and pharmacy access availability. BMJ Global Health. 2019;4(3):e001402. 24 9. World Health Organization. Maintaining essential health services: operational guidance for the 25 COVID-19 context: interim guidance, 1 June 2020. World Health Organization; 2020. 26 10. Riley T, Sully E, Ahmed Z, Biddlecom A. Estimates of the Potential Impact of the COVID-19 27 Pandemic on Sexual and Reproductive Health In Low- and Middle-Income Countries. Int 28 29 Perspect Sex Reprod Health. 2020;46:73-6. 30 11. Brolin Ribacke KJ, Saulnier DD, Eriksson A, von Schreeb J. Effects of the West Africa Ebola 31 Virus Disease on Health-Care Utilization - A Systematic Review. Frontiers in public health. 32 2016;4:222. 33 12. Sharma KA, Zangmo R, Kumari A, Roy KK, Bharti J. Family planning and abortion services in 34 COVID 19 pandemic. Taiwanese journal of obstetrics & gynecology. 2020;59(6):808-11. 35 13. Tolu LB, Feyissa GT, Jeldu WG. Guidelines and best practice recommendations on 36 reproductive health services provision amid COVID-19 pandemic: scoping review. BMC public 37 health. 2021;21(1):276. 38 World Health Organization. COVID-19 and violence against women: What the health 14. 39 sector/system can do. World Health Organization; 2020. 40 15. Haddad LB, RamaRao S, Hazra A, Birungi H, Sailer J. Addressing contraceptive needs 41 exacerbated by COVID-19: A call for increasing choice and access to self-managed methods. 42 Contraception. 2021:103(6):377-9. 43 16. Aly J, Haeger KO, Christy AY, Johnson AM. Contraception access during the COVID-19 44 pandemic. Contracept Reprod Med. 2020;5:17. 45 17. Wood SN, Karp C, OlaOlorun F, Pierre AZ, Guiella G, Gichangi P, et al. Need for and use of 46 contraception by women before and during COVID-19 in four sub-Saharan African geographies: 47 results from population-based national or regional cohort surveys. Lancet Glob Health. 48 49 2021:9(6):e793-e801. 50 18. World Health Organization. WHO Handbook for Guideline Development. World Health 51 Organization; 2014. 52 19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic 53 reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. 54 20. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JP, Thomas J, Chandler 55 J, Cumpston M, Li T, Page MJ, et al., editors2019. 56 57

59 60

- **BMJ** Open 21. Kennedy CE, Fonner VA, Armstrong KA, Denison JA, Yeh PT, O'Reilly KR, et al. The Evidence Project risk of bias tool: Assessing study rigor for both randomized and non-randomized intervention studies. Systematic Reviews. 2019;8(1):1-10. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2020 22. (developed by Evidence Prime, Inc.): 2020. 23. Arnet I, Frey Tirri B, Zemp Stutz E, Bitzer J, Hersberger KE. Emergency hormonal contraception in Switzerland: a comparison of the user profile before and three years after deregulation. The European Journal of Contraception & Reproductive Health Care: The Official Journal of the European Society of Contraception. 2009;14(5):349-56. 12 Atkins DN. Association between increased availability of emergency contraceptive pills and the 24. 13 sexual and contraceptive behaviors of women. J Public Health Policy. 2014;35(3):292-310. 14 25. Atkins DN. Bradford WD. The effect of changes in state and federal policy for nonprescription access to emergency contraception on youth contraceptive use: a difference-in-difference 16 analysis across New England states. Contemporary Economic Policy. 2015;33(3):405-17. 26. Bumbul E. Starek M. Szymusik I. Pietrzak B. Bumbuliene Z. Kosinska-Kaczynska K. et al. 18 Advantages and disadvantages of over-the-counter availability of emergency contraception. 20 Neuro Endocrinology Letters. 2013;34(7):655-9. Cintina I. Behind-the-Counter, but Over-the-Border? The Assessment of the Geographical 27. 22 Spillover Effects of Emergency Contraception on Abortions. Health Economics. 2017;26(10):1249-63. Cintina I. Johansen MS. The Effect of Plan B on Teen Abortions: Evidence from the 2006 FDA 28. Ruling. Contemporary Economic Policy. 2015;33(3):418-33. 29. Durrance CP. The Effects of Increased Access to Emergency Contraception on Sexually Transmitted Disease and Abortion Rates. Economic Inquiry. 2013;51(3):1682-95. 28 30. Falah-Hassani K, Kosunen E, Shiri R, Rimpelä A. Emergency contraception among Finnish 29 adolescents: awareness, use and the effect of non-prescription status. BMC public health. 30 2007;7:201. 31. Girma S, Paton D. The impact of emergency birth control on teen pregnancy and STIs. Journal 32 of Health Economics. 2011;30(2):373-80. 33 32. Harper CC, Cheong M, Rocca CH, Darney PD, Raine TR. The effect of increased access to 34 emergency contraception among young adolescents. Obstetrics and Gynecology. 2005;106(3):483-91. 36 Killick SR, Irving G. A national study examining the effect of making emergency hormonal 33.
  - contraception available without prescription. Hum Reprod. 2004;19(3):553-7.
- 39 34. Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency 40 hormonal contraception available over the counter in Great Britain: repeated cross sectional 41 surveys. Bmj. 2005;331(7511):271.
- 42 Moreau C, Bajos N, Trussell J. The impact of pharmacy access to emergency contraceptive pills 35. 43 in France. Contraception. 2006;73(6):602-8.
- 44 36. Mulligan K. Access to Emergency Contraception and its Impact on Fertility and Sexual 45 Behavior. Health Economics (United Kingdom). 2016;25(4):455-69. 46
- 37. Novikova N, Weisberg E, Fraser IS. Does readily available emergency contraception increase 47 women's awareness and use? Eur J Contracept Reprod Health Care. 2009;14(1):39-45.
- 48 38. Payakachat N, Ragland D, Houston C. Impact of emergency contraception status on unintended 49 pregnancy; observational data from a pharmacy practice. Pharmacy Practice. 2010;8(3):173-8. 50
- 39. Pentel PR, Nelson B, Wikelius N, Cooper C. Hospital-based program for increasing the 51 availability of emergency contraception: simulating nonprescription access. American journal of 52 health-system pharmacy: AJHP: official journal of the American Society of Health-System 53 Pharmacists. 2004;61(8):777-80. 54
- 40. Raine T, Harper C, Rocca CH, Fischer R, Padian N, Klausner D, et al. Direct access to 55 emergency contraception through pharmacies and effect on unintended pregnancy and STIs: A 56 57

58

1

2 3

4

5

6

7

8

9

10

11

15

17

19

21

23

24

25

26

27

31

35

37

#### BMJ Open

	randomized controlled trial. JAMA - Journal of the American Medical Association. 2005;293(1):54-62.
41.	Rocca CH, Schwarz EB, Stewart FH, Darney PD, Raine TR, Harper CC. Beyond access: Acceptability, use and nonuse of emergency contraception among young women. America
	Journal of Obstetrics and Gynecology. 2007;196(1):29.e1e6.
42.	Rubin AG, Gold MA, Kim Y, Schwarz EB. Use of Emergency Contraception by US Teens: of Access on Promptness of Use and Satisfaction. Journal of Pediatric and Adolescent
	Gynecology. 2011;24(5):287-90.
43.	Soon JA, Levine M, Osmond BL, Ensom MHH, Fielding DW. Effects of making emergency contraception available without a physician's prescription: A population-based study. Cana Medical Association Journal. 2005;172(7):878-83.
44.	Aneblom G, Larsson M, Von Essen L, Tydén T. Women's voices about emergency contraceptive pills "over-the-counter": A Swedish perspective. Contraception. 2002;66(5):3
45.	43. Aneblom G, Lundborg CS, Carlsten A, Eurenius K, Tyden T. Emergency contraceptive pill over-the-counter: practices and attitudes of pharmacy and nurse-midwife providers. Patien
40	Educ Couns. 2004;55(1):129-35.
46.	Bissell P, Anderson C. Supplying emergency contraception via community pharmacies in t UK: reflections on the experiences of users and providers. Social Science & Medicine (198 2003;57(12):2367-78.
47.	Bissell P, Savage I, Anderson C. A qualitative study of pharmacists' perspectives on the su
	of emergency hormonal contraception via patient group direction in the UK. Contraception 2006;73(3):265-70.
48.	Blackwell D, Cooper N, Taylor G, Holden K. Pharmacists' concerns and perceived benefits deregulation of hormonal emergency contraception (HEC). British Journal of Family Plann
40	1999;25(3):100-4.
49.	Cooper RJ, Bissell P, Wingfield J. Ethical, religious and factual beliefs about the supply of emergency hormonal contraception by UK community pharmacists. The Journal of Family Planning and Reproductive Health Care. 2008;34(1):47-50.
50.	David M, Berends L, Bartley J. Current Opinion of Obstetricians on the Prescription of Emergency Contraception: A German-American Comparison. Geburtshilfe Und
51.	Frauenheilkunde. 2012;72(11):1004-8. Dixit A, Khan ME, Bhatnagar I. Mainstreaming of emergency contraception pill in India:
51.	challenges and opportunities. Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive & Social Medicine. 2015;40(1):49-55.
52.	Downing SG, Payze C, Doyle-Adams S, Gorton C. Emergency contraception over-the-coupractices and attitudes of pharmacists and pharmacy assistants in far North Queensland.
53.	N Z J Obstet Gynaecol. 2011;51(6):527-31.
55.	Dunn S, Brown TER, Cohen MM, Cockerill R, Wichman K, Weir N, et al. Pharmacy provisi emergency contraception: the Ontario emergency contraception pilot project. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique et gynecologie du Can
- 4	JOGC. 2003;25(11):923-30.
54.	Ehrle N, Sarker M. Emergency contraceptive pills: knowledge and attitudes of pharmacy personnel in Managua, Nicaragua. Int Perspect Sex Reprod Health. 2011;37(2):67-74.
55.	El-Ibiary SY, Raine T, McIntosh J, Darney PD, Harper CC. Pharmacy access to emergence contraception: Perspectives of pharmacists at a chain pharmacy in San Francisco. Journal
	the American Pharmacists Association : JAPhA. 2007;47(6):702-10.
56.	Folkes L, Graham A, Weiss M, Folkes L, Graham A, Weiss M. A qualitative study of the viewomen aged 18-29 on over-the-counter availability of hormonal emergency contraception.
	Journal of Family Planning & Reproductive Health Care. 2001;27(4):189-92.

57. Foster DG, Landau SC, Monastersky N, Chung F, Kim N, Melton M, et al. Pharmacy access to emergency contraception in California. Perspectives on Sexual and Reproductive Health. 2006;38(1):46-52. 58. Fuentes EC, Azize-Vargas Y. Knowledge, attitudes and practices in a group of pharmacists in Puerto Rico regarding emergency contraception. P R Health Sci J. 2007;26(3):191-7. 59. Gainer E, Blum J, Toverud EL, Portugal N, Tyden T, Nesheim BI, et al. Bringing emergency contraception over the counter: experiences of nonprescription users in France, Norway, 10 Sweden and Portugal. Contraception. 2003;68(2):117-24. 11 Golden NH, Seigel WM, Fisher M, Schneider M, Quijano E, Suss A, et al. Emergency 60. 12 contraception: Pediatricians' knowledge, attitudes, and opinions. Pediatrics. 2001;107(2):287-13 92. 14 61. Griggs SK, Brown CM. Texas community pharmacists' willingness to participate in pharmacist-15 initiated emergency contraception. Journal of the American Pharmacists Association: JAPhA. 16 2007;47(1):48-57. 17 62. HäggstrÖm-Nordin E. Tydén T. Swedish teenagers' attitudes toward the emergency 18 contraceptive pill. Journal of Adolescent Health. 2001;28(4):313-8. 19 20 63. Hariparsad N. Attitudes and practices of pharmacists towards emergency contraception in 21 Durban, South Africa. European Journal of Contraception and Reproductive Health Care. 22 2001;6(2):87-92. 23 64. Harvey SM, Beckman LJ, Sherman C, Petitti D. Women's experience and satisfaction with 24 emergency contraception. Fam Plann Perspect. 1999;31(5):237-40, 60. 25 65. Hellerstedt WL, Van Riper KK. Emergency contraceptive pills: dispensing practices, knowledge 26 and attitudes of South Dakota pharmacists. Perspect Sex Reprod Health. 2005;37(1):19-24. 27 Hernandez JH, Muanda M, Garcia M, Matawa G. Awareness and Perceptions of Emergency 66. 28 Contraceptive Pills Among Women in Kinshasa, Democratic Republic of the Congo. 29 International Perspectives on Sexual and Reproductive Health. 2017;43(3):121-30. 30 67. Hickey MT, Shedlin MG. Emergency contraceptive pill users' risk perceptions for sexually 31 transmitted infections and future unintended pregnancy. J Am Assoc Nurse Pract. 32 2017:29(9):527-34. 33 Hobbs M, Taft AJ, Amir LH. The emergency contraceptive pill rescheduled: a focus group study 68. 34 of women's knowledge, attitudes and experiences. J Fam Plann Reprod Health Care. 35 2009;35(2):87-91. 36 Hopkins D, West D. Arkansas pharmacists' perceptions toward emergency contraception and 37 69. nonprescription Plan B. Pharmacy Practice. 2008;6(2):98-102. 38 39 70. Hussainy SY, Stewart K, Chapman CB, Taft AJ, Amir LH, Hobbs MK, et al. Provision of the 40 emergency contraceptive pill without prescription: attitudes and practices of pharmacists in 41 Australia. Contraception. 2011;83(2):159-66. 42 71. Irfan F, Karim SI, Hashmi S, Ali S, Ali SA. Knowledge of emergency contraception among 43 women of childbearing age at a teaching hospital of Karachi. Journal of the Pakistan Medical 44 Association. 2009;59(4):235-40. 45 72. Joseph N, Shetty B, Hasreen F, Ishwarya R, Baniya M, Sachdeva S, et al. Awareness and 46 Attitudes Toward Emergency Contraceptives Among College Students in South India. Journal of 47 Obstetrics and Gynaecology of India. 2016;66(Suppl 1):363-9. 48 73. Karim SI, Irfan F, Al Rowais N, Al Zahrani B, Qureshi R, Al Qadrah BH. Emergency 49 contraception: Awareness, attitudes and barriers of Saudi Arabian women. Pakistan Journal of 50 Medical Sciences. 2015;31(6):1500-5. 51 74. Khan ME, Dixit A, Bhatnagar I, Brady M. Medical barriers to emergency contraception: a cross-52 sectional survey of doctors in North India. Glob Health Sci Pract. 2014;2(2):210-8. 53 75. Kim HW. Sex differences in the awareness of emergency contraceptive pills associated with 54 unmarried Korean university students' intention to use contraceptive methods: an online survey. 55 Reprod Health. 2015;12:91. 56 57 58 59

60

1

2 3

4

5

6

7

8

76.	Krassovics M, Viragh G. Usage patterns and attitudes towards emergency contraception: the International Emergency Contraception Research Initiative. Eur J Contracept Reprod Health Care. 2016;21(4):310-7.
77.	Krishnamurti T, Eggers SL, Fischhoff B. The impact of over-the-counter availability of "Plan B"
78.	on teens' contraceptive decision making. Soc Sci Med. 2008;67(4):618-27. Kumar AS, Hall LC, LePage A, Lim PC. Providing emergency contraceptive pills "behind-the-
79.	counter": opinions among Minnesota healthcare providers. Contraception. 2003;68(4):253-9. Landau S, Besinque K, Chung F, Dries-Daffner I, Maderas NM, McGhee BT, et al. Pharmacist interest in and attitudes toward direct pharmacy access to hormonal contraception in the United States. Journal of the American Pharmacists Association : JAPhA. 2009;49(1):43-50.
80.	Landau SC, Tapias MP, McGhee BT. Birth control within reach: a national survey on women's attitudes toward and interest in pharmacy access to hormonal contraception. Contraception. 2006;74(6):463-70.
81.	Langille DB, Allen M, Whelan AM. Emergency contraception: knowledge and attitudes of Nova Scotian family physicians. Can Fam Physician. 2012;58(5):548-54.
82.	Larsson M, Eurenius K, Westerling R, Tyden T. Emergency contraceptive pills over-the-counter: a population-based survey of young Swedish women. Contraception. 2004;69(4):309-15.
83.	Lee ES, Lee CA, Lee JH, Park BR, Lee I. The attitudes of Korean physicians toward emergency contraceptive pills: regarding women's access and rescheduling. Obstetrics & Gynecology Science. 2019;62(3):173-8.
84.	Lim SW, Iheagwara KN, Legano L, Coupey SM. Emergency contraception: are pediatric residents counseling and prescribing to teens? J Pediatr Adolesc Gynecol. 2008;21(3):129-34.
85.	Lo SST, Kok WM, Fan SYS. Emergency contraception: Knowledge, attitude and prescription practice among doctors in different specialties in Hong Kong. Journal of Obstetrics and Gynaecology Research. 2009;35(4):767-74.
86.	Maharaj P, Rogan M. Missing opportunities for preventing unwanted pregnancy: A qualitative study of emergency contraception. Journal of Family Planning and Reproductive Health Care. 2011;37(2):89-96.
87.	Miller LM. College student knowledge and attitudes toward emergency contraception. Contraception. 2011;83(1):68-73.
88.	Peremans L, Verhoeven V, Philips H, Denekens J, Van Royen P. How does a Belgian health care provider deal with a request for emergency contraception? The European Journal of Contraception & Reproductive Health Care: The Official Journal of the European Society of Contraception. 2007;12(4):317-25.
89.	Ragland D, West D. Pharmacy students' knowledge, attitudes, and behaviors regarding emergency contraception. American Journal of Pharmaceutical Education. 2009;73(2).
90.	Syahlul DE, Amir LH. Do Indonesian medical practitioners approve the availability of emergency contraception over-the-counter? A survey of general practitioners and obstetricians in Jakarta. BMC Women's Health. 2005;5.
91.	Vahratian A, Patel DA, Wolff K, Xu X. College students' perceptions of emergency contraception provision. Journal of Women's Health (2002). 2008;17(1):103-11.
92.	Wan RSF, Lo SST. Are women ready for more liberal delivery of emergency contraceptive pills? Contraception. 2005;71(6):432-7.
93.	Whelan AM, Langille D, Hurst E, Aylward S, Wedlake S. Nova Scotia pharmacists and emergency contraception pills: Attitudes and beliefs. Canadian Pharmacists Journal. 2011;144(5):e39.
94.	Wu J, Gipson T, Chin N, Wynn LL, Cleland K, Morrison C, et al. Women seeking emergency
95.	contraceptive pills by using the internet. Obstet Gynecol. 2007;110(1):44-52. Xu X, Vahratian A, Patel DA, McRee AL, Ransom SB. Emergency contraception provision: a survey of Michigan physicians from five medical specialties. J Womens Health (Larchmt). 2007;16(4):489-98.
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 96. Yam EA, Gordon-Strachan G, McIntyre G, Fletcher H, Garcia SG, Becker D, et al. Jamaican and Barbadian health care providers' knowledge, attitudes and practices regarding emergency contraceptive pills. International Family Planning Perspectives. 2007;33(4):160-7.
  - 97. Yuksel N, Schindel T, Siyam T, Hocevar S. Pharmacists' beliefs about Plan B as an over-thecounter product. Canadian Pharmacists Journal. 2011;144(5):e40.
- 98. Ziebland S, Graham A, McPherson A. Concerns and cautions about prescribing and deregulating emergency contraception: a qualitative study of GPs using telephone interviews. Fam Pract. 1998;15(5):449-56.
- 99. Foster DG, Raine TR, Brindis C, Rostovtseva DP, Darney PD. Should providers give women advance provision of emergency contraceptive pills? A cost-effectiveness analysis. Women's Health Issues: Official Publication of the Jacobs Institute of Women's Health. 2010;20(4):242-7.
   400 Marginate KD, Cardner JS, Magneter DL, Sulliver SD, Madeling the sectored puter.
- 100. Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. Am J Public Health. 2001;91(9):1443-5.
- 101. Soon JA, Meckley LM, Levine M, Marciante KD, Fielding DW, Ensom MHH. Modelling costs and outcomes of expanded availability of emergency contraceptive use in British Columbia. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 2007;14(3):e326-38.
- 102. World Health Organization. Devastatingly pervasive: 1 in 3 women globally experience violence 2021 [Available from: https://www.who.int/news/item/09-03-2021-devastatingly-pervasive-1-in-3-women-globally-experience-violence.
  - 103. Glasier A, Fairhurst K, Wyke S, Ziebland S, Seaman P, Walker J, et al. Advanced provision of emergency contraception does not reduce abortion rates. Contraception. 2004;69(5):361-6.
- 104. Lakha F, Glasier A. Unintended pregnancy and use of emergency contraception among a large cohort of women attending for antenatal care or abortion in Scotland. Lancet. 2006;368(9549):1782-7.
- Hu X, Cheng L, Hua X, Glasier A. Advanced provision of emergency contraception to postnatal women in China makes no difference in abortion rates: a randomized controlled trial.
   Contraception. 2005;72(2):111-6.
  - 106. Raine TR, Harper CC, Rocca CH, Fischer R, Padian N, Klausner JD, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. Jama. 2005;293(1):54-62.
  - 107. Newmeyer MN, Concheiro M, da Costa JL, Flegel R, Gorelick DA, Huestis MA. Oral fluid with three modes of collection and plasma methamphetamine and amphetamine enantiomer concentrations after controlled intranasal I-methamphetamine administration. Drug Test Anal. 2015;7(10):877-83.
  - 108. O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: Using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. Journal of Clinical Epidemiology. 2014;67(1):56-64.






Figure 2. Map showing distribution of studies included in the values and preferences review.

109x63mm (300 x 300 DPI)

## PRISMA 2009 Checklist

Page 29 of 44		BMJ Open	
PRISMA 2	2009	Checklist Photometry 202	
<sup>4</sup> Section/topic	#	Checklist item 4122	Reported on page #
<sup>6</sup> 7 TITLE		9 9	
8 Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
		a rch	
1 Structured summary 12 13	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
16 Rationale	3	Describe the rationale for the review in the context of what is already known.	4
14 Objectives 18 19	4	Provide an explicit statement of questions being addressed with reference to participants, in error outcomes, and study design (PICOS).	4
20 METHODS			
<ul> <li>Protocol and registration</li> <li>23</li> </ul>	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	2
24 Eligibility criteria 25	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4-5
26 27 28	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
29 Search 30	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	25
3 Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
34 Data collection process 35	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
36 Data items 37	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4-5
39 Risk of bias in individual 40 studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
<sup>4</sup> Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	NA
44 43 Synthesis of results 44	14	Describe the methods of handling data and combining results of studies, if done, including network of consistency (e.g., l <sup>2</sup> ) for each meta-analysis.	NA
45 46 47	· ·	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	



## PRISMA 2009 Checklist

		BMJ Open	Page 30 of 4
PRISMA 2	009	Checklist no pen-202	
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publicarion bias, selective reporting within studies).	NA
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS	•		
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOs, follow-up period) and provide the citations.	6-10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (	6-10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summar data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	6-8, 11- 12
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	NA
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	NA
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7-8
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; congider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING	<u> </u>		
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data), role of funders for the systematic review.	17
	J, Altm	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med	d 6(7): e1000097.
doi:10.1371/journal.pmed1000097		For more information, visit: <u>www.prisma-statement.org</u> .	
		For more information, visit: <u>www.prisma-statement.org</u> .	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

60

1 2 3 WHO self-care v2 (2020) 4 Over the counter emergency contraception 5 Search strategy documentation 6 7 Search date: 27 April 2020 / updated 02 Dec 2020 8 9 Total hits: 3902 10 After removing duplicates: 2581 11 Assigned for primary screening: 2581 12 13 Pubmed: 1492 hits 14 ("Contraceptives, Oral" [Mesh] OR "Contraceptives, Postcoital" [Mesh] OR "emergency contraceptive 15 pill" [tiab] OR "emergency contraceptive pills" [tiab] OR "morning-after pill" [tiab] OR "Plan B One-Step" 16 [tiab] OR "Take Action" [tiab] OR "Next Choice One-Dose" [tiab] OR "My Way" [tiab] OR "AfterPill" [tiab] 17 OR "Preventeza" [tiab] OR "My Choice" [tiab] OR "Aftera" [tiab] OR "Athentia Next" [tiab] OR "EContra 18 Ez" [tiab] OR "Fallback Solo" [tiab] OR "Opcicon One-Step" [tiab] OR "Option 2" [tiab] OR "Afirmelle" 19 20 [tiab] OR "Altavera" [tiab] OR "Amethia" [tiab] OR "Amethia Lo" [tiab] OR "Amethyst" [tiab] OR "Aubra" 21 [tiab] OR "Ayuna" [tiab] OR "Aviane" [tiab] OR "Camrese" [tiab] OR "CamreseLo" [tiab] OR "Chateal" 22 [tiab] OR "Cryselle" [tiab] OR "Elinest" [tiab] OR "Enpresse" [tiab] OR "Falmina" [tiab] OR "Introvale" 23 [tiab] OR "Jolessa" [tiab] OR "Kurvelo" [tiab] OR "Lessina" [tiab] OR "Lenovest" [tiab] OR "Levora" [tiab] 24 OR "LoSeasonique" [tiab] OR "Low-Ogestrel" [tiab] OR "Lutera" [tiab] OR "Marlissa" [tiab] OR "Myzilra" 25 [tiab] OR "Nordette" [tiab] OR "Orsythia" [tiab] OR "Portia" [tiab] OR "Quasense" [tiab] OR "Seasonale" 26 [tiab] OR "Seasonique" [tiab] OR "Setlakin" [tiab] OR "Sronyx" [tiab] OR "Triphasil" [tiab] OR "Trivora" 27 [tiab] OR "Vienva" [tiab] OR "After-1" [tiab] OR "Agesta" [tiab] OR "Ai Wu You" [tiab] OR "Aleze EC" 28 29 [tiab] OR "Alterna" [tiab] OR "Amor" [tiab] OR "An Ting" [tiab] OR "Anlitin" [tiab] OR "Anthia" [tiab] OR 30 "Auxxil" [tiab] OR "Bao Shi Ting" [tiab] OR "Bi Yun" [tiab] OR "Ciel EC" [tiab] OR "Contragest" [tiab] OR 31 "Contraplan II" [tiab] OR "Control NF" [tiab] OR "Control Uno" [tiab] OR "Copill" [tiab] OR "Curesinor" 32 [tiab] OR "D-Sigyent" [tiab] OR "Dan Mei" [tiab] OR "Dia S MP" [tiab] OR "Diad" [tiab] OR "Dreams" [tiab] 33 OR "Duet" [tiab] OR "Duprisal 30" [tiab] OR "Dvella" [tiab] OR "E Pills" [tiab] OR "E-72" [tiab] OR "e-con" 34 [tiab] OR "ECee2" [tiab] OR "ECP" [tiab] OR "ella" [tiab] OR "ellaOne" [tiab] OR "Emcon" [tiab] OR 35 "Emergyn" [tiab] OR "Emkit" [tiab] OR "Emkit Plus" [tiab] OR "Escapel" [tiab] OR "Escapel-1" [tiab] OR 36 "Escapel-2" [tiab] OR "Escapelle" [tiab] OR "Escinor" [tiab] OR "Estinor" [tiab] OR "Evadir 2" [tiab] OR 37 "Evital" [tiab] OR "Evitarem" [tiab] OR "Fermerleve Sagiram" [tiab] OR "Feminor" [tiab] OR "Fertilan" 38 39 [tiab] OR "Fu Nai Er" [tiab] OR "G-Nancy" [tiab] OR "Glanique" [tiab] OR "Glanix" [tiab] OR "Glostinor 2" 40 [tiab] OR "Gynepriston" [tiab] OR "Gynotrel 2" [tiab] OR "Hispratel" [tiab] OR "Hou Ding Nuo" [tiab] OR 41 "Hua Dian" [tiab] OR "Hui Ting" [tiab] OR "i-pill" [tiab] OR "Imediat" [tiab] OR "Imediat N" [tiab] OR 42 "Impreviat" [tiab] OR "Jin Xiao" [tiab] OR "Jin Yu Ting" [tiab] OR "Ka Rui Ding" [tiab] OR "L Novafem" 43 [tiab] OR "Laliades" [tiab] OR "Le Ting" [tiab] OR "Lenor 72" [tiab] OR "Levo-72" [tiab] OR "Levodonna" 44 [tiab] OR "Levogest" [tiab] OR "Levogynon 1500" [tiab] OR "Levonelle" [tiab] OR "Levonelle-1" [tiab] OR 45 "Levonia" [tiab] OR "Levonorgestrol Biogaran 1500" [tiab] OR "Levonorgestrel Richter" [tiab] OR 46 "Levonormin" [tiab] OR "Lonel" [tiab] OR "Longil" [tiab] OR "Lydia 1Safe Pill" [tiab] OR "Lydia Post Pill" 47 [tiab] OR "Madonna" [tiab] OR "Max-72" [tiab] OR "Me Tablet" [tiab] OR "Mergynex" [tiab] OR 48 49 "Mifepristone 72" [tiab] OR "Mifestad 10" [tiab] OR "Minipil 2" [tiab] OR "Morning After" [tiab] OR "MS 50 Pill" [tiab] OR "Negele" [tiab] OR "Nerostinor" [tiab] OR "Next Choice" [tiab] OR "Nicpostinew" [tiab] OR 51 "Nogestrol" [tiab] OR "Nogravide" [tiab] OR "Norgestrel Max Unidosis" [tiab] OR "Norgestrel-Max" [tiab] 52 OR "NorLevo" [tiab] OR "Nortrel 2" [tiab] OR "Novalen" [tiab] OR "Oportuna" [tiab] OR "Optinor" [tiab] 53 OR "Ovocease" [tiab] OR "Ovulol" [tiab] OR "P2" [tiab] OR "PiDaNa" [tiab] OR "Pilem" [tiab] OR "Pill 72" 54 [tiab] OR "Pillanor 2" [tiab] OR "Pillex" [tiab] OR "Pilule S" [tiab] OR "Planfam" [tiab] OR "Poslov" [tiab] 55 OR "PostDay" [tiab] OR "Poster Tablets" [tiab] OR "Postiga 4" [tiab] OR "Postinor" [tiab] OR "Postinor 1" 56

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

[tiab] OR "Postinor 1.5" [tiab] OR "Postinor 1500" [tiab] OR "Postinor 2 SD" [tiab] OR "Postinor Duo" [tiab] OR "Postinor Life" [tiab] OR "Postinor PI" [tiab] OR "Postinor Uno" [tiab] OR "Postinor-2" [tiab] OR "Postinor-2 Unidosis" [tiab] OR "Postpill" [tiab] OR "Pozato" [tiab] OR "Pozato Uni" [tiab] OR "PPMS" [tiab] OR "Pregnon" [tiab] OR "Pregnon 1" [tiab] OR "Pregnon 1.5" [tiab] OR "Prevemb" [tiab] OR "Preventol" [tiab] OR "Previdez 2" [tiab] OR "Previfem" [tiab] OR "Prevyol" [tiab] OR "Prikul" [tiab] OR "Pronta" [tiab] OR "Prudence for Her" [tiab] OR "Rely-X" [tiab] OR "Revoke 1.5" [tiab] OR "Revoke 72" [tiab] OR "Rigesoft" [tiab] OR "Rogotinor" [tiab] OR "Secufem" [tiab] OR "Seguidet" [tiab] OR "Segurit" [tiab] OR "Segurite UD" [tiab] OR "SEKURE" [tiab] OR "Sendinor 2" [tiab] OR "Sexcon One&One" [tiab] OR "Si Mi An" [tiab] OR "Silogin" [tiab] OR "Smart Lady (Pregnon)" [tiab] OR "So-Ezzy" [tiab] OR "Tace" [tiab] OR "Tibex" [tiab] OR "Truston-2" [tiab] OR "Ulipristal 30" [tiab] OR "Unlevo 1500" [tiab] OR "Unofem" [tiab] OR "Unwanted 72" [tiab] OR "Upostelle" [tiab] OR "UPRIS" [tiab] OR "Vermagest" [tiab] OR "Vika" [tiab] OR "Vikela" [tiab] OR "Vonstrel" [tiab] OR "Xian Ju" [tiab] OR "Yi Ting" [tiab] OR "Yu Ting" [tiab] OR "Zimtemore" [tiab])

#### AND

1

2 3

4

5

6

7

8

9

10 11

12

13

14

15

16

17 18

19 20 21

22

23

24

25

26

27 28 29

30

31

32

33

34

35

36 37

38 39

40

41 42

43

44

45

46

47 48

49

60

("Nonprescription Drugs" [Mesh] OR nonprescription [tiab] OR "over the counter" [tiab] OR "over-thecounter" [tiab] OR "without a prescription" [tiab] OR "pharmacist-prescribed" [tiab] OR "pharmacy access" [tiab] OR "clinician-prescribed" [tiab] OR "physician-prescribed" [tiab] OR "GP-prescribed" [tiab] OR "general practitioner prescribed" [tiab] OR "without prescription" [tiab] OR "community pharmacy services" [Mesh] OR "community center" [tiab] OR "community centre" [tiab] OR store [tiab] OR shop [tiab] OR online [tiab] OR mobile [tiab] OR telehealth [tiab])

### CINAHL: 184 hits

AB ("Contraceptives postcoital" OR "emergency contraception" OR "emergency contraceptive" OR "emergency contraceptives" OR "morning after pill" OR "plan b") AND AB ("Nonprescription Drugs" OR nonprescription OR "over the counter" OR "over-the-counter" OR "without a prescription" OR "pharmacist-prescribed" OR "pharmacy access" OR "clinician-prescribed" OR "physician-prescribed" OR "GP-prescribed" OR "general practitioner prescribed" OR "without prescription" OR "community center" OR "community centre" OR store OR shop OR online OR mobile OR telehealth)

## LILACS: 204 hits

Title/abstract/subject: ("Contraceptives postcoital" OR "emergency contraception" OR "emergency contraceptive" OR "emergency contraceptives" OR "morning after pill" OR "plan b")

## EMBASE: 494 hits

AB,TI ('Contraceptives postcoital' OR 'emergency contraception' OR 'emergency contraceptive' OR 'emergency contraceptives' OR 'morning after pill' OR 'plan b') AND AB,TI ('Nonprescription Drugs' OR nonprescription OR 'over the counter' OR 'over-the-counter' OR 'without a prescription' OR 'pharmacistprescribed' OR 'pharmacy access' OR 'clinician-prescribed' OR 'physician-prescribed' OR 'GP-prescribed' OR 'general practitioner prescribed' OR 'without prescription' OR 'community center' OR 'community centre' OR store OR shop OR online OR mobile OR telehealth) Page 33 of 44

#### Appendix 3: Risk of Bias Assessments

#### Non-Randomized Trials (n=18): Evidence Project Risk of Bias Tool

f 44						Open		-	open-202	
Appendix 3: Ris <u>Non-Randomize</u>			e Project Risk c	of Bias Tool					Vbmiopen-2021-054122 on 14 M	
Citation ID	Pre/Post	Comp. group	Cohort	Baseline Eq Demos	uivalence Outcome	Random selection	Random allocation	Control for	Follow-up	Specific Concerns
Arnet et al. 2009 [23]	Yes	No	No	NA	NA	No	No		Winhoaded f	Lack of comparison group, no control for confounding
Atkins & Bradford 2015 [25]	Yes	No	No	NA	NA	No	No	Yes -	om NA	Lack of comparison
Atkins 2014 [24]	Yes	No	No	NA	NA	No	No	Yes	S NA	Lack of comparison
Bumbul et al. 2013 [26]	No	Yes	No	No	NA	NR	No	No	NA	No pre/post, no contro for confounding
Cintina & Johansen 2015 [28]	No	Yes	No	NR	NA	No	No	Yes	<del>on Abril 20.</del>	No pre/post
Cintina 2017 [27]	Yes	No	No	NA	NA	No	No	Yes	<del>2024</del> NA ₩	Lack of comparison
Durrance 2013 [29]	Yes	No	No	NA	NA	No	No	res	A A A A A	Lack of comparison
Falah- Hassani,et al. 2007 [30]	Yes	No	No	NA	NA	Yes	NA	No	- <del>Protected by c</del> opyright.	Lack of comparison, no control for confounding

Page 3	4 of 44
--------	---------

					BMJ	Open			bmiopen-2		Pag
									/bmiopen-2021-0 <del>54122 o</del>	(though random selection)	]
Girma & Paton 2011[31]	No	Yes	No	No	NA	No	No	Yes	A A A A A A A A A A A A A A A A A A A	No pre/post	-
Killick & Irving 2004 [33]	No	Yes	No	NR	NR	No	No	No	6 20 20 222	No pre/post, no control for confounding	-
Marston et al. 2005 [34]	Yes	No	No	NA	NA	Yes	No	Yes		Lack of comparison	-
Moreau et al. 2006 [35]	Yes	No	No	NA	NA	Yes	No	Yes	8 8 1 1 1	Lack of comparison	
Mulligan 2016 [36]	Yes	No	Yes	NA	NA	NR	No	Yes	¥ NR	Lack of comparison	-
Novikova et al. 2009 [37]	Yes	No	No	NA	NA	No	No	No	NA	Lack of comparison group, no control for confounding	-
Payakachat et al. 2010 [38]	Yes	No	No	NA	NA	No	No	No	₽ Sont NA	Lack of comparison group, no control for confounding	-
Pentel et al. 2004 [39]	Yes	No	No	NA	NA	No	No		<del>brii 20, 202</del>	Lack of comparison group, no control for confounding	-
Rubin et al. 2011 [42]	No	Yes	No	NA	NA	No	No	Yes 2		No pre/post	
Soon et al. 2005 [43]	Yes	No	No	NA	NA	No	No	No	<del>St. Protocio</del>	Lack of comparison group, no control for confounding	-

## Randomized Controlled Trials (n=3 papers reporting 1 RCT): Cochrane Collaboration Tool

andomized Controlled Trials (na	=3 papers re	porting 1 RCT	): Cochrane (	Collaboratior	<u>n Tool</u>		-004 12		
udy ID : Harper et al. 2005 [32]	; Raine et al.	2005 [40]; Ro	occa et al. 200	07 [41]				ž ,	
omain 1: Risk of bias aris	sing from	the randon	nization pr	ocess				2 2 2	
Signalling questions	EC use	Pregnanc Y	Unprotect ed sex	Consisten t condom use	Condom use last sex	Multiple partners	Contrace ptive method		Comments
1.1 Was the allocation sequence random?	Y	Y	Y	Y	Y	Y		<u>Y</u>	
1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	Y	Y	Y C C	Y C	Y	Y		Y	
1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	N	N	N	N	N	N			There was also a slightly highe proportion of blacks in the clinic access group (P=.045), but no other notable differences
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low y guess.	Low	
Optional: What is the predicted direction of bias	NA	NA	NA	NA	NA	NA	NA copyright	NA	

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracept ive 14 method March	Missed pills	Comments
2.1. Were participants aware of their assigned intervention during the trial?	Y	Y	Y	Y	Y	Y	Y 2022.	Y	Blinding not possibl given the intervention
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y		× 500	Y	Y	Ŷ	vnloaded from ht	Y	
2.3. <u>If Y/PY/NI to 2.1 or 2.2</u> : Were there deviations from the intended intervention that arose because of the trial context?	N	N	N	N C	N N	N	Downloaded from http://bmjopen.bmj.com	N	California legalize pharmacy access si months into th trial, but this is no related to tria context
2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA	NA	NA	NA	NA	NA	N on April 2 NA	NA	
2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA	NA	NA	NA	NA	NA	NA ,	NA	
2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	Ϋ́	Y	Y	Y	Ϋ́	Y	2024 by guest. Protected by	Y	Modified ITT used

f 44 BMJ Open Domain 2: Risk of bias due to deviations from the intended interventions (*effect of assignment to* 

 i/bmjopen-202

			1					1-05		
2.7 <u>If N/PN/NI to 2.6:</u> Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	NA	NA	NA	NA	NA	NA	NA	4122 on 14 March 2022.	NA	
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low	Dow	Low	
Optional: What is the predicted direction of bias due to deviations from intended interventions?	NA	NA	NA	NA	NA	NA	NA	nloaded from h	NA	
					Viel			21-0\$4122 on 14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.		
								est. Protected by cop		

2	
3	Do
4	
5	S
6	
7	
8	
9 10	2
10 11	0
12	i
13	
14	2
15	d
16	а
17	а
18	t
19	
20	2
21	Y
22	i
23	i
24	а
25	-
26	2
27 28	t
28 29	i
29 30	iı
31	а
32	2
33	t
34	a
35	r
36	
37	a
38	0
39	
40	
41	
42	
43	
44	

45 46

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracep	Atervention Missed pills	Comments
2.1. Were participants aware of their assigned intervention during the trial?	Y	Y	Y	Y	Y	Y	Y	2022 Y	Blinding not possibl given the intervention
2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	Y	Y Dee	Y	Y	Y	Y	Downloaded from http://bmionen.hmi.com	
2.3. [If applicable:] <u>If</u> <u>Y/PY/NI to 2.1 or 2.2</u> : Were important non-protocol interventions balanced across intervention groups?	NA	NA	NA	NA	NA	NA	NA	NA Internet in the second	
2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?	Y	Y	Y	Y	Y	YO	Y C	on April 20 2024	Yes, deviations because of change in CA law but rerandomized
2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants' outcomes?	ΡΥ	РҮ	ΡΥ	ΡΥ	ΡΥ	РҮ	PY y	PY PY Protected by	Contamination between groups du to change in law

				ВМЈ Ор	en		i/bmjopen-2021-054122 ۲۱		
							-2021-05		
2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?	Ϋ́	Ϋ́	Ϋ́	Ϋ́	Y	Y	Y 4122 on 14 March 2022 Some 22		
Risk-of-bias judgement	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	concerns	concerns	
Optional: What is the predicted direction of bias due to deviations from intended interventions?	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors experime ntal	Favors a experime ntal for	ntal	
							ttp://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected		
							April 20, 2024 by guest. Pr		
							rotecte		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ttp://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

i/bmjopen-2021-054122

2	
2	
3	
4	
5	
6	
7	
2 8	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
20	
21	
22	
2 3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 14 15 16 17 18 9 20 21 22 324 25 6 27 8 9 30 11 22 33 4 5 6 7 8 9 30 11 12 33 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 4 5 6 7 8 9 10 11 12 3 14 15 16 7 8 9 10 11 12 3 2 4 5 2 6 7 8 9 10 11 12 2 3 2 4 5 2 6 2 7 2 2 3 2 4 2 5 2 6 2 7 2 2 3 2 4 2 5 6 7 7 8 9 3 1 2 2 3 2 4 2 5 2 6 2 7 2 2 3 2 4 2 5 6 2 7 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
24	
24 25	
25	
26	
27	
28	
29	
30	
31	
21	
∠ בר	
33	
34	
35	
36	
37	
38	
30	
39	
40	
41	
42	
43	
44	
45	
40	

46

# Domain 3: Missing outcome data

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	method change	14 March	Missed pills	Comments
3.1 Were data for this outcome available for all, or nearly all, participants randomized?	<u>PY</u>	PY	<u>PY</u>	<u>PY</u>	<u>PY</u>	<u>PY</u>	<u>PY</u>	2022.	<u>PY</u>	814/889 pharmacy access; 826/884 advance provision; 310/344 clinic access
3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	NA	NA	NA	NA	NA	NA	NA	Downloaded from http://bmiopen.bmi.com/ on April 20,	NA	
3.3 <u>If N/PN to 3.2</u> : Could missingness in the outcome depend on its true value?	NA	NA	NA	NA	NA	NA	NA	bmjopen.br	NA	
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA	NA	NA	NA	NA	NA	NA	ii.com/ on Apr	NA	
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low			Low	
Optional: What is the predicted direction of bias due to missing outcome data?	NA	NA	NA	NA	NA	NA	NA	v quest. Prote	NA	
							-	2024 by guest. Protected by copyright.		

Domain 4:	Risk of	bias in	measurement	of the	outcome
-----------	---------	---------	-------------	--------	---------

Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracept 14 March ive method change	Missed pills	Comments
4.1 Was the method of measuring the outcome inappropriate?	N	N	<u>N</u>	N	N	N	2022. <b>Z</b>	<u>N</u>	
4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N	N	≥ Dee	N	N	N	Downloaded from http://bmjopen.bmj.com ∠I	<u>N</u>	
4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants?	Y	Y	Y	Y CO	Y	Y	/bmjopen.bmj.com Y	Y	
4.4 <u>If Y/PY/NI to 4.3</u> : Could assessment of the outcome have been influenced by knowledge of intervention received?	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	PN	on April 20, 2024	<u>PN</u>	
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	<u>PN</u>	t by guest. Protected by copyright. 	<u>PN</u>	

				BMJ	Open			vmjopen-2		
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low	22	Low	
Optional: What is the predicted direction of bias in measurement of the outcome?	NA	NA	NA	NA	NA	NA	NA	on 14 March 2022. C	NA	
								wnloaded fror		
								om http		
								o://bmjop		
								o://bmjopen.bmj.com/ o		
								o://bmjopen.bmj.com/ on April 20, 202		
								by gue		
								o://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.		

Page 43 of 44

24

44 45

omain 5: Risk of bias in s	selection o	f the repor	ted result	BMJ Op	en		i/bmjopen-2021-05412;		
Signalling questions	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracept 14 ive 14 March change	Missed pills	Comments
5.1 Were the data that produ unblinded outcome data wer			accordance	with a pre-sp	ecified analy	sis plan that	was finalize	d before	
	<u>Y</u>	<u>Y</u>	<u>Y</u>	<u>Y</u>	<u>Y</u>	<u>Y</u>	Y ownl	<u>Y</u>	
Is the numerical result being	assessed like	ly to have bee	en selected, o	on the basis o	of the results	, from	bade		
5.2 multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N	N	N R R R R	N	N	N	oaded from http://bmjopen.bmj.com/ on	N	
5.3 multiple eligible analyses of the data?	N	N	N	N	N	N	en.bmj.com/ on Zl	N	
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	1 April 20, 2024 LOW	Low	
Optional: What is the predicted direction of bias due to selection of the reported result?	NA	NA	NA	NA	NA	NA	NA NA	NA	
							Protected by copyright.		

## Overall risk of bias

ŀ				ВМЈ Ор	en		i/bmjopen-2021-054122		
verall risk of bias							21-05412		
Overall assessment	EC use	Pregnancy	Unprotect ed sex	Consistent condom use	Condom use last sex	Multiple partners	Contracept	Missed	Comments
Risk-of-bias judgement	Low	Low	Low	Low	Low	Low	Low . Downloaded fr	Low	
Optional: What is the overall predicted direction of bias for this outcome?	NA	NA	NA	NA	NA	NA	NA http://b	NA	
						20,	14 March 2022. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.         Low         NA		
		For peer revie	ew only - http:	//bmjopen.br	nj.com/site/ał	bout/guideline			